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Chapter 1 
1 General Introduction 
During the last few years, research efforts on the prostate have increased considerably. 111is 
was stimulated by the fact that prostatic diseases, such as prostate cancer and benign 
hyperplasia of the prostate (BPH), have become a major medical problem, particularly 
since prostate diseases occur most frequently in elderly men, and life expectancy of the 
male population has increased over the past several years. Consequently, prostate research 
has mostly focussed on issues associated with these diseases, such as factors involved in 
their etiology, and the identification of new markers for early prostate cancer detection, 
prostate cancer staging, monitoring of prostate cancer treatment, and development of new 
therapeutic applications. Recent research also shows an increasing interest in regulatory 
regions of prostate marker genes which are potentially useful for gene therapy by directing 
expression of cytotoxic compounds to prostate cancer cells. In contrast to the considerable 
progress that was made in these research areas, knowledge of (normal) prostate physiology 
has increased to a more limited extent. 
The present study was undertaken to investigate the OCCUlTence and possible function of 
human prostate· specific transglutaminase (hTGp), an enzyme produced by the human 
prostate. hTGp is one out of seven distinct human transglutaminases (TGase) that are 
presently known. With one exception, all TGases share a common enzymatic function, 
leading to the post· translational modification of proteins by means of cross-linking. The 
specific function of each TGase is defined by its tissue location, differential regulation, 
substrate specificity, and other distinct functional ( e.g. enzymatic) characteristics present 
within each enzyme. Although the rodent prostate TGase has already been described in 
1896 by Galllus and Gley (see AUllluller and Seitz 1990), and extensively characterized 
during later years, only minimal research data up to now address the human analogue. The 
physiological function of hTGp has not yet been elucidated. 
The first part of Chapter I describes in Illore detail the physiology and pathology of the 
prostate and the usefulness of prostate markers in diagnosis and monitoring of prostate 
cancer. The second part of this chapter focusses on general characteristics of TGases and 
presents more specific data abo\lt the individual TGase family members. 
2 Prostate physiology and prostate-specific proteins 
2.1 Human prostate histology and anatomy 
The prostate is a male accessory sex gland sit\lated around the urethra just below the 
urinary bladder. It is an exocrine gland composed of branching secretOlY tubules and acini 
lined with secretory epithelium. The prostate excretory ducts originate from, and secrete 
their products into, the uretlua (C\lnha et al. 1987, AUll1\ll!er and Seitz 1990). 
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Several cell types can be distinghuished within the prostate. The epithelial cell 
compartment contains basal, luminal, and neuroendocrine cells. Basal epithelial cells are 
flattened cells with little cytoplasm localized parallel to the underlying basement membrane 
(McNeal 1988). InmlUnohistochemically, these cells can be selectively stained with 
antibodies against basal-cell specific cytokeratins such as 34fi-El2 which stains keratins 5, 
10 and 11 (Allsbrook and Pfeifer 1997, Bostwick and Devaraj 1997). The basal epithelial 
cell layer consists of undifferentiated cells. There is some evidence that the basal cell 
compartment harbors the pluripotent stem cell population of the prostate that have the 
potency to differentiate into luminal secretory and neuroendocrine cells (McNeal 1988, 
Bonkhoff and Remberger 1996, Bostwick and Devaraj 1997, Xue et al. 1998). The basal 
cells have the capacity to divide and represent a considerable part of the proliferative 
compartment of the prostate (Bonkhoff and Remberger 1996). 
The luminal epithelial cells are the fully differentiated secretOlY cells of the prostate. These 
cells have a cuboidal to high columnar appearance and contain numerous secretory 
vacuoles (McNeal 1988, Aumuller and Seitz 1990). In contrast to basal cells, luminal 
epithelial cells express typical prostatic secretory proteins like prostate-specific antigen 
(PSA) and prostatic acid phosphatase [PAP, (Cleary et al. 1983, McNeal 1988, Allsbrook 
and Pfeifer 1997)]. Proposed mechanisms of secretion by prostate epithelial cells are 
merocrine and apocrine secretion (Aumuller and Seitz 1990, Aumuller et al. 1997a, 1997b). 
The merocrine pathway uses N-temlinal signal peptides present in particular secretory 
proteins, that direct the proteins to storage granules which in tum release their contents into 
the glandular lumen by fusion with the plasma membrane. Apocrine secretion represents 
the regulated release from the apical membrane of membrane-bound blebs containing 
secretory proteins. Evidence for secretion in the apocrine fashion has been obtained for 
dorsal protein I (DP1) or rat prostate TGase (Seitz et al. 1990, Steinhoff et al. 1994). 
Neuroendocrine or endocrillc-paracrine cells represent only a small part of the epithelial 
cell population and are randomly scattered through the prostate (Di Sant'Agnese 1992, 
Noordzij et al. 1995). Ultrastmcturally, neuroendocrine cells can be recognized by the 
presence of dense secretory granules. The cells frequently display long dendritic processes 
extending under or between adjacent epithelial cells. Neuroendocrine cells express and 
secrete a wide variety of products including chromogranins A and B and many peptide 
homlones with potential growth modulating propc11ies e.g. seretonin, bombesill, 
somatostatin, parathyroid honnone-related protein and calcitonin. Of these, chromogranin 
A and serotonin are most conmlOuiy expressed by prostatic neuroendocrine cells. The other 
peptides are produced by subsets of neuroendocrine cells. The role of prostatic 
neuroendocrine ccBs is so far unclear, but an autocrine or paracrine influence on growth 
and secretory activity of prostate cells has been suggested (Di Sant'Agnese i997, 1998). 
The epithelial cell layer is separated from the surrounding stromal component by a 
basement membrane. Important components of prostate stroma are s11100th muscle cells, 
fibroblasts, nerve terminals, blood and lymph vessels, all of which are embedded in a loose 
collagenous extracellular matrix (Aumuller 1983, Cunha et al. 1987). Stroma-epithelial 
interactions play an essential role in prostate growth and development and in determining 
the final organ size in the adult (Cunha et al. 1987, Chung et al. 1991). Mesenchyme 
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influences gene expression and secretOlY cytodifferentiation of the luminal epithelial cells 
of the prostate (Cunha et al. 1992, Hayashi et al. 1993, Kinbara et al. 1996). The smooth 
muscle cells, present in thin sheaths around the acini or as broad strands separating larger 
parts of the gland, make the prostate well suited for the rapid expulsion of secretOlY fluid 
during ejaculation (Aumuller 1983, McNeal 1988). 
McNeal has proposed that the human prostate can be subdivided in three major glandular 
regions: the peripheral zone, the central zone and the transition zone (McNeal 1988, 1997). 
These zones are distinguished by specific architectural and stromal features and their 
position relative to the urethra. Whereas the typical prostate epithelial cell markers PSA and 
PAP are expressed throughout the entire prostate, the expression of other proteins 
(pepsinogen II, tissue plasminogen, lactofenin) is differentially regulated in the separate 
zones. Pathologically, this zonal subdivision is important because the majority of the 
prostate carcinomas arise in the peripheral zone, whereas the transition zone is the place of 
origin ofBPH (McNeal 1992). 
2.2 Prostate-specific proteins and their regulation by androgens 
The human prostate is characterized by the expression of several tissue-specific proteins. 
By definition, their expression should be strictly confmed to the prostate. However, as a 
consequence of the use of sensitive detection methods such as RT-PCR and extension of 
the number of tissues investigated, a previously established prostate-specific mRNA and/or 
protein is later often detected in other organs as well. This is also tme for most of the 
proteins discussed below. It can be anticipated that more prostate-specific proteins will be 
identified in the near future (Vasmatzis et al. 1998). 
Prostate-specific proteins can be categorized into secretolY and non-secretory proteins. In 
Table I some properties of the discussed proteins are summarized. Most of the presently 
identified prostate-specific proteins are secretory proteins expressed by the luminal 
epithelial cells. These proteins are secreted into the prostatic ducts and ultimately become 
part of semen during ejaculation. To this group belong the structurally related kallikreins 
PSA and hK2 (for recent review, see Rittenhouse et al. 1998), PAP (Lilja and Abrahamsson 
1988, Solin et al. 1990), prostatic secretory protein94 [p-microseminoprotein, PSP94 (Lilja 
and Abrahamsson 1988)], and human prostate-specific TGase [hTGp (Dubbink et al. 
1999b)]. Recently, a third prostate-specific kallikrein, called prostase, has been discovered 
(Nelson et a!. 1999). Putative functions ofhK2, PSA and hTGp in semen physiology will be 
discussed in more detail below. The physiological functions of PSP94 and PAP are unclear 
as yet and their discussion is beyond the scope of this chapter. The non-secretory proteins 
include prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), 
and Nkx3.1. PSMA is a transmembrane glycoprotein (Israeli et al. 1994, Liu et al. 1997) 
that possesses hydrolase activity (Carter et al. 1996) and might function as a receptor 
mediating the intemalization of a ligand (Liu et al. 1998). Immunohistochemically, PSMA 
has been demonstrated in luminal epithelial cells of normal and benign prostates, but 
usually not in basal cells (Wright et al. 1995, Bostwick et al. 1998). By ill situ 
hybridization. however, PSMA expression could only be observed in the basal epithelial 
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Table 1. Prostate-specific proteins" 
Protein Epithelial Property Androgen" 
Localization regulation 
hK2 luminal secretory + 
hTGp IUlilinal secretory + 
Nkx3.1 luminal non-secretory + 
PAP luminal secretory +1-
Prostase luminal secretory + 
PSA luminal secretory + 
PSCA basal non-secretory nd 
PSMA luminal non-secretory 
PSP94 luminal secretory ai 
11 For references, see text 
b +, lip-regulated; _, down-regulated; +/_, both up- and down-regulation have been observed 
c Consists of two disulfide-linked 50-kDa subunits 
ai, androgen independent; nd, not determined yet. 
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Mass 
kDa 
31 
77 
38 
100 ' 
33 
33 
24 
100 
16 
cell layer (Kawakami and Nakayama 1997). Although PSMA is not a typical secretory 
proteiu it can readily be detected in seminal plasma, perhaps due to membrane shedding 
during the secretory process (Aumuller and Seitz 1990, Troyer et al. 1995). PSCA is a 
glycosylphosphatidylinositol (GPI)-anchored cell surface antigen of the basal epithelial 
cells, and the biological function of this antigen is so far unknown (Reiter et al. 1998). 
Overexpression of PSCA by cDNA transfection shows that the protein can be secreted 
(Reiter et al. 1998). It is conceivable, however, that PSCA is usually not secreted into 
prostatic fluid, because the protein is expressed by the basal epithelial cells. Nkx3.1 is a 
homeodomain-containing protein and probably represents a transcription factor. During 
development of the prostate in mice, Nkx3.1 has an intriguing, male-specific, expression 
pattent that suggests a regulatory role in the earliest stages of prostate fOlmation: its 
expression (shown by ill silll hybridization) coincides with the regions where prostatic buds 
will arise from the urogenital sinus epithelium, Also poshlatal Nkx3, 1 mRNA expression 
appeared to be indicative for ductal outgrowth and morphogenesis of the prostate. Nkx3.1 
expression increases during sexual maturation, and in adulthood it may regulate the 
expression of specific secretory proteins (Sciavolino et al. 1997, Bhatia-Gaur et al. 1999). 
In contrast to PSA, hK2, PAP, and PSP94, which are expressed by most luminal epithelial 
cells (Lilja and Abrahamsson 1988, Young et al. 1992, 1996), hTGp and PSMA expression 
is heterogeneous among the cells of the normal prostate (Wright et al. 1995, Bostwick et al. 
1998, Dubbink et al. 1999b). 
The expression of many of these prostate-specific proteins is under androgen control. 
Androgens act through interaction with the nuclear androgen receptor (for review, see 
Trapman and Cleutjens 1998). The complex which is fOlmed by this interaction can directly 
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regulate transcription by binding to androgen response elements (AREs) present in the 
regulatory regions of target genes. The secretory proteins PSA, hK2, prostase, and hTGp, as 
well as Nkx3.1 have been shown to be up-regulated by androgens (Riegman et a!. 1991a, 
Young et a!. 1992, Banas et a!. 1994, Dubbink et a!. 1996, He et al. 1997, Prescott et a!. 
1998, Nelson et al. 1999), whereas PSMA is down-regulated (Israeli et al. 1994). 
Contradictory results were reported on androgen regulation of PAP (Henttu et a!. 1992, 
Banas et al. 1994). In case of hK2 and PSA several functional AREs have been 
demonstrated in the conesponding promoters (Riegman et a!. 1991 b, Murtha et al. 1993, 
Schuur et a!. 1996, Cleutjens et a!. 1997b, Yu et a!. 1999). For the gene promoters of other 
prostate-specific proteins the presence of functional AREs remain to be elucidated. The 
proximal 1.5-2.1 kb of the PAP and hTGp promoter regions do not respond to androgen and 
thus seem not to contain functional AREs (Shan et a!. 1997, Dubbink et a!. 1999a). It is 
possible that expression of these genes is more indirectly influenced by androgens, e,g. by 
stabilization of their transcripts or by regulation of other factors that can direct their 
transcription. In this regard, it would be of interest to know whether Nkx3.1, as prostate-
restricted h'anscription factor, directly or indirectly is involved in the transcriptional 
regulation of genes encoding secretOlY proteins of the prostate. 
2.3 Prostate-specific proteins as tumor markers 
Prostate cancer is the most frequently diagnosed malignancy and the second highest cause 
of cancer death in men in Western counh'ies (Parker et a1. 1996). The specific causes of 
prostate cancer are poorly understood. Prostate cancer incidence increases as a function of 
age, family history of prostate cancer and, due to envirollllental fhctors (possibly diet), 
living in a westemized society (Carter and Coffey 1990, Giovannucci 1995, Key 1995). As 
long as prostate cancers remain confined to the prostate, surgical removal of the prostate by 
radical prostatectomy can cure the patient (Zincke et a!. 1994). Once metastasized, 
however, prostate cancer becomes a fatal disease for which no curative treatment is 
presently available (Isaacs 1997). 
Prostate-specific proteins might be useful for the early detection of organ-confined disease, 
for staging of prostate cancer and for monitoring of the patient's response towards a 
treatment schedule. At present, only PSA has been found suitable in a clinical setting. PSA 
meets many of the criteria for an ideal tumor marker (Oesterling 1991, Montie and Meyers 
1997). In healthy man, PSA is almost completely confined to the prostate due to natural 
barriers which prevent leakage into the blood circulation and ensure that it is secreted into 
the prostatic ducts. Physical trauma or diseases like prostatitis, BPH and prostate cancer can 
dismpt these barriers causing PSA to be released into the circulation (Rittenhouse et a!. 
1998). Circulating levels of PSA rise and decline with tumor size increase and decrease, 
respectively, and can therefore be used for detection and monitoring the effects of prostate 
cancer treatment. DetelT11ination of PSA senun levels is complicated by the fact that 
multiple molecular fOlms exist, i.e., free and complexed with protease inhibitors. There is 
evidence that the relative amount of free and complexed PSA can be used as a prognostic 
indicator (for reviews, see Vessella and Lange 1997, Rittenhouse et al. 1998). Although 
14 
Introduction 
PSA expression reduces after malignant transformation, many hlmor cells continue to 
express PSA (Abrahamsson et al. 1988, Gallee et al. 1990). During prostate tumor growth, 
cells may be shedded into the bloodstream. Measurement of PSA mRNA levels by RT-PCR 
in the peripheral blood cell population is therefore potentially useful in detecting circulating 
prostate tumor cells and may indicate metastatic cancer (Olsson et al. 1997, Verkaik et al. 
1997). 
Currently, there is a search for new prostate tumor markers complementary to or even better 
than PSA, Of particular interest would be to have markers that are only expressed after 
malignant transformation of the prostate occurs and can reliably be detected at the time the 
tumor achieves clinical importance (Oesterling 1991). Thus far such an ideal tumor marker 
has not been found, but also markers up-regulated after malignant h'ansfonnation could be 
of importance. In this respect hK2 and PSMA might be of interest. Like PSA, hK2 leaks 
into the circulation and its senun concenh'ation is elevated (Finlay et al. 1998) and may be 
present at levels comparable to PSA in patients with prostate cancer (Rittenhouse et al. 
1998). Contrary to PSA, hK2 expression is found to be the highest in poorly-differentiated 
prostate adenocarcinoma when compared to benign and well-differentiated tissue and thus 
appears to be more tumor-associated than PSA (Rittenhouse et al. 1998). PSMA expression 
is enhanced with increasing tumor grade both due to increased expression and an increased 
number of positive cells (Wright et al. 1995, Kawakami and Nakayama 1997, Bostwick et 
al. 1998). SelUm PSMA levels of prostate cancer patients are elevated (Murphy et al. 1998). 
In addition, like PSA, PSMA can often be demonstrated imll1unohistochemically in 
metastatic cancers (Wright et al. 1995). Research is ongoing to determine if hematogenous 
spread of prostate cancer cells can be measured with high sensitivity and specificity by 
means ofRT-PCR of ilK2 and PSMA transcripts (Young et al. 1996, Olsson et al. 1997, 
Verkaik et al. 1997, Gala et al. 1998, Rittenhouse et al. 1998). It can be expected that the 
clinical value of these markers will soon be determined and that other prostate markers that 
become up-regulated after malignant transformation will be discovered in the near future 
(Israeli et al. 1997, Vasmatzis et al. 1998, Nelson et al. 1999). 
2.4 Proeesses in the male genital tract 
During the semen ejaculatory process, products of the prostate become part of the ejaculate 
(Figure 1). To understand the prostate function, it is important to know more of semen 
generation and composition, 
After at least two months of spermatogenesis in the testis, the still infertile and inmlOtile 
flagellar spenmatozoa undergo further maturation in the epididymis into fertile spernl cells 
(Mann and Lutwak-Mann 1981, Kirchhoff et a1. 1997). Sperm cells leaving the epididymis 
are motile, though this capacity is not used until after ejaculation (MaIm and Lutwak-Mann 
1981). During the ejaculatory process sperm cells encounter secretions from the male 
accessory glands which are located along the reproductive tract, including seminal vesicles, 
ampullae, prostate and bulbourethlal or Cowper's glands, and become surrounded by the 
secretory products from these organs, The ultimate ejaculate consists for over 95% of 
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Figure 1. Major processes and proteins in semen. See text for details. 
PSA 
hK2 
Prostate 
hTGp? 
secretions derived from the accessory glands. The contributions of the prostate and the 
seminal vesicles to an ejaculated semen volume of 2-6 Illi are approximately 30% and 60%, 
respectively. Immediately upon ejaculation, semen rapidly hlms into a gel or coagulum in 
which most spermatozoa become entrapped (Zaneveld et aL 1974, Matm and Lutwak-Matltl 
1981). Subsequent liquefaction of the coagulum in 5 to 20 minutes releases the trapped 
immotile spemlatozoa, which then gain progressive motility. Full fertilizing competence of 
the spemlatozoa is acquired in the female reproductive tract after a process called 
capacitation. During this process further modifications occur at the sperm plasma 
membrane (Fraser 1995, Aitken 1997, Cooper and Yeung 1997). 
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2.5 Secretory products of the prostate in semen physiology 
The precise biological importance of many of the seminal plasma constihlellts, including 
those contributed by the prostate, for fertilization and other aspects of spenn function, 
including interaction of spermatozoa with the immune system, is largely unclear. In 
general, it is suggested that secretions of the accessory glands optimize the fertilization 
process. Potential functions and biochemistry of selected prostatic products will be 
discussed in relation to physiological functions which can be attributed to semen as an 
entity (Figure I). 
2.5.1 Semell coagulatioll alld liquefactioll 
Seminal gel jorllla/ion 
The main source of the gel-fonning proteins is the secretory epithelium of the seminal 
vesicles, as has become clear from biochemical studies with split (partitioned) ejaculates 
(Tauber et al. 1980) from patients with a congenital absence or functional deficiency of 
these glands (Amelar 1962, Lilja et al. 1987) and from immunohistochemical studies (Lilja 
et al. 1989, Aumuller et al. 1990, 1997b). The predominant structural proteins of the 
seminal gel are now identified as fibronectin, semenogelill I and semenogelin II, which are 
high molecular mass proteins of 200-250 kDa, 52 kDa and dependent on its glycosylation 
status 71 or 76 leDa, respectively (Lilja et al. 1987, 1989, 1990, MaIm et al. 1996). Despite 
the presence of disulphide linkages in the coagulum (Chaistitvanich and Boonsaeng 1983, 
Lilja and Laurell 1985), gel fonnation essentially results from non-covalent interactions of 
seminal vesicles proteins, because interference with nOll-covalent bonds, but not cleavage 
of the disulphide bonds, solubilizes the clot (Lilja and Laure1l1984, 1985). 
Seminal gel proteolysis 
Lysis of the gel is achieved by cleavage of the gel-fanning proteins by proteolytic enzymes 
mainly derived from the prostate, generating low molecular mass protein products (Tauber 
et al. 1976, 1980, Lilja 1985). Gel proteolysis is important since poor semen liquefaction is 
often associated with subfertility (Zaneveld ef al. 1974, Mann and Lutwak-Mann 1981). 
Although other prostatic proteases may participate in the liquefaction process, e.g 
metalloproteases, caseinolytic and gelatinoiytic activities (see Wilson 1995), at present 
most is known about the involvement of the kallikreins hK2 and prostate-specific antigen 
(PSA or hK3, recently extensively reviewed by Dube and Tremblay 1997, Rittenhouse et 
al. 1998). PSA is one of the major protein constituents of seminal plasma and is present at 
concentrations ranging from 0.5 mg/ml to 5.5 mg/ml (Wilson 1995, Rittenhouse et al. 
1998). Its contribution to and importance for gel hydrolysis is well established (Lilja 1985, 
Lilja et a!. 1987). For hK2, this is more difficult to prove, because the seminal plasma 
concentration of hK2 is much lower, in the order of 2-12 ~Ig/ml, and in contrast to PSA its 
activity disappears soon after ejaculation, because of proteolyic cleavage and complexation 
with seminal vesicle secreted protein C inhibitor (PCI (Deperthes et al. 1996, Dube and 
Tremblay 1997)]. PSA and hK2 are proposed to fulfill synergistic or complementary roles 
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in dissolving the coagulum, because they have different substrate specificities (Deperthes et 
al. 1996). Apart from the fact that PSA has chymotrypsin-like protease activity and hK2 
hypsin-like activity (Mikolajczyk et al. 1998), determining their specific cleavage sites 
within protein substrates, both enzymes may show differential degradation potentials 
toward the same substrate. Semenogelin I and semenogelin II are hydrolyzed with 
comparable rate by PSA and hK2 ill vitro, although distinct fragmentation patterns were 
obtained due to cleavage sites differences (Deperthes et al. 1996, Lovgren et al. 1997). 
Contrary to the degradation of the semenogelins, proteolysis of fibronectin occurs much 
more efficiently by hK2 (Deperthes et al. 1996). In fact, it has been shown that the hK2 
protease activity may be 20.000-fold higher than PSA on the appropriate synthetic 
substrates (Rittenhouse et al. 1998). Therefore, the ill vivo consequence of these distinct 
substrate specificities may be that the semenogelins are largely broken down by the action 
of PSA, whereas a substantial part of fibronectin might be degraded by hK2, despite the 
huge differences in seminal plasma concentrations of these kallikreins (Deperthes et al. 
1996). However, the relative contribution of PSA and hK2 to gel-lysis ill vivo still remains 
to be defined. 
PSA and hK2 are both produced in zymogen form or as proenzymes and require proteolytic 
activation by cleavage of their propeptide sequence. Recently, experimental clues for 
possible mechanisms underlying their activation have been obtained, It has been 
demonstrated that hK2, in contrast to PSA, can become catalytically active by 
autoactivation (Mikolajczyk et al. 1997) and that hK2 additionally can convert pro-PSA 
into an enzymatically active mature form of PSA (Kumar et al. 1997, Lovgren et al. 1997, 
Takayama et al. 1997). hK2 thus appears to be the physiological activator of itself as well 
as of PSA. Recent studies have demonstrated that PSA and hK2 are secreted in their 
zymogen form into the spent medium of LNCaP or tTansfected cells, respectively, 
suggesting that proteolytic activation of the enzymes is an extracellular event (Kumar et a1. 
1997, Mikolajczyk et al. 1997, Rittenhouse et al. 1998). Since both enzymes are present in 
their mahlre active form in seminal plasma directly after ejaculation (Lilja 1985, Deperthes 
et al. 1996), this may indicate that physiologic activation of both enzymes occurs inside the 
lumen of the prostate (Lovgren et al. 1997). With the recent identification of prostase, 
which has structural features of serine proteases, the emerging picture may become even 
more complex. It has been speculated that this new enzyme is involved in a cascade of 
reactions together with PSA and hK2, finally culminating in the physiological processes 
described above (Nelson et al. 1999). 
Copula/OJ)I plug formation and dissolution in rodents 
In rodents, seminal clotting and subsequent dissolving is obviously different from the 
human gel-forming and liquefaction process (extensively reviewed by Williams-Ashman 
1984). In these animals, a copulatory or vaginal plug is swiftly formed after depositon of 
the ejaculate in the vagina which differs from the soft gel of the human ejaculate in that it is 
a hard, mbbery lump which can stay for many hoUl's to days and which does not contain 
spennat020a (Zaneveld et al. 1974, Williams-Ashman 1984). In contrast to the relative slow 
release of the entrapped spennatozoa from the coagulum in humans, a substantial portion of 
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the spenllatozoa in rodents is catapulted via the cervix into the utellls within seconds after 
ejaculation, Dissolution of the plug is thought to result from infiltrating leukocytes and their 
proteases instead of from lysis by prostatic enzymes (Williams-Ashman 1984), Plug 
fonnalion and stability is acquired by the strong protein cross-linking activity of dorsal 
protein 1 (DPI) or prostate-specific TGase [for enzymology of TGases, see below 
(Williams-Ashman et al. 1972)], In this regard it is important to note that the morphology 
of the rat prostate is different from the human prostate, The rat (rodent) prostate is 
composed of several distinct lobes: the ventral, lateral type 1 and 2, dorsal and anterior 
lobes (coagulating gland) (Hayashi et al. 1991), DP I is a major secretory glycoprotein of 
the rat dorsal prostate, the lateral type 1 prostate and the coagulating gland, and is produced 
in minor amounts by the lateral type 2 prostate, and not by the venh'al prostate (Wilson and 
French 1980, Romijn 1990, Hayashi et al. 1991, Kinbara and Cunha 1996), TIle protein is 
synthesized in large quantities, because approximately 25 % of the total cytosol protein of 
the dorsal prostate and the coagulating gland consists of DP I, leading to a final conh'ibution 
to the ejaculated seminal fluid of about 5% of the total protein content (Wilson and French 
1980), Subsh'ates of DPI are synthesized by the seminal vesicles, Rat seminal vesicle 
secretions contain several proteins, designated seminal-vesicle-secreted protein 1-VIII (SVS 
I-VIII), according to their electrophoretic mobility (Aumuller and Seitz 1990, Seitz and 
Aumuller 1990), The major plug component and subsh'ate for DPI appeared to be the 49 
kDa basic SVS II, although other SVS proteins may be integrated in the copulatory plug 
and can be subsh'ates for DPI as well (Fawell et al. 1986, Fawell and Higgins 1987, Seitz 
and Aumuller 1990), It has been proposed that plug formation can be modulated by 
polyamines which occur in high concenh'ations in seminal fluid (Williams-Ashman 1984) 
and are established physiological substrates for TGases (Folk et al. 1980), 
Concluding remarks 
Together, these data show that, although rodents and humans have a completely different 
coagulation and liquefaction system, in each case the enzymic contribution is derived from 
the prostate, whereas the corresponding protein substrates are produced by the seminal 
vesicles. Both in humans and rodents, the prostate contributes high amounts of polyamines 
to seminal plasma (Mann and Luhvak-Mann 1981, Williams-Ashman 1984, Romijn 1990), 
It also illustrates the different nahlfe of the seminal coagulum. The human gel is essentially 
formed by non-covalent interactions in which TOase-specific bonds, if present at all, 
probably do not play an important role (Chaislitvanich and Boonsaeng 1983, Lilja and 
Laurell 1985, Lilja et al. 1987), whereas large quantities of isopeptide bonds due to TGase 
activity are present in the vaginal plug of rodents (Williams-Ashman et al. 1972), 
Therefore, the existence of a human prostate-specific TOase in semen, as recently has been 
demonstrated (Dubbink et al. 1999b), might be expected to play a different role in 
reproductive physiology than rat DP I, 
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2.5.2 lJllIIlIIllolllo(/u/atoIJ' mechanisms ill semen 
immunological (J!<.pects of semen 
Only limited knowledge has been obtained so far about the contribution of the prostate to 
reproductive immunology. For reviews on semen immunology, see Alexander and 
Anderson 1987, Marshburn and Kutteh 1994, Naz and Menge 1994, Kelly 1995, and Kelly 
and Critchley 1997. Two important aspects can be considered. First, the male reproductive 
tract is open to the extenlal environment and needs to be protected against invading 
organisms. Seminal plasma contains high concentrations of zinc and spermine, up to 140 
gg/ml and 3.5 mg/ml, respectively. These compounds appear to originate primarily from 
secretions of the prostate, which is the richest source in the body of zinc and spermine. 
Both zinc and spermine (oxidized) are considered to have antibacterial potency and are 
possibly involved in local defence mechanisms in the lower male reproductive tract, 
although this remains to be established (Williams-Ashman and Lockwood 1970, Partin and 
Coffey 1998). Second, spermatozoa contain components that are antigenic and need to be 
protected both against the male and female inmmne system. Anti-sperm antibodies can be 
directed against multiple spermatozoal epitopes and may affect fertility by interference with 
sperm motility leading to spenn migration inhibition through the cervical canal and the 
upper reproductive tract. Altematively, anti-sperm antibodies may interfere with events 
essential for the fertilization process such as capacitation or spenn~egg interaction due to 
sterical hindrance or blocking of the receptor involved in Spe1111-egg attachment (Mahony 
and Alexander 1991). It has been suggested that even after fertilization, anti-sperm 
antibodies may affect implantation and may decrease pregnancy rates and the viability of 
developing emblYos (Menge and Naz 1988, Marshbul11 and Kutteh 1994, Naz and Menge 
1994). Furthermore, because the female is repeatedly exposed to spermatozoal antigens, 
establishment of anaphylaxis (a sensitized immunological response) must be prevented. It is 
important to note here that a majority of women do not develop anti-sperm antibodies and 
become not sensitized despite repeated introduction of millions of spenn cells in the vagina 
after intercourse (Marshburn and Kutteh 1994). These immunological aspects need to stay 
in balance to achieve a situation of both minimal chances for invading micro~organisms and 
maximal spennatozoa survival (Kelly 1995, Kelly and Critchley 1997). 
Alodulatioll C?f immunological responses ill the female genital tract 
Several mechanisms are proposed to prevent or modulate immunological responses in the 
female reproductive hoact against seminal components. It needs to be stressed that 
information about the immunomoduiating effects suggested for seminal plasma components 
come from ill vitro experiments and that the ill vivo significance of these effects remains to 
be elucidated, Only those mechanisms will be discussed in which characteristic secretOlY 
products of the prostate might be involved. 
Direct immunosuppressive mechanisms 
Seminal plasma is a potent inhibitor of proliferation and activity of cells of the immune 
system, e.g. lymphocytes, lllonocytes and NK cells, and thus may affect cell-mediated and 
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humoral immunity in both the male and the female genital tract (James and Hargreave 
1984, Alexander and Anderson 1987). Several studies point towards an inhibitory role for 
polyamines, i.e., spermine and spennidine, of T-Iymphocyte proliferation after antigen 
challenge. To display this bioactivity, the polyamines need to be converted to an oxidized 
form by the action of polyamine oxidase (Byrd et a!. 1977, Qnan et a!. 1990, Imade et a!. 
1997, Kelly and Critchley 1997). Therefore, some caution has to be taken considering this 
role of polyamines in seminal immunosuppression, because it is not without discussion 
whether the observed effects are artifactually caused by direct cytotoxicity of oxidized 
polyamines (see Alexander and Anderson 1987). InIDmllosnppressive properties, i.e., 
inhibition of 1\TK cell activity, have been attributed to a seminal plasma protein fraction 
containing TOase activity, but it is unclear from these experiments how such inhibition is 
achieved (Ablin et a!. 1990). 
Aladulatiall a/sperm cell im11lullogellicity 
A more indirect though potentially important modulation of female immune responses is 
rendering spelnmtozoa less immunogenic when they leave the epididymis by coating them 
with seminal plasma components during ejaCUlation. Several reports suggest that the 
antigenicity of Spel111atozoa can be modified by the enzymatic action of seminal plasma 
TGase, which in humans most probably is hTGp (Dubbink et a!. 1999b). Although no 
covalent TOase cross-links could be detected in human seminal plasma (Lilja and Laurell 
1985), the possibility of TGase catalyzed cross-links at the spennatozoal surface has not 
intensively been investigated. Most evidence in this direction comes from studies using rat 
and rabbit spermatozoa. Uteroglobin, which is produced and secreted by epithelial cells of 
numerous organs, is an excellent substrate for different TOase types ill vitro (Manjullath et 
a!. 1984, Miele et a!. 1994). Pretreatment of rabbit epididymal spermatozoa with prostatic 
fluid or with pure uteroglobin, but not with TOase alone, decreased the immunological 
response of allogeneic splenocytes to these cells. However, simultaneous treatment with 
both uteroglobin and TGase completely inhibited sperm antigenicity. On the other hand, 
prostatic fluid which had first been exposed to antibodies either against uteroglobin or 
TOase could not decrease the inullunological response against spennatozoa. It has been 
suggested that these observations could be explained by the covalent TGase-mediated 
attachment of uteroglobin to proteins of the spennatozoal membrane, thereby masking 
antigenic determinants (Mukherjee et a!. 1983, Manjunath et a!. 1984). 
Comparable results were described for immullomociulation of rat epididymal spermatozoa 
by SVS-IV and TGase. SVS-IV has intrinsic immunosuppressive properties which could be 
increased by the TGase-mediated incorporation of spermidine (Porta et a!. 1993). Treatment 
of epididymal spermatozoa with SVS-IV led to inhibition of splenocyte proliferation in 
response to these cells, and decreased their ability to induce several aspects of peritoneal 
macrophage activation, shO\ving a reduced spelID il11ll1unogenicity. As described above for 
uteroglobin, this effect was far greater if the spermatozoa were simultaneously pretTeated 
with TGase, but was absent if incubated with TGase alone (Peluso et a!. 1994). In contrast 
to what has been suggested for uteroglobin, this action ofTGase may not be ascribed to the 
direct covalent binding of SVS-IV to sperm surface proteins, but is suggested to result 
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indirectly from increasing the sperm binding properties of SVS-IV through branched SVS-
IV homopolymer formation (Paonessa et a!. 1984, Porta et a!. 1991, Peluso et a!. 1994). 
Furthennore, TGase was shown to be able to modify the speml surface by covalent binding 
of the polyamines spermine and spemlidine (Paonessa et a!. 1984). It remains to be studied 
whether the latter cell surface changes also affect the inll1Unological properties of 
spelumto2oa. 
These studies, though performed with spemIatozoa from rat or rabbit, may be indicative for 
a potential function of seminal plasma TOase or hTGp in immunomodulation of sperm cells 
in humans. Recently} hTGp has been demonstrated in human prostatic fluid and seminal 
plasma by Westem blotting with a polyclonal antisennn against the hTGp C-terminal 
(Dubbink et a!. I999b). Immunoreactivity has also been found on the spennatozoal neck 
and tail with a polyclonal antisennn against a purified seminal plasma TGase, which may 
represent hTGp (Ablin and Whyard 1991). TGase activity has been found both in human 
seminal plasma and on the spermatozoal surface (Porta et a!. 1986). Indirect evidence 
suggests that this spenn-bonnd TGase activity derives from seminal plasma and becomes 
attached to the spennatozoa during ejaculation. TOase-mediated incorporation of 
spermidine into human sperm membrane and seminal plasma proteins has been 
demonstrated ill vi/ro (Porta et a!. 1986). In addition, several candidate protein substrates 
for TOase, through which hTGr may modify the sperm membran.e, are present in seminal 
plasma. Clara cell IOkDa (cclOkDa) is proposed as the human connterpart of uteroglobin. 
The secretory cc 1 OkDa protein has immullomodulatory activities, is present in prostate 
epithelium and can sen'e as acyl donor and acceptor for TGase (Mantile et a!. 1993, Miele 
et a!. 1994). p,-microglobulin (P,M) is recognized as a TGase substrate. It is present in 
seminal plasma in high concentrations (James and Hargreave 1984) and has been detected 
on cell surfaces (Feslls et a!. 1981). The gel-fOiming proteins semenogelin I, semenogelin 
II, and fibronectin, all can act as TGase substrates (Barsigian et a!. 1988, Peter et a!. 1998). 
Although the proteins may not become cross-linked in the gel, it is possible that they are 
covalently attached to the sperm surface. In fact, semenogelin epitopes have been found on 
the postacrosomal sheath of the sperm head, the mid region and the spelru tail (Lilja et a!. 
1989), and fibronectin immunoreactivity on the equatorial segment and several other parts 
of ejaculated spermatozoa (Glander et a!. 1987, Anmuller et a!. 1997b). Because binding 
and cross-linking may represent dissociable events, it remains to be established if TOase 
cross-linking is involved (Barsigian et a!. 1988). For all of these TGase substrates present in 
human seminal plasma, it needs to be confirmed that they indeed can act as physiological 
substrates for hTGp . Evidence for this has been obtained only by using purified tissue type 
TGase (TGc) or plasma factor XIIIa (FXIlIa), whereas hTGp might be the only naturally 
occurring TGase type in seminal plasma (Dubbink et a!. I 999b). In addition to TGase 
substrates deposited by the male, it cannot be excluded that proteins from the female 
become cross-linked to the spenll surface, e.g. by sperm bound hTGp during transport 
through the female genital tract. With regard to an inmmllomodulating function of hTGp, it 
is of interest that protein modifications brought about by TOe ill vivo indeed can change the 
antigenic properties of proteins. Specific deamidations caused by TOe in the protein 
gliadin, a component of wheat gluten, alters its antigenicity and makes the protein a better 
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target for gut T-cells. The resulting change is suggested to playa role in the pathogenesis of 
celiac disease (Molberg et a!. 1998). Although this shows gain of antigenicity, it obviously 
illustrates the influence of a TGase enzyme on the antigenic structure of a protein substrate. 
Reduction of the alltigellic load by extellsive proteolysis of semillal plasma proteills 
The antigenic load offered by seminal plasma proteins may also need to be reduced. It has 
been suggested tlrat this occurs by extensive proteolytic degradation of residual seminal 
plasma proteins in the vagina, which still remain present after liquefaction by PSA and hK.2 
proteolysis. For this to be achieved, pepsinogen II (also named gastricsin) might be 
responsible. This enzyme is secreted as a zymogen both by the prostate and seminal 
vesicles. Pepsinogen II becomes active by autocatalytic activation 2-7 h after semen 
deposition, after the vaginal pH has decreased back to its physiological pH of 3.4-4.5 
(Szecsi and Lilja 1993, Wilson 1995). It still needs to be established whether this 
degradation indeed reduces the females inunune response to seminal plasma proteins. 
2.5.3 Sperll/II/otility am/flll'ther spel'lI/ sllliace chauges 
Spemratozoa need to acquire progressive motility to be able to move through the cervical 
mucus and the upper reproductive tract and also need to undergo capacitation to become 
fully fertile. 
There is evidence for the presence of a seminal plasma motility inhibitor (SPMI) factor in 
semen, which is able to completely inunobilize spenn cells at a physiological 
concentration. SPMI is exclusively produced by the seminal vesicles and has recently been 
identified as one of the semenogelins, probably semenogelin I (Robert and Gagnon 1995, 
1996). Liquefaction, which has been discussed in more detail above, is essential for 
spelnmtozoa to become motile. However, this may not simply be caused by the release of 
entrapped and inunobilized spennatozoa from the coagulum meshwork, because purified 
SPMI at soluble concentrations can completely arrest flagellar beating (Robert and Gagnon 
1996). Degradation of SPMI by prostatic secretions or PSA considerably decreases the 
capacity of SPMI to inhibit sperm motility although SPMI fragments still have residual 
inhibitory capacity (Robert and Gagnon 1995, 1996). Recently, also fibronectin was 
suggested to playa role in sperm motility inhibition since fibronectin antibodies increase 
spenTI motility and fibronectin protein decreases sperm motility (Aumuller et a!. 1997b). It 
ean be hypothesized that fibronectin proteolysis by PSA and hK.2 is necessary for reduction 
of this biological activity ill vivo. The mechanisms underlying sperm motility inhibition by 
SPMI and fibronectin are still unclear, but may result from their attachment to specific 
areas on the sperm surface, like the tail (SPMI) and the midpiece (fibronectin) of the 
spermatozoa (Lilja et a!. 1989, AUllluller et a!. 1997b). 
Capacitation is the time~dependent acquisition by spennat020a to become fully prepared for 
interaction with the oocyte (Fraser 1995). It renders the spermatozoa capable of undergoing 
the acrosome reaction and, although this may be a separate event, capable of expressing 
hyperactivated motility (Mortimer et a!. 1998). Among other things, capacitation involves 
the removal or alteration of factors, referred to as decapacitation factors, from the sperm 
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surface. These decapacitation factors are of epididymal or seminal plasma origin (Fraser 
1995). It cannot be exclnded that some of the prostatic enzymes mentioned earlier are 
involved in this process. Furthelnlore, the involvement of a fertilization promoting factor 
(FPP; pGlu-Glu-ProNH,) has been considered (for reviews on FPP, see Fraser et al. 1997, 
Fraser 1998a, 1998b). FPP is a tripeptide stmcturally related to thyrotrophin-releasing 
hormone, and is released by the prostate into seminal plasma, Physiological concentrations 
of FPP can accelerate capacitation and inhibit spontaneous acrosomal exocytosis of 
capacitated spermatozoa, together giving spermatozoa an increased chance of fertilization. 
FPP is thonght to act through a spermatozoal receptor named TCP-II, thereby modulating 
intracellular adenyly1 cyclase and hence cAMP production. Elevated intracellular levels of 
cAMP are known to stimulate capacitation and may therefore be important for the 
acquisition of fertilizing ability (for review, see Aitken 1997). 
3 The transglutaminase family of proteins: tissne distribntions, 
activation mechanisms and physiological functions 
3.1 Enzymology of tl'ansglntaminascs 
Transglutaminases (TGases, protein-glutamine: amine y-glutamyltransferase, EC 2.3.2.13) 
are Ca'+-dependent enzymes that catalyze an acyl transfer reaction between peptide-bound 
glutamine residues and either peptide-bound lysine residues or primary amines (for 
reviews, see Folk 1980, Lorand and Conrad 1984). The y-carboxamide of the glutamine 
serves as acyl donor or amine acceptor and binds to the acyl-acceptor or amine-donor E-
amino group of the lysine or the primary amino group of a polyamine (Figure 2). The 
reaction occurs by the formation of an acyl-enzyme intermediate through the transient 
binding of the y-carboxamide with the sulfhydryl group of the active-site cysteine under 
simultaneous release of ammonia, Subsequently, the amine donor substrate is bound to the 
enzyme and cross-linking takes place. After cross-linking of a polyamine a free amine 
group remains that can be cross-linked to another y-carboxamide group of a peptide-bound 
glutamine. The post-translational TGase bonds that hence can be formed are "-(y-
glutamy1)lysine isopeptide bonds between different protein substrates or within the same 
protein substrate (Figure 2A), (y-glutamyl)polyamine bonds yielding protein-polyamine 
conjugates (Figure 2B) and bis(y-glutamy1)polyamine bonds consisting of polyamine cross-
bridges between two proteins or intramoleculariy (Figure 2C). In the absence of an amine 
substrate the acyl-enzyme intenuediate may react with water, resulting in deamidation of 
the y-carboxamide group of the peptide-bound glutamine, yielding a glutamic acid residue 
instead (Figure 2D). 
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Figure 2. Transglulal11il1ase-calalyzed reactions. Formation of s-(y-glutamyl)lysinc isopeptide bonus (A), 
(y-glutamyl)polyaminc bonds (8), and bis(y-glutumyl)polyamine bonds (e), and deamiuation of pcptide-
bound glutamine. 
Many TOase protein substrates have already been identified, that can serve as amine 
acceptor and/or amine donor, and this list will certainly grow (Steinert and Marekov 1995, 
McDonagh and Fukue 1996, Zeeuwen et al. 1997). In a particular protein substrate only a 
limited number of lysine or glutamine residues react with TGases (Murthy et al. 1998). 
Substr'ate specificity is dependent on the TGase type involved, and detennined by the 
primary stmcture flanking both the amine donor and acceptor amino acids, the 
confonnational properties of the substrate protein, and the accessibility of the amino acid 
residues (Folk 1983, Grootjans et al. 1995, Steinert and Marekov 1995, Tarcsa et al. 1998). 
TOases possess a differential specificity for peptide-bound lysine- and glutamine residues, 
being much less selective toward the amine dOllar lysine residues in proteins than toward 
peptide-bound glutamine residues (Folk 1980). However, although a broad range of amino 
acid residues flanking the substrate lysine are tolerated, and thus in theory many lysine 
residues may participate in the fonnation of the E-(y-glutamyl)lysine isopeptide bonds, 
amino acid residues directly preceding an accessibJe lysine can considei·ably affect their 
TOase reactivity and therefore may define the final number of amine donor lysines in a 
given native protein substrate (Grootjans et al. 1995). Polyamines can serve as competitive 
inhibitors of TGase-catalyzed E-(y-glutamyl)lysine cross-link formation by competition 
with peptide-bound Iysines for incorporation into a protein substrate (Folk 1980, Lorand 
and Conrad 1984, Williams-Ashman 1984). 
The action of TOases leads to the formation of high molecular mass hOl11o- or 
heteropolymeric protein complexes, if protein substrates are involved that can serve both as 
amine donor and acceptor (Lorand and Conrad 1984). Large macromolecular str11ctures 
fomled by TGase-catalyzed cross-linking obtain an increased rigidity and become less 
susceptible to mechanical, chemical and enzymatic dismption (Greenberg et al. 1991). It 
was believed that this was due to the ineversibility of the covalent E-(y-glutamyl)lysine 
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isopeptide bonds, and that hence the complexes could only be dissolved by proteolytic 
degradation of the protein tails. In agreement with this hypothesis was the failure to isolate 
an enzyme which could cleave the TGase catalyzed cross-links. Only recently, it has been 
detected that, utilizing artificial substrates, distinct TGases possess the intrinsic potential 
also to hydrolyse TGase-generated bonds, suggesting that TGases could playa dynamic 
biological role in being able to catalyze both the fonnation and the cleavage of e-(y-
glutamyl)lysine isopeptide bonds (Parameswaran et at. 1997). Degradation of cross-linked 
protein complexes may therefore be the consequence of both bond hydrolysis and 
proteolysis, and stability of the protein complexes may be due to a decreased access of the 
macromolecular stlUctures resulting in a prolonged proteolysis. 
Although the presence of a TGase in a tissue of interest can be detennined by 
immunohistochemistty or by in vitro methods, i.e., assaying TOase activity in protein 
lysates, this does not necessarily implicate that the enzyme is also active ill vivo. An 
estimation of in vivo functioning of TGases is usually made by measuring the amount of 
enzyme product in tissue Iysates or body fluids. For this purpose, protein isolates are 
completely degraded by proteolysis, and subsequently the amount of B-(y-glutamyl)-Iysine 
isopeptide or (y-glutamyl)polyamine bonds is evaluated by HPLC (Lorand and Conrad 
1984). More recently, it was also found to be possible to detect B-(y-glutamyl)-Iysine 
isopeptide bonds by means of inmmnohistochemistry with a monoclonal antibody or 
polyclonal antisenuu raised against this cross-link, allowing in situ localization of the 
TGase product (el Alaoui et at. 1991, Aeschlimalm et at. 1995). 
3.2 The TGase protein family 
TGases are widely distributed in various organisms, including vertebrates, invertebrates, 
plants and bacteria. For example, analogues of manunalian TGases have been found in 
grasshopper embryos (Singer et al. 1992), in horseshoe crab hemolymph (Tokunaga et al. 
1993), inuni- and multicellular plants (reviewed by Serafini-Fracassini et al. 1995), and in 
several bacteria (Kanaji et al. 1993). 
In humans, seven distinct TGase types have been described, and their respective cDNAs 
and deduced primary protein sequences have been resolved. These include keratinocyte 
TGase [TGK (Rice et al. 1992)], tissue-type or cellular TGase [TGc (Gentile et al. 1991)], 
epidermal TGase [TGE (Kim et al. 1993)], prostate-specific TGase [hTGr (Dubbink et al. 
1996)], TGx, identified in keratinocytes (Aeschlimanll et al. 1998), plasma factor XIIIa 
(lchinose et al. 1990), and the catalytically inactive TGase-like erythrocyte membrane 
protein band 4.2 (Korsgren et al. 1990). TGase nomenclature is presented in Table 2. The 
organization of most TGase genes has been resolved. The TGase genes encompass 13 or 15 
exons and, with the exception of the TGli'f2 and TGli13 genes, are scattered over different 
chromosomes. These data and corresponding transcript and protein sizes are summarized in 
Table 2. 
26 
Introduction 
Table 2.111e human TGase gene family". 
Gene name Chromosomal Gene size Exon number mRNA size Protein name Protein mass 
localization (kb) (kb) (kDa) 
TOMI 14qll.2-q13 14.1 15 2.7 TOK (TOasel) 92/106 b 
TOM2 20q 11.2-20q 12 32.5 13 4.0 TOc (TOase2) 85 
TOM3 20q 11.2-20q 12 42.8 13 2.9 TO, (TOase3) 77 
TGM4 3p21.33-p22 35 13 3.5 TOp (TOase4) 77 
TOM5 nd nd C nd 2.2/2.8 TOx (TOase5) 81 
Factor XIIla 6p24-p25 >160 15 3.9 FXllla 83 
Balld 4.2 15q15-q21 20 13 2.4 Band 4.2 72 
(/ References used: TGMf, Kim et al. 1992, 1995b, Phillips et a!. 1992, Yamailishi et al. 1992; TGM2, 
Gentile et al. 1991, 1994, Fraij and Gonzales 1997; TGAI3, Kim ct al. 1993, 1994a, Gentile ct al. 1994; 
TGM4, Gentile et al. 1995, Dubbink ct al. 1996, 1998, 1999b; TGAI5, Aeschlimann et al. 1998; FactorXIIIa, 
Grundmann et al. 1986, Board et al. 1988, Jchinose and Davie 1988; Baud 4.2, Sung et al. 1990, 1992, 
Korsgren and Cohen 1991. 
h The 106 kDa protein represents the size of the post-translation ally modified enzyme 
<' nd, not determined 
Human TGases have a molecular mass between 76 and 92 lcDa which may be slightly 
higher in some cases because of post-translational modifications. They share an overall 
amino acid sequence identity of 25% to 45% (Table 3). Sequence similarities are 
particularly high in tl,e middle portions or catalytic core domains of the proteins (see 
below), vmying from 33% up to 56% (Table 4). 11,e active-site cysteine of functionally 
active human TGases is located in the amino acid sequence GQCWVFA (for sequence 
aliglmlent, see Chapter 2). Site-directed mutagenesis of this cysteine into a serine or alanine 
completely abolishes TGase activity, as has been sholVn for TGc (Lee et al. 1993) and 
FXIIIa (Heltasch and Greenberg 1994), because of interference with the fonnation of an 
acyl-enzyme intermediate. In band 4.2 this cysteine has been replaced by an alanine, 
explaining why the protein could not be functionally active (Korsgren et al. 1990). 
Interestingly, however, converting this alanine to cysteine does not lead to an active 
enzyme (Risinger, M.A. and Cohen, C.M., cited by Heltasch and Greenberg 1994), 
demonstrating that for catalytic activity also other amino acids are required. 
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Table 3. Identities of human TGascs us calculated from multiple alignment of the corresponding amino acid 
sequences. 
TG K TGc TG, TG p TGx FXlIIa Band 4.2 
TGI( 100% 
TGc 35.8% 100% 
TGE 36.1% 37.7% 100% 
TGp 36.4% 32.0% 33.8% 100% 
TGx 36.8% 42.3% 45.4% 33.1% 100% 
FXIIla 42.1% 36.6% 34.0% 31.2% 34.1% 100% 
Band 4.2 27.3% 33.6% 31.2% 28.2% 33.0% 25.3% 100% 
Table 4. Identities of the core domains of human TGases as calculated from multiple alignment of the 
corresponding amino acid sequences (sec Aeschlimal1l1 et al. 1998). 
TGJ( TGc TG, TG p TGx FXIIla Band 4.2 
TGJ( 100% 
TGc 47.2% 100% 
TG, 48.5% 47.4% 100% 
TG, 48.6% 46.1% 47.1% 100% 
TGx 49.8% 56.4% 55.4% 47.3% 100% 
FXIIla 52.9% 50.9% 46.1% 43.8% 47.4% 100% 
Band 4.2 34.3% 42.1% 34.5% 37.5% 41.4% 33.1% 100% 
So far, the three-dimensional stmcture has been resolved for FXIlIa monomeric and 
dimeric forms. Because of the high sequence identities among TGases, in particular in the 
catalytic center region, it seems likely that at least part of the secondary structure is 
identical for the other family members. FXlIIa is made up of four sequential domains~ an 
N-terminall3-sandwich, a core domain, banell, and barrel 2 (Yee et al. 1994). The central 
core domain is largest in size and contains the active-site cysteine. The reaction center was 
found to be made up of a catalytic triad consisting of the active-site Cys, a His and an Asp 
(corresponding to residue Cys-268, His-327 and Asp-350 in hTGp ; see alignment in 
Chapter 2) which interact through hydrogen bonds (Cys-His, His-Asp). The catalytic triad 
residues are located at the base of a cavity bounded by the core and balTel I domains. 11,e 
arrangement of the catalytic triad resembles that of cysteine proteases (Yee et al. 1994). All 
catalytically active TGases contain these catalytic triad amino acids. Band 4.2 , however, 
lacks the His residue, which further explains why the Ala to Cys substitution at the active-
site position does not result in an active TGase. 
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3,3 Ph)'siologic~1 functions of TG~ses 
TGases are involved in many physiological processes. The next sections are intended to 
give an impression of the most obvious processes in which distinct TGases are involved, 
and to describe biochemical mechanisms underlying their activation. 
3.3,] P/aslllajacloJ'XIIla (FXII]a) 
Human plasma factor XIII (FXIII) is involved in the fiual stages of the blood coagulation 
cascade. It circulates as an inactive heterotetrameric complex consisting of two FXlIIa 
subunits that are noncovalently associated \vith two canier b subunits [AlBl (for recent 
reviews, see !chinose et al. 1990, Greenberg et al. 1991, Muszbek et al. 1996)]. It has been 
suggested that the b subunits protect FXlIIa against proteolysis and increase its half-life in 
the circulation. TIley may also prevent a slow, non-proteolytic activation (Board et at. 
1993). In the nonactivated zymogenic form of FXllI, the N-terminal activation peptides of 
the FXllIa subunits, i.e., the first 37 amino acids, cross the interface between two a subunits 
and binds to the core domain of the opposite monomer meanwhile precluding subsh'ate 
binding to the catalytic center (Yee et al. 1994). For activation of FXIII, it is necessary that 
the peptide bonds between Arg37 and Gly38 of the a subunits are cleaved by thrombin. 
Subsequently, a Ca'+ -dependent dissociation of the b subunits from the A,B, complex 
occurs. Crystal stmcture analysis of thrombin-cleaved FXllIa suggests that the activation 
peptide still rem~ins attached to the zymogen while still occluding the active-site cavity. To 
get an enzymatically active configuration and exposure of the active-site thiol group, it 
therefore seems necessary that the FXIlla dimer undergoes large confonuational changes 
which are most likely induced by subsu'ate binding (Yee et al. 1996). Biochemical data 
indeed indicate that FXIlla substrates arc regulators of the activation process. For example, 
fibrinogen reduces the Cal+ concentTation required for b subunit dissociation to plasma 
levels, enhances the release of the activation peptide and increases the rate of exposure of 
the active-site thiol (Credo et aJ. 1978, Janus et al. 1983, Hornyak and Shafer 1991). FXIIIa 
contains also a second thrombin cleavage site between Lys513 and Ser514 at the junction 
of the catalytic core domain and barrel I. Thrombin-cleavage at both sites yields the 4-kDa 
activation peptide, a SI-kDa FXllIa core domain polypeptide which has retained its 
catalytic activity, and a 2S-kDa C-terminal peptide (Greenberg et al. 1988, Lai et al. 1994). 
The major source of FXIIla appears to be cells of bone manow origin, being 
megakaryocytes, monocytes and macrophages. Also blood platelets contain large amounts 
of FXIIIa, i.e., 100- to ISO-fold higher than in the sUlTounding plasma, which may have 
been obtained during platelet formation from megakatyocytes. Extrahemopoietic synthesis 
of FXlIIa has been observed in hepatocytes around the central veins in the liver (Adany 
1996, Adany and Antal 1996). Within the cell, FXlIIa is localized in the cytoplasm and 
present in a 11Omodimeric form of two identical a chains (Al)' Activation of intracellular 
FXIlla is supposed to occur by a slow non-proteolytic mechanism without the release of the 
activation peptide (Muszbek et al. 1995). 
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During blood coagulation, fibrinogen molecules are cleaved by thrombin into fibrin 
monomers. This is followed by a self-assembly process by which a loose meshwork of 
hydrogen-bonded fibrin monomers is fOlmed (Mosesson 1992). Activated FXIIla stabilizes 
the blood clot by the fOlmation of intermolecular cross-links between adjacent fibrin chains 
and by cross-linking other plasma proteins to fibrin, such as a,-antiplasmin and fibronectin. 
The final result is a clot with greatly enhanced elasticity and mechanical strength and an 
increased resistance towards degradation by plasmin, the major clot-lysing enzyme 
(Ichinose et a1. 1990, Greenberg et a1. 1991, Mosesson 1992). Patients with impaired fibrin 
cross-linking due to inherited FXIIla deficiency have lifelong bleeding complications, 
which can be life-threathening, and severe problems with wound healing. In early life these 
patients carry a high risk of death from intracanial bleedings. Female patients are unable to 
carry a pregnancy to term and suffer from recurrent abortions. Part of these problems can 
be overcome by FXIII replacement therapy (Fisher et a1. 1966, Kitchens and Newcomb 
1979, Board et a1. 1993, Egbring et a1. 1996). 
3.3.2 Tissue-type 01' cellular TGase (TGcJ 
Enzymatic activities o/TGe 
In contrast to most other TGase family members, TGc is widely expressed throughout the 
body [another exception might be TGx (Thomazy and Fesus 1989)]. TGc is unique in that it 
can display two enzymatic activities, i.e., cross-linking activity and a Mg2+-dependent 
GTPase activity (Lee et a1. 1989, Lai et al. 1996, 1998). Site-directed mutagenesis has 
shown that the active-site cysteine, which is indispensable for TGase activity, is not 
required for GTP hydrolysis activity. TGase and GTPase activity are thus co-ordinated by 
two separate and independent active sites (Lee et a1. 1993). TGc contains a single GTP-
binding site to which the nucleotide can reversibly bind (Achyuthan and Greenberg 1987, 
Bergamini and Signorini 1993). Both the GTP-binding site and the intrinsic GTPase 
activity reside within the N-terminal part of the TGc core domain (Singh et a1. 1995, Lai et 
a1. 1996, lismaa et a1. 1997). Binding of GTP (or Mg-GTP complexed forms) induces 
confolmational changes leading to a strong non-competitive inhibition of TGase activity 
which can be partly reversed by high Calt levels (Achyuthan and Greenberg 1987, Lai et a1. 
1998, Monsonego et a1. 1998). Manipulation of the intracellular Ca'+ and GTP 
concentrations in a physiological setting using permeabilized or intact cells has indeed 
demonstrated that the TGase activity is strictly controlled by these compounds (Smethurst 
and Griffin 1996, Zhang et a1. 1998). In fact, under nonnal physiological GTP 
concentrations, the intrinsic TGase activity is strongly repressed and might even be absent. 
Moreover, induction of TGc expression is not accompanied with a parallel rise in 
intracellular TGase activity, unless the intracellular Ca2+ concentration is increased and 
lowering of the intracellular GTP concentration results in increased TGase activity 
(Smethurst and Griffin 1996, Schittny et a1. 1997, Lai et a1. 1998, Verderio et a1. 1998, 
Zhang et a1. 1998). 
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TOe i1l sigllaltra1lsductioll 
Intriguingly, TGc was found to be implicated in signal transduction. The enzyme has been 
identified as the GTP-binding regulatory protein (G protein), Gah, which is involved in the 
h'ansmembrane h'ansmission of the ligand~bound alB-adrenergic receptor signal to its 
effector enzyme, phospholipase C-ol [PLC-81 (Nakaoka et al. 1994, Feng et al. 1996)]. 
Coupling of TGC/Gah to PLC activates the hydrolysis of membrane-bound inositol 
phopholipids leading to the generation of the second messengers 1,4, 5-triphosphate (IP3) 
and diacylglycerol and subsequent intracellular Ca2+ mobilization and protein kinase C 
activation (for a review on G proteins and TGc, see 1m et al. 1997). Interaction with and 
stimulation of PLC occurs via an eight amino acid region near the C-tenninus of TGc/Gah 
(Hwang et al. 1995). The C-terminal region also mediates its binding to the alB-adrenergic 
receptor (Feng et al. 1999). The function of TGe/Gah in signal transduction is independent 
of its TGase activity (Chen et al. 1996), but its intrinsic GTPase activity is essential. Once 
the receptor is activated, it stimulates TGC/Gah to become GTP-bound and to activate PLC, 
thus meanwhile negatively regulating its intrinsic TOase activity, The intrinsic GTPase 
activity is supposed to be involved in the subsequent deactivation of the signalling pathway, 
i.e., turning the enzyme from a GTP-bound into a GDP-bound state (Nakaoka et al. 1994, 
1m et al. 1997). Besides mediating signal transduction of the alB-adrenergic receptor, 
TGdGah was also found to act in signal transmission of the oxytocin, the thrornboxane and 
the aID-adrenergic receptor to PLC (Baek et al. 1996, Chen et al. 1996, Vezza et al. 1999). 
The oxytocin receptor is also coupled to PLC-81 by TGdGa" (Park et al. 1998). TGdGah 
might therefore appear to be more generally involved in signal transduction pathways by 
coupling receptors to PLC-o 1. 
TOcfimctiollS il1 cellular processes 
It has been difficult to come to a decisive clue on the fil11ction(s) of TGc. It is conceivable 
that a function ofTGc is determined by the relative contribution of its cross-linking activity 
and the receptor mediator function. The enzyme has been implicated in a diverse alTay of 
cellular processes including apoptosis or programmed cell death (Fe sus et al. 1987), cell 
growth and adhesion (Gentile et al. 1992), wound healing (Upchurch et al. 1991 , 
Raghunath et al. 1996), extracellular matrix formation (Aeschlimatlll et al. 1995), and 
axonal growth and regeneration (Eitan and Schwartz 1993, Eitan et al. 1994). Some of the 
functions initially ascribed to its cross-linking activity might need to be reconsidered with 
respect to its actions in the signal transduction pathway. In agreement with the obvions 
functional diversity is that intracellularly TGc can be found in cytosol and plasma 
membrane fractions (Singh and Cerione 1996) as well as in the nucleus (Singh et al. 1995, 
Lesort et al. 1998, Piredda et al. 1999). Although the nuclear-bound TGc may represent 
only a minor fraction of the total amount, i.e., 7% in the neuroblastoma cell line SH-SY5Y 
(Lesort et al. 1998), there is evidence that it is functionally active in the nucleus and thus 
significant. A number of nuclear proteins can be modified by TGc as detemuned for the 
core histones H2A and H2B ill vitro (Ballestar et al. 1996) and for the retinoblastoma gene 
product (pRB) ill vivo (Oliverio et al. 1997). In addition, histone H2B was recently also 
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identified as one out of a few proteins that specifically interact with TGc (Piredda et a1. 
1999) and nuclear TGase activity has been measured in sitl{ (Lesort et a1. 1998). 
TGe and apoptosis 
Although the exact role of TGc in apoptosis is still not fully understood a relation with this 
cell death process is suggested by several ill vitro and in vivo shtdies. Expression of TGc is 
frequently induced in cells which are committed to apoptosis and usually occurs early in the 
apoptotic pathway (for reviews, see Fesus et a1. 1991, Piacentini 1995, Melino and 
Piacentini 1998). Activation of the intrinsic TGase activity is thought to be a late event 
during the effector phase of the apoptotic pathway, once the intracellular Ca2+ level rises. 
This will lead to the assembly of a protein shell or apoptotic envelope by cross-linking 
intracellular proteins (Fe sus et a1. 1989, Knight et a1. 1991), of which the major contributor 
may be cytoplasmic actin (Nemes et a1. 1997, Oliverio et a1. 1997). Ultimately, the highly 
cross-linked protein shells may prevent leakage of intracellular compounds before 
clearance of the dying cells by phagocytosis, resulting in an immunologically silent process 
without inflanunation and thus maintaining the structural integrity of the tissue in which 
apoptosis occurs (Piredda et a1. 1997). In transfection studies, overexpression of TGc in 
distinct cell lines was found to increase their susceptibility towards apoptosis, whereas 
antisense TGc cDNA was reported to repress the apoptotic process (Gentile et a1. 1992, 
Melino et a1. 1994). In this respect it is of particular interest to note the well documented 
influence of retinoic acids on TGc expression, Distinct retinoic acids were found to be able 
to induce both apoptosis and TGc expression in various cell lines, through retinoic acid 
receptor andlor retinoic X receptor signaling pathways (Zhang et al. 1995, Melino et al. 
1997, Joseph et al. 1998). Retinoids were found to regulate TGc expression at the 
transcriptional level probably via a complex retinoid response element in the TGM2 gene 
promoter (Chiocca et al. 1988, Nagy et al. 1996, 1997). 111e effect ofretinoic acids may not 
be confllled to enhancement only ofh'anscription of TCA,f2, but may also include activation 
of pre-existing TGase enzyme (Melino et al. 1994), enhancement of the ability of TGc to 
bind GTP, association with the plasma membrane, and stimulation of phospholipase C 
activity (Singh and Cerione 1996). Experiments with transgenic mice containing 3.8 kb of 
the TGM2 promoter linked to a reporter gene in a retinoie acid receptor-deficient genetic 
background suggest that a direct modulation of TGc expression by retinoids also occurs in 
vivo, These mice showed a decreased transgene expression in the interdigital web of the 
embryonic limb, thus coinciding with a region which is destined to undergo apoptosis, 
Moreover, the lack of retinoic acid receptors in these animals causes a severe and fully 
peneh'ant interdigital webbing which, at least in part, seems to be due to a decrease in cell 
death in the interdigital mesenchym during embryogenesis (Dupe et al. 1999). In line with a 
role of TGc in physiological tissue remodeling by apoptosis during development is that 
genetically normal mice as well as chickens show high expression of the enzyme in the 
interdigital web of the developing limb, but also in morphogically apoptotic myoblasts 
(Nagy et al. 1997, Thomazy and Davies 1999). A close association between increased TGc 
expression and apoptosis has further been shown in several induced and/or physiological 
processes ill vivo, resulting in tissue involution such as lead nitrate-induced hyperplasia of 
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the liver (Fesus et al. 1987), androgen withdrawal from the prostate (Guenette et al. 1994b, 
Rittmaster et al. 1995), forced weaning of the manll1lalY gland (Guenette et al. 1994a, 
Nemes et al. 1996), and post partulll involution of the uterus (Piacentini and Autuori 1994). 
In a number of these studies, TGc was confumed to become activated, as shown by the 
presence of increased levels of 8-(y-glutamyl)lysine isopeptide bonds. 
TOe in cell adhesion and extracellular matrix/ormation 
Several lines of evidence indicate a role of TGc in cell adhesion and extracellular cell 
matrix (ECM) formation. A prerequisite for functioning in ECM fonnation is that the 
enzyme can be expressed on the cell surf.:1ce or secreted into the extracellular space. 
Although the secretOlY pathway for TGc is unclear, the protein has been identified in tllO 
ECM of several tissues, e.g. differentiating cartilage (Aeschlinlallll et al. 1995), lung during 
postnatal development (Schittny et al. 1997), and breast cancer tissues (Hettasch et al. 
1996). Upon deposition of the enzyme in the ECM, TGc will meet optimal conditions for 
its activation (Ca'+ and GTP concentrations high and low, respectively) and many potential 
substrates (Aeschlimann and Paulsson 1994). These include fibronectin, fibrinogen 
(Barsigian et al. 1988), collagen II, osteonectin (Aeschlimann et al. 1993, 1995), collagen V 
and XI (Kleman et al. 1995), and osteopontin (Kaartinen et al. 1997). Binding of TGc to 
fibronectin was found to occur via its most N-tenninul 7 amino acids (Jeong et a1. 1995). 
Proof for an extracellular function comes both from ill vitro and ill vivo studies. 111 vitro 
transfected cells overexpressil1g TGc show an increased adhesion to their substratum 
(Gentile et at. 1992, Jollllson et al. 1994). In conu'ast, antisense u'ansfected cells, expressing 
reduced levels ofTGc, display a decreased adhesion and decreased ability to cross-link the 
fibronectin on which the cells were layered (Jones et al. 1997). ContradictOlY results were 
obtained with stably u'ansfected cells with TGc cDNA under control of an inducible 
promoter which showed no increased adhesion of the cells after TGc induction, although 
extracellular fibronectin cross-linking was increased. This discrepancy might be due to 
endogenous TGc already present in the noninduced cells, or because of clonal selection of 
adhesive cells in case TGc expression is controlled by a constitutive promoter (Verderio et 
at. 1998). Extracellular polymerization of fibronectin by TGc reinforced the attachment of 
cultured human umbilical vein endothelial cells to the subendothelial ECM. Whether this 
was due to direct cross-linking of cell surfhce proteins to the ECM or a higher affinity of 
the cells for cross-linked fibronectin was not determined (Martinez et al. 1994). TGc was 
found to mediate both binding of fibrinogen and fibronectin to the extracellular surface of 
hepatocytes and incOlporation of these proteins into large cross-linked protein complexes 
(Barsigian et al. 1988, 1991). Furthermore, A204 rhabdomyosarcoma cells deposite 
collagen VIXI fibrils, in culture, which appeared to be highly insoluble due to TGc cross-
linking (Kleman et al. 1995).111 viVO, TGc could be co-localized by immunohistochemisu'y 
with 8-(y-gllltamyl)-lysine isopeptide bonds in the ECM of posh lata I maturing lung. TGc is 
intracellularly expressed before birth and becomes externalized and activated 2-3 weeks 
after birth in the period that mature lung parenchyma is fanned. A similar observation was 
made for the fonnation of lung blood vessels and large airways, which precedes 
parenchyma maturation. TOe may thus stabilize remodeling processes and ECMs in the 
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lung (Schittny et a1. 1997), In the same way, sequential expression and activation of TOe 
could be demonstrated in cartilage of maturing trachea and of the hypertrophic zone of long 
bone growth plate (for review, see Aeschlimmm et a1. 1996), TOe is up-regulated in 
hypertrophic cmiilages and externalized upon maturation or terminal differentiation of the 
chondrocytes, respectively, Subsequent cross-linking of matrix proteins may lay the basis 
for mineralization of both tracheal and long bone cartilage which is in the latter case 
succeeded by endochondral ossification (Aeschlimann et a1. 1993, 1995, Thomazy and 
Davies 1999). Post-translational modification by TOe may promote the mineralization 
process by clustering Ca2+-binding proteins (Aeschlimann et a1. 1996), which may occur 
indirectly by changing properties of cartilage mah-ix proteins, as has been shown for 
osteopontin (Kaatiinen et a1. 1999), Cross-linking of osteopontin ill vitro leads to increased 
affinity for several distinct collagens, probably due to conformational changes, Induction of 
protein aggregation, caused by cross-linking or otherwise, and leading to enhanced collagen 
binding ability of phosphoproteins such as osteopontin, might be an essential event in 
matrix maturation and in the mineralization process in cartilage and bone (Kaartinen et a1. 
1999, and references therein), In addition to elevated TOe levels, hypertrophic 
chondrocytes of chicken also express an iucreased FXIlIa level, and the protein becomes 
extet11alized in significant amounts, In fact, FXIIla was shown to represent the major TGase 
type in avian growth region cartilage (Nurminskaya et aL 1998, Thomazy and Davies 
1999), This may implicate that FXIIIa is involved in mammalian bone and cartilage 
fOlmation as well, although so far no clearcut evidence has been obtained for such a role 
(Aeschlimanll et a1. 1996), The expression of TOe in hypertrophic chondrocytes as well as 
in the apoptotic region of the interdigital web can be directed via a 3,8 kb promoter region 
5'-flanking the TGM2 gene (Nagy et aL 1997), TOe may also playa role in skin 
regeneration after transplantation of cultured epithelial autografts by cross-linking of the 
papillary dennis and the denno-epidermal junction (Raghunath et aL 1996), Together, the 
studies described above strongly suggest that TOe can act both in stabilization of the ECM 
and in anchoring cells to their basement membranes, 
Impact of TGe modifications Oil tlze biological jill/ctioll of proteills 
The TOase action of TOe can also modify the biological function of several proteins such 
as osteopontin (as already described above, and Kaartinen et aL 1999), the latent form of 
transforming growth factor-p [TOF-P (Kojima et aL 1993, Nunes et aL 1995)], midkine 
(Mahoney et aL 1996, Kojima et aL 1997), and interleukin-2 [IL-2 (Eitan and Schwartz 
1993)], TOF-P is secreted in a large latent complex consisting ofTOF-p, its propeptide, and 
latent TOF-p-binding proteins (LTBPs), TOe mediates anchoring of the latent complex ill 
the pericellular matrix by cross-linking LTBP-l to ECM components (Taipale et aL 1994, 
Nunes et aL 1997), This may create a pool of large latent TOF-p complexes and/or 
modulate subsequent plasmin activation (Nunes et a1. 1997), In this respect it is interesting 
that TOe expression can be transcriptionally either up- or down-regulated via a TOF-j31 
response element in the TGM2 promoter (Ritter and Davies 1998), Fmihermore, 
dimerizationfmultimel"ization of midkine by TOe cross-linking tums the molecule into a 
better growth-promoting factor for neurons (Mahoney et a1. 1996) and may also be of 
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biological importance in enhancing plasminogen activator activity (Kojima et al. 1997). 
Post-translational dimerization of interleukin-2 (IL-2) converts the molecule into an 
apoptosis-inducing compound for oligodendrocytes (Eitan and Schwartz 1993, Eitan et al. 
1994, Eizenberg et al. 1995). In the absence of cross-linked IL-2, oligodendrocytes smvive 
and inhibit axonal outgrowth after injury. These data are further demonstrated by the fact 
that administration of TOase in injured rat optic nerves leads to recovery of the visual 
response and concunellt appearance ofaxons. These findings may have clinical 
significance, in helping to overcome nerve regeneration blocks that normally occur after 
injmy (Eitan et al. 1994). 
TOc involvemenl ill pathological processes 
TOe might play an important role in a variety of disease processes including cataract 
formation (Lorand and Conrad 1984), pathogenesis of renal (Johnson et al. 1997) and 
hepatic fibrosis (Mirza et al. 1997), celiac disease (Dieterich et al. 1997, Molberg et al. 
1998, van de Wal et al. 1998), and many neurodegenerative diseases (for reviews, see 
Lorand 1996, Cooper et al. 1999). Celiac disease patients have severe damage of the small 
intestine which is initiated by the ingestion of gluten. Recently, it has been demonstrated 
that these patients developed auto-antibodies against TGe, in addition to antibodies against 
gliadin, a component of wheat gluten (Dieterich et al. 1997, Marsh 1997). TGe expression 
is increased in affected tissues and TGe could change the antigenic properties of gliadin by 
deamidation of selective glutamines (Q to E conversion, Figure 2D). Selective deamidatiol1 
was found to generate an epitope that eftlciently binds and stimulates gliadin-specific T 
cells. Altogether, these data suggest that TGe plays a central role in the pathogenesis of 
celiac disease (Molberg et al. 1998, van de Wal et al. 1998). TGe is suggested to be 
involved in the pathologic proteinaceous aggregate formation in several diseases of the 
central nervous system. These include Alzheimer's disease and neurodegellerative diseases 
caused by proteins containing expanded polyglutamine sh'etches such as Huntington's 
disease (for reviews, see Lorand 1996, Cooper et al. 1999). In the latter group of disorders 
there is a close association between the length of the polyglutamine domain and disease 
occunence. In vitro studies have shown that an increased polyglutamine sequence improves 
the TGe substrate properties of a protein, supporting a role of TGe in these diseases 
(Kahlem et al. 1996, 1998). However, for all ultimate proof of TGase involvement in these 
diseases, the ill vivo existence of the E-(y-glutamyl)lysine isopeptide bound has to be 
demonstrated in the affected brain regions or deposits (Lorand 1996). 
No disorders have been described for which inherited or acquired TGc mutations are 
causative to give additional information on the function of TOe. Important clues on the 
physiological role of TGe in development and adult life may ultimately come from studies 
of TGM2 knockout mice which are now in progress (Melino and Piacentini 1998). 
3.3.3 Keralil/ocyle TGase (TGJJ 
TOK is primarily expressed in sh'atified squamous epithelia. In skin, TGK is present 
throughout the entire epidermis, including the basal layer, but predominantly in the granular 
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layer beneath the stratum corneum. TGK hns been found to be upregulated both at the 
mRNA and protein level at the time keratinocytes differentiate (Thacher and Rice 1985, 
Kim et al. 1995b, Steinert et al. 1996a). It is the predominant and most extensively studied 
TGase in keratinocytes, but these cells also express TOe) TOE and TGx (111acher and Rice 
1985, Kim et al. 1995a, Aeschlimann et al. 1998). TGc seems not essential for epidennal 
differentiation since it is mainly expressed in the basal cells and is down regulated during 
differentiation (Floyd and Jetten 1989, Kim et al. 1995a), Therefore, its putative functions 
in the skin will not be discussed. Some data on TOE and TGx in keratinocyte differentiation 
are presented in the next sections. 
During skin formation, epidermal keratinocytes differentiate into a barrier of cornified cells 
which protects the organism against pathogens, chemical and physical insults. The skin is 
also essential for an optimal fluid balance of the organism (for reviews, see Roop 1995, 
Eckert et al. 1997, Melina et al. 1998). TGases are indispensable for the final stages of skin 
differentiation, particularly in the formation and assembly of the comified cell envelope 
(CE), a 15-nm thick layer of insoluble protein deposited just inside the cell periphery 
(Thacher and Rice 1985, Rice et al. 1992, Melina et al. 1998). Terminal differentiation of 
the keratinocytes and CE formation can be considered as a specialized form of apoptosis 
(Melina et al. 1998). The CE consists of an array of proteins which are covalently 
connected through TGase cross-links. These include the major CE protein loricrin as well 
as elafin, filaggrin, involucrin, keratin intennediate filaments and small proline-rich 
proteins 1 and 2 (SPRI and 2). Both intrachain cross-links of loricrill and interchain cross-
links of loricrins between themselves or with the other proteins have been found. SPRs are 
suggested to be primarily cross-bridging proteins by mediating links between epidermal 
proteins resulting in e.g. loricrin-SPRI-ioricrin or loricrin-SPRI-keratill I complexes. 
Formation of cross-links in the CE are supposed to occur in a sequential order and only a 
limited number of glutamine and lysine residues within a given substrate might be of 
particular importance (Steinert and Marekov 1995, Candi et al. 1998b, Steinert et al. 1998, 
Tarcsa et al. 1998). 
The importance of TGK in skin differentiation has become clear in patients with autosomal 
recessive lamellar ichtyosis (LI). LI is a severe congenital disease representing a 
phenotypically and genetically heterogeneous group of keratinization disorders that are 
characterized by an abnormally increased thickness of the sh'atul11 comeUlll or 
hyperkeratosis, generalized large scales, and reddened skin. Newborns with this disease are 
often encased in a tough and inelastic membrane that breaks easily, resulting in a high risk 
of sepsis and dehydration. Linkage studies and rOAJJ analysis have s11O\vn that a subgroup 
of LI patients have inherited mutations in this gene causing decrease or absence of TGK 
activity (Huber et al. 1995, Parmentier et al. 1995, Russell et al. 1995) and unability to form 
cross-linked envelopes (Jean et al. 1998). Transgenic TGM1-null mice have identical 
symptoms which substantiate the findings in LI patients. At birth, these mice have an 
erythematous and shiny skin with abnormal keratinization and defective cell envelope 
assembly. Although the mice survive pregnane)" they die within several hours after birth 
due to dehydration (Matsuki et al. 1998). 
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TGK is acylated at its amino-terminus by myristate and palmitate, through which most of 
the enzyme is attached to the inner surface of the keratinocyte plasma membrane 
(Chalaavarty and Rice 1989, Steinert ct aJ. 1996b). Only a small proportion of the enzyme 
is present in the cytosol fraction. TIle intact 106-leDa (zymogenic) form ofTGK displays a 
low specific activity. After proteolytical processing during terminal keratinocyte 
differentiation the specific activity ofTGK increases up to 200-fold. Although cleaved, the 
enzyme remains mainly membrane-bound as a 67/33/10-kDa complex by means of 
secondaty interactions via the acylated amino-terminal lO-kDa membrane anchorage 
fragment (Kim et aJ. 1995a, Steinert et aJ. 1996a). The cleavage positions were found to 
coincide with the thrombin cleavage sites of FXIIIa, i.e, at the junction of the membrane 
anchorage domain and the B-sandwich and at the junction of the catalytic core domain and 
banel I. The 67- kDa fragment encompasses the core domain. Although the major TGK 
activity resides in the processed 6713311O-kDa complex, the core domain alone displays 
TGase activity (like FXIIla) even at a higher level than the 106-leDa zymogen (Kim et aJ. 
1994b, 1995a, Candi et aJ. 1998a). 
3.3.4 Epif/el'/J/al TGase (TG,j 
Apart from hair follicle cells, the terminal differentiating epidermis is the principal tissue in 
which TGE is expressed. Like TGK• TGE expression is induced during keratinocyte 
differentiation, although mRNA and protein levels are much lower (Kim et aJ. 1995a). It is 
a pro-enzyme that requires proteolytic activation by cleavage in a flexible hinge region 
located between the predicted core domain and barrel I which is in the same region as 
described for the second cleavage site for FXlIIa and TGK• This results in a 50-leDa, still 
catalytically active, fragment containing the active center and a C-tenninal 27-kDa 
fragment (Kim et a!. 1990, 1993). Contrary to TGK , TGE is a cytosolic enzyme and appears 
to occur only in the granular epidennallayer (Kim et a!. 1990, PolakolVska et a!. 1994). 
TGE is believed to be essential for CE assembly. No diseases have been associated with a 
TGE deficiency or defect which makes it more difficult to address its specific function in 
skin fomlUtion. It is obvious from the phenotype of LI and the TGM I-null mice that TGE 
cannot replace or compensate for the lack of cross-links usually performed by TGK. TGE 
and TGK may therefore cross-link in a complementmy manner in CE formation. This is 
supported by the fact that both enzymes possess distinct preferences for glutamine and 
lysine residues within the same substrates as has been observed for loricrill, SPRI and 
SPR2. From ill vitro cross-linking assays performed with these substrates, it has been 
proposed that TGE is primarily responsible for intrachain cross-linking of loricrin and for 
initial cross-linking of loricrin and SPRs together or of loricrin alone to form small 
interchain oligomers. Large polymeric stmchues only occur after further cross-linking by 
TGK• Interchain polymerization may direct the oligomers from the cytoplasm to the cell 
periphe1y and anchor them into the developing CEo Such a model is consistent with the 
phenotypes seen in cases ofTGK deficiency (Candi et a!. 1995, 1999, Matsuki et al. 1998, 
Tarcsa et al. 1998). Because there are many substrates known to be cross-linked ill vivo in 
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the eE, the final picture is expected to be very complex. For a recent review on protein 
cross-links in the CE and the involvement of TOE and TOK therein, see Melino et a1. 1998. 
Ca'+ is required for full catalytic activity of TOE and TOK• Interestingly, the Ca2+ 
conceno'ation in the epidermis is higher in the supra basal layers than in the basal layer. 
During the final stages of skin differentiation, the keratinocyte plasma membrane becomes 
permeabilized, resulting in increased cytosolic Ca2+ concentrations. 111is change, together 
with increased TGE and TGK expression levels and Ca2+ dependent activation of proteases, 
may lead to a substantial increase of TGase activity and cross-linking reactions at final 
stages ofkeratinocyte differentiation (TIlacher and Rice 1985, Eckert et a1. 1997). 
3.3.5 TGx 
TOx is only recently discovered and therefore little data are available at present 
(AeschlimaIUl et a1. 1998). It has been identified by means of RT-PCR on human 
keratinocyte mRNA with degenerated primers deduced from the active-site region. TI,e 
enzyme is expressed in the keratinocytes at a slightly higher level than TOe and is, like TOE 
and TOK, induced during keratinocyte differentiation. In addition to TOE and TOK, TOx 
might therefore participate in the fOImation of the cornified cell envelope. TOx expression 
is, however, not restricted to keratinocytes and hence may fUIlction in other tissues as well. 
3.3.6 BUild 4.2 
Band 4.2 is one of the major constituents of erythrocyte membranes, where it comprises 
about 5% of the total protein mass (for reviews, see Cohen et a1. 1993, Yawata 1994b). 
There are contradictory data conceming its expression in nonerythroid tissues. By 
immunohistochemistry as well as Northern blotting, expression was found in kidney, heart, 
brain and liver (White et a1. 1992, Cohen et al. 1993). However, in a recent study in mice, 
using Northern blot analysis and ill situ hybridization, band 4.2 was found to be restricted to 
cells of the erythroid lineages in adult spleen and bone marrow. The embryonal liver was 
found to express band 4.2 during the period that erythropoiesis occurs in this organ. In fact, 
these authors found a complete temporal coincidence of band 4.2 expression and 
erythropoiesis during emblyogenesis and after birth, Le., embtyonal expression in the yolk 
sac (E7.5-E11.5 days) is followed by synthesis in the liver (EI2,5-16.5), and around and 
after birth, expression is fully taken over by spleen and bone marrow (Zhu et al. 1998). 
Although the exact function of band 4.2 remains to be established, several data point 
towards a role in maintaining the shape and stability of erythrocytes (Cohen et al. 1993, 
Yawata 1994b). Band 4.2 is myristylated at its N-terminal glycine by which it might 
become associated to other proteins or the erythrocyte membrane (Risinger et a1. 1992). 
The protein is firmly associated with the cytoplasmic domain of the major integral 
erythrocyte membrane protein and anion exchanger band 3. In addition, binding to the 
erythrocyte membrane skeletal proteins ankyrin, band 4.1 and spectrin was described 
(Cohen et al. 1993, Rybicki et a1. 1995, Oolan et a1. 1996). Biophysical studies suggest that 
band 4.2 serves as an accessory linking protein to strengthen the interaction between band 3 
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and the cytoskeletalnetwork (Oolan et at. 1996, Rybicki et at. 1996). In accordance with a 
function in stabilization of the membrane skeleton of erythrocytes, band 4.2 deficiencies are 
associated with mild to intermittently severe hemolytic anemia. In these cases, erythrocytes 
have abnormal shapes and may have an increased osmotic fragility, possibly due to 
membrane skeletal instability or to weakening of cytoskeleton-membrane associations. 
Band 4.2 deficiencies can be inherited via mutations in the conesponding gene, but may 
also occur as a secondary effect due to defects in other erythrocyte proteins, e.g band 3 
(Cohen et at. 1993, Yawata 1994a, 1994b). 
3.3.7 Prostate-specific TGase (ilTGp) 
Rodent TOp has been described as early as 1896 by Oamus and Oley (see Aumuller and 
Seitz 1990), and thus is the longest ktlO\Vn TOase. Most research has been done so far on 
rat TOp or dorsal protein 1 (DP1). Much less is known on its human analogue hTOp since in 
fact evidence for its presence has only been obtained a few years ago by the demonstrated 
cross-reactivity of an anti-DPI antisennll with human seminal plasma (Enderle-Sclilllitt et 
at. 1989, AUll1uller and Seitz 1990) and the isolation of its cOlTesponding cDNA (Orant et 
at. 1994, Dubbink et at. 1996). In an earlier study, TOase activity had already been detected 
in seminal plasma (Porta et al. 1986) which was most probably due to hTOp (Dubbink et at. 
1999b). Because DPI and hTOp have been discussed above in relation to tllCir possible 
functions in reproductive biology, only some additional information 011 DPl will be 
presented here. 
rTOp/DP 1 is highly glycosylated and possesses a complex lipid anchor that is retained 
during secretion. Close examination of the lipid and sugar components of the lipid anchor 
suggest that it might be a glycosylphosphatidylinositol-like shucture [OPI-anchor (Seitz et 
al. 1991a, Esposito et at. 1996)]. The function of this OPI-anchor is unclear so far, but there 
is some evidence that it protects the enzyme from autocatalytic self-aggregation (Seitz et al. 
1991a, Steinhoffet at. 1994).lt has also been hypothesized that it might anchor the enzyme 
to the spenn surface (Esposito et at. 1996). Like other TOases, DPI is Ca2+-dependent even 
though it requires significantly less Ca2+ for optimal activation than other TGases (Seitz et 
a1. 1991a). Furthermore, in in vitro experiments the enzyme is strongly activated by sodium 
dodecyl sulfate (SDS) and a Variety of phosphatidic acids (Esposito et at. 1996). It is 
therefore tempting to speculate that DPI activity becomes enhanced after limited 
proteolysis, like is described for TOK (see above). Immunohistochemical studies have 
demonsh'ated DP 1 in apical blebs of the dorsal prostate and coagulating gland epithelium, 
suggesting that it is released via the apocrine pathway (Seitz et al. 1990, Steinhoff et at. 
1994, and see above). Secretion ofDPl is a rapid process that occurs within 40 min after its 
synthesis and may not involve the Golgi apparatus, whereas another abundant prostate 
secretory protein (DP2) requires more than 8 h while following a traject through the Oolgi 
apparatus (Bartlett et at. 1984, Oroos et al. 1999). Several ill vivo studies with rats have 
shown that DP 1 synthesis is androgen-dependent. DP I expression is down-regulated, in 
both dorsal prostate and coagulating gland, by castration, and subsequent re~addition of 
androgen restores the expression level back to normal (Wilson and French 1980, Bartlett et 
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at. 1984, Ho et at. 1992). In explant cultures of rat prostatic tissues, DP I expression can be 
induced by a broad panel of natural and synthetic androgens, which is blocked by 
simultaneous incubation with anti-androgen, whereas in the absence of honnone no 
expression could be observed (Lopes et at. 1996). Androgen regulation is thought to occur 
via stabilization of the DPI mRNA transcript through decreasing its degradation rate and 
prolonging its half-life (Ho et at. 1992). The expression of DPI in the dorsal prostate is age-
dependent since only few cells express the enzyme 12 days atier birth while the number of 
DP I-positive cells substantially increase during day 13 and 14. The tlrst appearance of DP I 
ill the coagulating gland is one day later but further follows the same induction pattern 
(Lopes et at. 1996). 
4 Scope of this thesis 
At the start of the study presented in this thesis, it was hypothesized that the human prostate 
could express at least two TGases, TGe and the human analogue of rTGp/DP!. To obtain 
evidence for the presence of human TOp and to be able to discriminate between these two 
TGases in future experiments, we set out to identify the corresponding hTGp eDNA 
(Chapter 2). During the course of the project, the research was focussed on increasing our 
knowledge of the expression and function of hTGp• 
Cloning of hTGp eDNA was achieved based upon the known high identities in the catalytic 
core domains of human TGases, The isolation of hTGp cDNA formed the basis for all the 
other experiments described in this thesis: characterization of the TG1H4 gene and promoter 
stmcture (Chapter 3), functional analysis of the promoter (Chapters 3 and 4), development 
of antisera against the hTGp C-tennillus, which were used to evaluate the expression of the 
hTGp protein in human tissues and body fluids (Chapter 5), and demonstration of the 
prostate-specific expression of the enzyme by both Northern blotting and 
immunohistochemical staining (Chapters 2, 3, and 5). Research has been done to study if 
hTGp could serve as a prostate tumor marker (Chapter 5) and if sequence determinants 
could be identified that are responsible for the regulation of its (prostate-specitlc) 
expression (Chapter 4). 
Insight into the expression and regulation of hTGp may add in understanding prostate 
function and dysfunction. 
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Abstract 
Transglutaminases (TGases) are calcium-dependent enzymes catalysing the post-
h"anslational cross-linking of proteins. In the prostate at least two TGases are present) the 
ubiquitously expressed tissue-type TGase (TGc), and a prostate-restricted TGase, (TGp). 
This paper deals with the molecular cloning and characterization of the eDNA encoding the 
human prostate TGase (hTGp). For this pmpose we have screened a human prostate cDNA 
library with a probe from the active-site region of TGc. The largest isolated cDNA 
contained an open reading frame encoding a protein of 684 amino acids with a predicted 
molecular mass of77 kDa as confinned by ill vitro transcription-translation and subsequent 
SDSIPAGE. The hTGp gene was tissue-specifically expressed in the prostate, yielding an 
mRNA of approx. 3.5 kb. Furthermore, a 3-fold androgen-induced up-regulation of hTGp 
mRNA expression has been demonstrated in the recently developed human prostate cancer 
cell line, PC346C. Other well established human prostate cancer cell lines, LNCaP and PC-
3, showed no detectable hTGp mRNA expression on a Northern blot. The gene coding for 
prostate TGase was assigned to chromosome 3. 
Introduction 
Transglutaminases (TGases, EC 2.3.2.13) are calcium-dependent enzymes that catalyse the 
acyl transfer reaction between peptide-bound glutamine residues and primary amine 
groups. This reaction results in the post-translational modification of proteins either by the 
incorporation of amines (such as polyumines) into proteins or by the cross-linking of 
proteins if the amine is a peptide-bound lysine. The cross-links are resistant to proteolytic 
enzyme degradation and thus contribute to the formation of highly insoluble 
macromolecules, which can be catabolized only by proteolysis of the protein chains 
(Greenberg et al. 1991, Aeschlimann and Paulsson 1994). 
Products of the enzymatic actions of TGases can be found in most tissues (Thomazy and 
Fesus 1989) and body fluids (Williams-Ashman 1984, Romijn 1990, AeschlimalUl and 
Paulsson 1994). A number of different TGases, with different stmctural properties and 
cellular origin, account for the formation of such reaction products, Well documented 
examples of TGases are plasma factor XlIla (lehinose et al. 1990), keratinocyte TGase 
[TGK (Kim et al. 1991, Rice et al. 1992)], epidermal TGase [TGE (Kim et al. 1993)], tissue-
type or cellular TGase [TGc (Gentile et al. 1991, 1992)] and prostatic TGase [TGp 
(Williams-Ashman 1984, Seitz and Aumuller 1990, Seitz et al. 1991a, Ho et al. 1992)]. 
While the physiological fimctions of factor XIIIa (blood clotting), TGE and TGK (squamous 
differentiation of the epidermis by formation of cornified cell envelopes) are evident, the 
roles of TGc and TGp are less well established. The ubiquitously expressed TGc was 
suggested to be involved in processes associated with cell growth regulation, differentiation 
and programmed cell death (el Alaoui et al. 1992, Fesus 1993, Johnson et al. 1994). TI,is 
enzyme may take part in such diverse events as apoptotic body formation (TIlOmazy and 
Fesus 1989, Knight et al. 1990, Fesus et al. 1991, Piacentini et al. 1992), extracellular 
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matrix stabilization (Thomazy and Fesus 1989, Knight et a!. 1990, Fesus et a!. 1991, 
Piacentini et a!. 1992, Aeschlimarm et a!. 1993, Aeschlimann and Paulsson 1994) and 
signal transduction (Nakaoka et a!. 1994). TGp was, until very recently, demonstrated only 
in rodents. In these animals, the enzyme is involved in the formation of copulatOlY plugs in 
the female genital tract after coitus (Williams-Ashman 1984), and may playa role in 
masking the antigenic.ity of the male gamete, thereby suppressing an inllllUne response in 
the female genital tract against the sperm cells (Mukherjee et a!. 1983, Paonessa et a!. 
1984). Isolation of the cDNA encoding rat prostate TGase (rTGp) happened to be achieved 
when Ho et a!. (1992) attempted to clone the gene for DPI, an abundantly expressed rat 
dorsal prostate protein. DP I occurred only in the dorsal rat prostate and the coagulating 
gland, where it comprised up to 25% of the total cellular protein, and its expression was 
found to be higher in intact than in castrated animals (Ho et a!. 1992). 
Also in the human prostate two types of TGases (TGe and TGp) might potentially be 
expressed, To isolate the human TGase similar to the rat DPI enzyme, we have searched 
for human TGp (hTGp) cDNA clones in a human prostate cDNA librmy. Here we present 
the molecular cloning and characterization of hTGp cDNA. In addition, this paper deals 
with chromosome assiglIDlent, organ specificity of hTGp expression and androgenic 
regulation of hTGp in human prostate cancer cells. 
Materials and Methods 
Cell culture 
LNCaP (Horoszewicz et at. 1983) and PC-3 (Kaighn et a!. 1979) cells were cultured in 
RPMI medium supplemented with 7.5% (v/v) fetal-calf semm (FCS) and antibiotics. The 
PC346C cell line was recently established in our laboratory (Romijn et a!. 1995). Cells 
were cultured in a Dulbecco's modified Eagle's medium (DMEM)1F12-based growth 
medium (GIBCO, Grand Island, NY, U.S.A.), essentially as described by Limon et a!. 
(1990), but dihydrotestosterone was replaced by the synthetic androgen RI881 (NEN, 
Boston, MA, U.S.A.) and with further supplementation of 2% (v/v) FCS. The growth of 
PC346C cells was stimulated by androgens (Romijn et a!. 1995). To study androgen 
regulation of gene expression, the cells were cultnred in the absence and presence of 0.1 
nM RI881 in growth medium containing dextran-charcoal treated (DCC) senUll. The cells 
were harvested from near confluent cultures (after 7 days for LNCaP and 10 days for 
PC346C), aud subjected to RNA isolation as described below. 
Screening of a human prostate cDNA librmy 
For the isolation of hTGp eDNA, au oligo(dT) and random-primed ,-gtll human prostate 
eDNA library (Clontech, Palo Alto, CA, U.S.A.) was screened with a random "P-Iabelled 
380 bp probe from the active-site region of TGe. This probe was obtained by PCR 
amplification with primer TRAGLU I and TRAGLU 2 (for list of primers, see Table I) of 
this area from pSG5.hTG, a plasmid containing the entire cDNA sequence of human TGc, 
which was kindly provided by Dr. PJA. Davies (Gentile et a!. 1992). 
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Table 1. Oligonucleotides used for isolation of eDNA clones and chromosomallocalizatioll of the hTGr 
gene. 
Primer Name Sequence <J." Length Orientation Source Position 
),GTI Lfar' 5'-GGTGGCGACGACTCCTGGAGCC-3' 22-mcr sense WTlI 
/,GTll.rc\' ( 5'-GACACCAGACCAACTGGT AA TG-3' 22-mer anti-sense WTlI 
TRAGLlJ I 5'-TMTTGGCCAGTGCTGGGTlT-3' 19-mer sense TOe 955 - 973 
TRAGLlJ2 5'-TTCfGACCTCC!GGTGAAGfCACGA-3' 19-mer anti-sense TOc 1328 - 1310 
TRAGLlJRI j'-GCTITGGCCAGTGCTGGGTT-J' 20-mer sense RaIDP! 820 - 839 
TRAGLlJ R2 5'-CACCTCCGTGAACACAAATGT-3' 21-mer anli-sense RatDPI 1196-1176 
HPSTG I 5'-CTCA TTCACAT AGGTGTCCAC-3' 21-mcr anti-sense hTGp 974 - 954 
HPSTG2 5'-TCATAGCACACATGGCCCT-3' 19-111cr anti-sense hTGp 702 - 684 
II The primers were designed from their corresponding mRNA sequences as reported by Gentile ct al. 1991 
(TRAGLU I and TRAGLlJ 2), by Ho cl aJ. 1992 (TRAGLlJ RI and TRAGLlJ R2), and in this paper 
(HPSTG I and HPSTG 2) 
"TRAGLU I and TRAGLU 2 are degenerated primers as is indicated by a slash. 
C AGTIl.for and ),GTJ I.rev represent the flanking I,GT! I primers used for peR. 
Hybond-N+ filters (Amersham, Aylesbury, Bucks, U.K.) were prehybridized with 100 
ftg/ml denatured salmon spem1 DNA in poly(ethylene glycol) (PEG)-hybridization mix, 
composed of 0.25 M Na2HPO,.2H20 (pH7.2), 0.25 M NaCI, 7% (w/v) SDS, 10% PEG 
6000 and I mM EDTA, for 2 h. Hybridizations were carried out overnight at 50°C, 
followed by two washes with 2 x SSC/O.I % SDS and two washes with I x SSC/O.I % SDS, 
each for 15 min at 50°C. \Vashed blots were covered \vith plastic film and exposed to RX 
medical X-ray film (Fuji) with intensifying screen for 4 days at -80°C. 
Positive plaques were picked up and rescreened at least twice until the selected plaques 
were completely purified. The inserts of these clones were amplified by PCR (see below), 
and directly sequenced with primer TRAGLU R2 (Table I). The selected phage clone was 
purified and treated as described below under 'DNA sequencing'. Since this procedure 
resulted in the isolation of a clone containing only pari of the hTGp cDNA sequence (see 
the Results section), a 2.2 kb Sac I-Hpa I fragment of this clone was used as a probe to 
rescreen the same cDNA librmy under more stringent conditions with the purpose of 
isolating the entire hTGp cDNA. Hybridizations and washes were performed at 65°C in 
stead of 50°C. Selected recombinant phage clones were purified and treated as described 
below. 
peR amplification and primer removal 
PCR amplifications of phage suspension aliquots, or of isolated DNA, were perfOlmed with 
superTaq polymerase (Sphaero Q, HT Biotechnology, U.K.) in the presence of 100 ng of 
each primer. All samples were first denatured at 94°C for 5 min. Amplification followed in 
35 cycles of 94°C, 1 min; 55°C, 1 min; 72°C, 2 min; and a final extension at 72°C for 10 
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min. peR products were analysed by agarose gel electrophoresis. If necessary, primers 
were removed with the QIAquick PCR purification kit (Qiagen, Hilden, Gemmny). 
DNA sequencing 
DNA was isolated from the selected and purified recombinant phage clones following 
standard procedures (Sambrook et aL 1989) and the cDNA fragments were subcloned into 
the EcoRI site ofpGEM-7Zf(+) (Promega, Madison, WI, U.S.A.) for sequencing. Plasmid 
isolations were perfonned with a Qiagen plasmid kit. Double-stranded DNA sequence 
analysis was perfol1ncd by dideoxy nucleotide chain tennination using a T7 sequencing kit 
(Pharmacia, LKB Biotech, Uppsala, Sweden). Oligonucleotide primers used for walking 
primer sequencing were designed and synthesized on the basis of the obtained sequences 
(Phannacia). 
III vitro transcription-translation ofltTGp and TOe eDNA 
For in vitl'o transcription-translation studies the entire open reading frame of hTGp cDNA 
was subc10ned into the eukaryotic expression vector pcDNA3 (Invitrogen Corporation, San 
Diego, CA, U.S.A.). For comparison the entire 3.3 kb cDNA for TGc (Gentile et aL 1992) 
was subcloned into the EcoRI site of pcDNA3 (pcDNA3-TGcl. An empty pcDNA3 vector 
was used as a negative control. Subsequently, a one hlbe, coupled transcription-translation 
was performed with the TNT" coupled reticulocyte lysate system from Promega using the 
T7 RNA promoter present in pcDNA3 for ill vitro transcription of sense RNA. The 
reactions were perfomled on 1 fIg of circular template DNA in a final volume of 25 ftl 
according to the manufacturerts protocol. TIle transcription-translation was carried out at 
30'C for 90 min in the presence of 35S-labelled methionine (Amersham). Labelled products 
were separated by SDS/IO%-PAGE. The gel was dried and the synthesized proteins were 
visualized by exposure to RX medical X-ray film (Fuji) for 4 h. Prestained markers 
(Novex, San Diego, CA, U.S.A.) were used as size standards. 
Northerll Hybl'idizati01I 
Isolation of total RNA was carried out by the guanidine isothiocyanate/cesium chloride 
centrifugation method (Sambrook et al. 1989). Total RNA (20 ftg) was electrophoresed ill a 
1 % agarose formaldehyde gel and h'ansferred to Hybond-N+. RNA was fixed to the 
membrane by UV cross-linking. The blot was hybridized overnight at 60'C with the 2.2 kb 
probe mentioned above in hybridization mix composed of 0,5 M Na,HP04.2H,O (pH7.2), 
7% SDS, 1% BSA, and 1 mM EDTA. The fInal wash step was in 0.3 x SSCIO.I% SDS at 
60'C for 30 min. The blot was exposed to RX medical X-ray film (Fnji) with intensifying 
screen for 4 days at -80'C. The signals were qnantifIed on a Phosphorlmager (Molecular 
Dynamics, Sunnyvale, CA, U.S.A,). 
A human mUltiple-tissue Northern blot (MTN II, Clontech) was used to detelmine the 
tissue specificity of hTGp expression. Hybridization was performed with the same eDNA 
fragment as above using conditions recommended by the manufacturer. Washes were 
perfomled under high sh'ingency conditions (up to 0,1 x SSCIO,I% SDS at 63'C for 30 
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min). The integrity of the blotted RNA was determined by hybridization with human p-
actin cDNA. 
Chromosolllallocalization of the gene encoding hTGp 
A human/hamster-human/mouse somatic cell hybrid panel (BIOS Research Laboratories, 
New Haven, CT, U.S.A.) was screened by PCR analysis with the HPSTOI-TRAOLU RI 
primer set (Table I). PCR reactions were performed on 50 ng of somatic cell hybrid DNAs 
as described above. An annealing temperature of 60°C was used. The resulting products 
were analysed by agarose gel electrophoresis. The specificity of the reaction products was 
confirmed by blotting and subsequent hybridization with a 32p random-labelled 2.2 kb Sac 
I-Hpa I hTOp fragment. Hybridization and washes were as described above for Northern 
hybridization. 
Results 
Isolation of eDNA clones 
Screening under low-stringency conditions of approx. 1.2 x 10' p.f.u. of a 1cgtll human 
prostate cDNA library with a 380 bp fragment from the active-site region of TOe, yielded 
nine positive clones. Partial sequence analysis with primer TRAOLU R2 (Table I) in the 
vicinity of the active site revealed that one clone (4.2) had high sequence similarity to rat 
DPI (Ho et al. 1992). The insert size was approx. 2.8 kb. The other clones appeared to be 
parts of TGc cDNA. Sequence analysis of the entire insert of clone 4.2 showed an open 
reading frame encoding a protein of 574 amino acids. Comparison with the amino acid 
sequences of other TGases, suggested that part of the 5' end of hTOp cDNA was missing, 
probably due to a cloning artefact. To obtain further cDNA infOimation, the same prostate 
cDNA library was rescreened under high stringency conditions with the 2.2 kb Sac I-Hpa I 
fragment from clone 4.2 (see Figure I for restriction map). This resulted in a large number 
of positive plaques (about 500) of which 24 were isolated. As our main interest concerned 
the 5' end of the hTGp cDNA, a further selection was made by PCR with combinations of 
primer HPSTG 1 or HPSTG 2 and one of the flanking 1cGT11 primers. In this way, three 
overlapping clones, clone 1.8, 1.12 and 1.17, were selected with inserts varying from 2.4 kb 
to 3.3 kb. TIle relative positions of the cDNAs of these clones are shown in Figure 1. EcoRl 
fragments of the tlu'ee clones were sequenced. Whereas clone 4.2 appeared to lack a coding 
region for 130 amino acids at its Nwtenninus, both clone 1.8 and clone 1.17 contained the 
entire open reading frame of hTGp cDNA. Further analysis showed a number of cloning 
aliefacts (see Figure I). Clone 1.17 contained amplifications of central parts of the hTGp 
cDNA sequence at its 5' and 3' terminal ends, and 1.12 appeared to have a 5' nucleotide 
stretch similar to that of clone 4.2 but situated more to the 5'-end. 
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Figure 1. Restriction map and relative positions of eDNA clones for hTGp, Black bars represent coding 
regions. Cloning artefacts are indicated by broken black bars. Clone 4.2 and 1.12 contained at their 5' ends 
the same artificial nucleotide sequence but at different positions. Clone 1.I7 contained amplifications of 
central paris of the hTGp eDNA at its terminal ends. Clone 1.8 had only three nucleotides in front of its start 
cadons. 
eDNA sequellee ofhTGp 
Figure 2 shows the composite nucleotide sequence of the hTGp cDNA as well as its 
deduced amino acid sequence. Its total length is 2983 bp with an open reading frame that 
conesponds to a protein of 684 amino acids with a predicted molecular mass of 77 kDa and 
a pI of6.94. 
Two start co dons are present at the beginning of the open reading frame, preceded by an in-
frame stop codon. Which one of the start codons is used for translational start cannot be 
deduced from the sequence. However, the DNA sequence surrounding the second 
methionine agrees well with the Kozak consensus sequence (Kozak 1994) with an A at 
position -3 and a G in position +4 (as the A of the ATG codon is designated +I). The 3' 
non-coding region of hTGp cDNA contains the variant polyadenylation signal, A IT AAA 
[Figure 2 (Wickens 1990). 
The active-site amino acid sequence GQCWVF (residues 266-271) is present, suggesting 
that the clone encodes for an active TGase. Also other amino acids recently shown to be 
cmcial for catalytic activity of TGases, but not part of the active centre, are present. These 
amino acids, Arg-37 (R), Arg-38 (R) [Huber et a!. 1995, Russell et a!. 1995], His-296 (H), 
His-327 (H) and Asp-350 (D) [Hettasch and Greenberg 1994], occur in all human TGases. 
The amino acid sequence shows no typical Ca"-binding site-motif, like an EF-hand 
stmcture, but two regions enriched with acidic residues (residues 144-154 and 433-453) 
may reflect Ca"-binding sites. In addition, the putative hTGp protein has seven potential N-
glycosylation sites (sites are indicated in Figure 2). 
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AGAGATAGAGTCTTCCCTGGCATTGCAGGAGAGAATCTGAAGGG ATG ATG GAT GCA 56 
• l>lNDA 4 
TCA AAA GAG eTG eM GTT eTC CAC ATT GAC rTC TTG MY CAG GAC Me Gee GrT 110 
S K E L Q v L HID F L N Q 0 N A V 22 
TeT CAe CAe ACA TGG GAG rTe eM ACG AGe AGT ceT GTG rTC eGG eGA GGA CAG 164 
S II H THE F Q T SSP V F R R G Q 40 
GTG TTT CAe eTG eGG erG GTG eTG Me CAG eec eTA eM Tce TAe CAe eM eTG 218 
v F H L R L V L N Q P L Q S Y Il Q L 58 
AM eTG GAA rTC AGe ACA GGG eeG MT ceT AGe ATC Gee AM CAe Ace eTG GTG 272 
K L E F S T G P N PSI A K H T L V 76 
GTG eTC GAC eeG AGG ACG eec TCA GAC CAe TAC Me TGG CAG GCA Ace CTT eM 326 
v L D P R T P S D H Y N ld QAT L Q 84 
MT GAG TeT GGC AM GAG GTC ACA GTG GeT GTC Ace AGT Tee eec MT Gee ATC 380 
N E S G K E V T V A V T SSP N A I 112 
• 
eTG GGC MG TAe eM eTA Me GTG AAA ACT GGA Me CAC ATC CTT MG TeT GAA 434 
L G K Y Q L N V K T G 11 II I I, K S E 130 
GAA Me ATC eTA TAC crT eTC rTC Me eCA TGG rGT AM GAG GAC ATG GTT TTC 488 
E NIL Y L L F N P N C K E 0 M V F 148 
ATG CCT GAT GAG GAC GAG CGC AAA GAG TAC ATC CTC AAT GAC ACG GGC TGC CAT 542 
M POE 0 E R KEY I L NOT G C H 166 
• TAC GTG GGG GCT GCC AGA AGT ATC AAA TGC AAA CCC TGG AAC TTT GGT CAG TTT 596 
Y V G A A R S I K C K P W N F G Q F 184 
GAG AAA AAT GTC CTG GAC TGC TGC ATT TCC CTG CTG ACT GAG AGC TCC CTC AAG 650 
E K N V L 0 C CIS L L T E S S L K 202 
CCC ACA GAT AGG AGG GAC CCC GTG CTG GTG TGC AGG GCC ATG TGT GCT ATG ATG 704 
P TOR R 0 P V L VCR A I-j CAM M 220 
AGC TTT GAG AAA GGC CAG GGC GTG CTC ATT GGG AAT TGG ACT GGG GAC TAT GAA 758 
S F E K G Q G V L I G N \'1 T GOY [;: 238 
• GGT GGC ACA GCC CCA TAC AAG TGG ACA GGC AGT GCC CCG ATC CTG CAG CAG TAC 812 
G G TAP Y K l'I T GSA P I L Q Q Y 256 
TAC AAC ACG AAG CAG GCT GTG TGC TTT GGC CAG TGC TGG GTG TTT GCT GGG ATC 866 
Y N T K Q A V C F G Q C W V FAG I 274 
CTG ACT ACA GTG CTG AGA GCG TTG GGC ATC CCA GCA CGC AGT GTG ACA GGC TTC 920 
L T T V L R A L G I PAR S V T G F 292 
GAT TCA GCT CAC GAC ACA GAA AGG AAC CTC ACG GTG GAC ACC TAT GTG AAT GAG 974 
o S A HOT ERN LTV 0 T Y V N E 310 
• AAT GGC AAG AAA ATC ACC AGT ATG ACC CAC C~C TCT GTC TGG AAT 1TC CAT GTG 1028 
N G K KIT S I·j T H D S V l'I N F H V 328 
TGG ACG GAT GCC TGG ATG AAG CGA CCG GAT CTG CCC AAG GGC TAC GAC GGC TGG 1082 
N T 0 A N 11 K R POL P K G Y D G W 346 
CAG GCT GTG GAe GCA ACG CCG CAG GAG eGA AGC CAG GGT GTe TTC TGC TGT GGG 1136 
Q A V 0 A T P Q E R S Q G V FCC G 364 
CCA TCA CCA CTG ACC GCC Nrc CGC AAA GGT GAC ATC TTT ATT GTC TAT GAC ACC 1190 
p S P L T A IRK G D I F I V Y D T 382 
AGA TTC GTC TTC TCA GAA GTG AAT GGT GAC AGG ere ATC TGG TTG GTG AAG ATG 1244 
R F V F S E V N G D R LIN L V K 1-1 400 
GTG AAT GGG CAG GAG GAG TTA CAC GTA ATT TCA ATG GAG ACC ACA AGC ATC GGG 1298 
V N G Q EEL H V I S NET T S I G 418 
AAA AAC ATC AGC ACC AAG GCA GTG GGC CAA GAC AGG CGG AGA GAT ATC ACC TAT 1352 
K N 1ST K A V G Q D R R R D I T Y 436 
• 
Androgen-regulated expression o/IITGp 
GAG TAC AAG TAT eeA GAA GGC Tce TeT GAG GAG AGG eAG GTe ATG GAT CAr Gee 1406 
E Y K Y P E G S S E E R Q V 1·1 D H A 454 
TTC eTC CTT eTC AGT TCT GAG AGG GAG CAC AGA CGA CCT GTA AAA GAG Me TTT 1460 
F L L L S S E R E H R R P V K E II F 472 
eTT eAC ATG TeG GTA CAA TCA GAT GAT GTG eTG eTG GGA Me reT GTT AAT 1TC 1554 
L II H S v Q s D D V L L G II S V II F 490 
• Ace GTG ATT crr AAA AGG AAG Ace GeT Gee eTA eAG AAT GTe Me ATC TTG GGC 1568 
T V I L K R K T A A L Q II V II I L G SOB 
TCC TTT GAA eTA eAG 1TG TAC ACT GGC AAG AAG ATG GCA AAA erG TGT GAC CTC 1622 
S F E L Q L Y T G K K 11 A K L e D L 526 
MT AAG Ace TCG eAG ATC CM GGT eM GTA TCA GAA GTG ACT eTG Ace TTG GAC 1676 
N K T S Q I Q G Q v S E V T L T L D 544 
• Tec MG ACC TAC ATC MC AGC CTG GCT ATA TTA GAT GAT GAG eeA GTT ATe AGA 1730 
S K T Y I II S L A I L D D E P V I R 562 
GGT TTC ATC ATT GCG GAA ATT GTG GAG reT AAG GAA ATC ATG Gee reT GAA GTA 1784 
G F I I A E I V E S K E I H A S E V 5BO 
TTC AeG TeT TTC CAG TAC CCT GAG TTC TeT ATA GAG TTG ceT MC ACA GGC AGA 1838 
F T S F Q y P E F S I E L P II T G R 59B 
ATT GGC CAG CTA CTT GTC TGC MT TGT ATC TTC AAG MT Ace CTG Gee ATC CCT 1892 
I G Q L L V C II C I F K N T L A I p 616 
TTG ACT GAC GTe AAG TTC TCT TTG GAA AGe (:TG GGC ATC TCC TCA erA CAG ACC 1946 
L T D V K F S L E S L G I S S L Q T 634 
TeT GAC CAT GGG ACG GTG CAG CCT GGT GAG Ace ATC CM TCC CAA ATA AAA TGC 2000 
S D H G T V Q p G E T I Q s Q I K C 652 
ACC CCA ATA AAA ACT GGA eec AAG AAA TTT ATC GTC AAG TTA AGT Tce AAA CM 2054 
T P I K T G P K K F I V K L S S K Q 670 
GTG AM GAG ATT MT GeT CAG AAG ATT GTT eTC ATC Ace AAG TAG CCTTGTCTGAT 2110 
V K E I II A Q K I V L I 'J' K 6B4 
GCTGTGGAGCCTTAGTTGAGATTTCAGCATTTCCTACCTTGTGCTTAGCTTTCAGATTATGGATGATTAAA 2181 
TTTGATGACTTATATGAGGGCAGATTCAAGAGCCl,GCAGGTCAAAAAGGCCAACACAACCATAAGCAGCCA 2252 
GACCCACAAGGCCAGGTCCTGTGCTATCACAGGGTCACCTCTTTTACAGTTAGAAACACCAGCCGAGGCCA 2323 
CAGAATCCCATCCCTTTCCTGAGTCATGGCCTCAAAAATCAGGGCCACCATTGTCTCAATTCAAATCCATA 2394 
GATTTCGAAGCCACAGAGTCTCTCCCTGGAGCAGCAGACTATGGGCAGCCCAGTGCTGCCACCTGCTGACG 2465 
ACCCTTGAGAAGCTGCCATATCTTCA.GGCCATGGGTTCACCAGCCCTGAAGGCACC-rGTCAACTGGAGTGC 2536 
TCTCTCAGCACTGGGATGGGCCTGATAGAAGTGCATTCTCCTCCTATTGCCTCCATTCTCCTCTCTCTATC 2607 
CCTGAAATCCAGGAAGTCCCTCrCCTGGTGCTCCAAGCAGTTTGAAGCCCAATCTGCAAGGACATTTCTCA 2678 
AGGGCCATGTGGTTTTGCAGACAACCCTGTCCTCAGGCCTGAACTCACCATAGAGACCCATGTCAGCAAAC 2749 
GGTGACCAGCAAATCCTCTTCCCTTATTCTAAAGCTGCCCCTTGGGAGACTCCAGGGAGAAGGCATTGCTT 2820 
CCTCCCTGGTGTGAACTCTTTCTTTGGTATTCCATCCACTATCCTGGCAACTCAAGGCTGCTTCTGTTAAC 2891 
TGAAGCCTGCTCCTTCTTGTTCTGCCCTCCAGAC~TTTGCTCAAATGATCAATAAGCTTTAAATTAAACTC 2962 
TACTTCAA~CCG 2983 
Figure 2. Nucleotide and deduced amino acid sequence ofhTGp cDNA. The deduced amino acid sequence 
is numbered from the first methionine. TIle active-site sequence GQCWVF is bold typed and the active-
center cysteine is marked with an asterisk. A putative polyadenylation signal is double underlined. An in-
frame stop codoll preceding the start codons is indicated by a closed circle. Two putative Ci+-binding 
regions are underlined. Potential N-glycosylation signals (N-X-S/T) are indicated by closed triangles. TIle 
sequence deviates at several positions from the sequence recently published by Grant el al. (1994). A 
remarkable difference was found at position 338-342 of the deduced amino acid sequence. In all four 
isolated clones we here found an insertion of the fivc amino acids DLPKG, which is also present at this 
position in all other TGases. Other amino acid substitutions were found at position K3 BE, R466Q and 
F584N. In addition, the 23 nuclcotides at the 3'-terminal end were found to be different (similar in clone 
4,2, 1.l2 and 1.17), 
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Figure 3. III vitro IranscriptiOlHransiation of hTG p 
and TOe eDNA. The entire open reading frames of 
the cDNAs encoding hTGp (pcDNA3~hTGr) an 
TOe (pcDNA3-TOe) were subcloned into th 
eukaryotic expression vcctor pcDNA3. One ~tg of 
each vector was used for a one tube ill vitro 
transcription-translation reaction. As a control 
peDNA3 without insert (-) was used. Protein 
products were separated by SDS/IO%-PAGE. 0 
the left-hand side the molecular mass of the 
tnmslatcd proteins and of the molecular mas 
standards are indicated. 
III vitro trallscriptioll-trallslatioll of hTGp alld TGc cDNA 
To verify whether the isolated cDNA was able to produce a protein product and whether 
the size of the encoded protein corresponds to its predicted molecular mass, the entire 
coding region of hTGp was cloned into pcDNA3 for ill vitro transcription-translation. For 
this purpose, we first subcloned the 3' EcoRI-EcoRI fragment of the largest clone, clone 
l.l7 (Figure I), into the EcoRI site of pcDNA3 , Subsequently, removal of the 3' EcoRI site 
(including the 3' artefact of clone l.l7) was achieved by cleavage with Hpa I (insert) and 
Xba I (vector), Because of the presence of a 5' artefact in clone l.l7 (see above), we used 
the 5' 184 bp EcoRI-EcoRI fragment from clone 1.8 for ligation to the EcoRI-Hpa I 
fragment of clone l.l7, In this way the entire coding region of hTGp was cloned into 
pcDNA3 (pcDNA3-hTGp) with only three nucleotides left in front of its start codon, 
Figure 3 shows that both pcDNA3-hTGp and pcDNA3-TGc produced a single protein, The 
molecular mass of the hTGp protein was established to be approx, 77 kDa which is in 
agreement with its predicted molecular mass. The TGc conSh1.1ct yielded a protein of 
approx, 85 kDa which size is somewhat larger than its predicted molecular mass of77 kDa, 
This observation is in agreement with the ill vitro translation results of Gentile et aL (1991), 
The control plasmid produced no protein bands, 
Expression of" TGp ill the prostate alld in prostate derived cell lilies 
To determine the expression pattel1l of hTGp a human multiple-tissue Northel1l blot with 
poly (Ar RNA from eigth different tissues including prostate was hybridized under high 
stringency conditions with a 2,2 kb Sac I-Hpa I fragment from clone 4,2, As shown in 
Figure 4 hTGp mRNA was exclusively expressed in the prostate, A single mRNA was 
detected with a length of approx, 3,5 kb, Prolonged exposure of the Northern blot did not 
result in a positive signal in either of the other tissues tested, The hTGp mRNA could be 
clearly distinguished from the approx, 4 kb TGc mRNA as was detennined by Northel1l-
blot analysis of total RNA from benign prostate hypelplasia tissue (results not shown), 
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Next it was investigated whether hTGp was also expressed in prostate cancer cell lines. For 
this plUl'ose we perfonned Northern-blot analysis of total RNA from the well-known 
human prostate carcinoma cell line LNCaP as well as from a prostate cancer ceJI line, 
PC346C, recently developed in our laboratory [Rornijn et a!. 1995 (see the Materials and 
methods section)]. While no hTGp mRNA in LNCaP could be detected, PC346C expressed 
one mRNA of the same length (3,5 kb) as has been found in prostatic tissue, The Northern 
blot resnlts for LNCaP and PC346C are shown in Figure 5, We could not detect hTGp 
mRNA in the androgen-independent cell line PC-3 [results not shown (Kaighn et a!. 1979)]. 
Alldrogellregulated expressioll ~f hTGp 
To investigate androgen regulation of hTGp expression, we used the androgen-responsive 
prostate cancer cell lines LNCaP and PC346C. Both cell lines were grown in the presence 
or absence of 0.1 nM RI881. Northern-blot analysis of total RNA from treated and 
untreated cells, using the 2.2 kb Sac I-Hpa I fragment from clone 4,2 as probe, showed that 
in PC346C cells the amount of hTGp mRNA was 3-fold increased in the presence of 
R1881, demonstrating that the hTGp expression can be upregulated by androgen. However, 
even after induction with R1881, no hTGp mRNA could be visualized in the LNCaP cells 
(Figure 5). The same blot was also hybridized with a probe for TGc, but neither in LNCaP 
nor in PC346C cells was TGc expression detected. 
kb 
9.5 
7,' 
4,4 
3.5kb ~ 
2,4 
us 
Figure 4. Northern-blot analysis of TGp 
expression in human tissues. A human l11ultiple-
tissue Northern blot was hybridized under high 
stringency conditions (see the Materials and 
methods section) with a random 32P~labelJed 2.2 
kb Sac I~Hpa I fragment from clone 4.2. Each 
lane contained 2 ~lg poly (At RNA. The integrity 
of the blot was determined by hybridization with 
human p~actin eDNA. 
LNCaP PC346C 
RI881 + + 
28S -
3.5 kb -->-
18S -
J3-actin ~ 
Figure 5. Androgen-regulated expression of 
hTGp mRNA. Northern-blot analysis of 
PC346C and LNCaP grown in the presence (+) 
or absence (-) of 0.1 11M of the synthetic 
androgen Rl88 I and further treated as 
described in the Materials and methods section. 
Each lane contains 20 pg of total RNA. TIle 
blot was hybridized under high stringency 
conditions (see the Materials and methods 
section) with a random 31P_label1ed 2.2 kb Sac 
I-Hpa I fragment from clone 4.2. Hybridization 
with a p-actin probe was performed as a 
control. 
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Figure 6. Assignment of the hTGp gene to human chromosome 3, A panel of human/hamster and 
human/mouse somatic cell hybrid DNAs was screened by peR with the HPSTGI-TRAGLU RI primer set 
(see Table I). peR products generated by this primer pair were separated on a 1% agarose gel (not shown). 
DNA was amplified from somatic hybrid cell lines (cell line designations arc indicated above figure), as 
well as human, hamster and mouse genomic DNA. TIle figure shows correlation between the presence of 
human chromosomes in the somatic cell line panel (as described by the manufactllfcr), and the presence or 
absence of a specific peR product. On the left side the human chromosome number is indicated. The 
somatic cell lines in which a specific peR product could be detected are indicated in the lower bar by the 
shaded areas. Percentage discordance is shown at the right. Assignment of the hTGr gene to chromosome 3 
had a discordance of 0%, while all other human chromosomes were excluded by .2': 10% discordance. 
Symbols: An asterisk indicates hummtlmouse somatic cell hybrid, all others are human/hamster hybrids; D, 
multiple deletions; +, >30% of the cells contain the givcn chromosomc; ±, 5~ 30% of the cells contain the 
given chromosome. 
Chromosomal localization of the hTGpgene 
Chromosomal localization of the gene encoding hTGp was performed by screening by PCR 
a panel of 20 human/hamster and human/mouse somatic-cell~hybrid cell lines that contain 
each of the human chromosomes in one or more of the hybrid DNAs (Figure 6). For this 
approach the primer pair HPSTG l-TRAGLU Rl was used (Table I). 
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PCR analysis on chromosomal DNA isolated from PC346C cells (results not shown) 
resulted in a product of 250 bp, while PCR on hTGp cDNA would have yielded a product 
of 150 bp (see Table I). 111is difference in size is most probably due to the presence of an 
intron of approx. 100 bp in this part of the gene. Comparison with the organization of other 
TGase genes in that region is in favour of this assumption (see Kim et a!. 1994a). 
As presented in Figure 6 only the presence or absence of human chromosome 3 is 
concordant with the presence of a peR product, whereas at least two discordancies were 
observed for all other chromosomes. The authenticity of the obtained 250 bp products was 
proven by hybridization with the 2.2 kb Sac I-Hpa I fragment from clone 4.2. No cross-
reactivity was found with hamster or mouse chromosomal DNA present in the DNA 
hybrids. 
Discussion 
In this paper, we describe the molecular characterization of the eDNA encoding a prostate 
TOase, hTGp. The composite eDNA sequence consists of 2983 llucleotides, containing all 
open reading frame encoding a protein of 684 amino acids. The deduced amino acid 
sequence contains significant similarity with other members of the human TOase family 
(Figure 7). Especially in the region of the active site these sequences display a high degree 
of similarity not only concerning the deduced primary amino acid sequences, but also the 
hydrophobicity directly C-terminal to the active site (Ichinose et a!. 1990, Kim et a!. 1991). 
The amino acid sequences of hTGp and rTGp share an identity of 53%. The overall identity 
of hTGp with the other TGases is approx. 30%. The degree of similarity is very low C-
temlinal to the putative Ca2+-binding site at position 433-453. Essential amino acids are 
present in the deduced amino acid sequence, such as the active-site cysteine which is an 
absolute prerequisite for TGase activity as well as the amino acids directly surrounding this 
cysteine (Hettasch and Greenberg 1994). Also other amino acids which are away from the 
active centre in the primary sequence but are required for catalytic function of TGases, 
because of their putative influence on the protein conformation, are present (Hettasch and 
Greenberg 1994, Huber et a!. 1995, Russell et a!. 1995). Together, these results suggest that 
we have isolated a cDNA encoding an active prostatic TOase. 
We assigned the gene encoding hTGp unambiguously to chromosome 3. No other human 
genes encoding TOases known so far are localized on this chromosome. The other TOase 
genes are assigned to chromosome bands 6p24-p25, FXlIIa (Board et a!. 1988), 14q11.2-
ql3, TGK (Kim et a!. 1992) and TGc as well as TGE to 20q11.2-20q12 (Gentile et a!. 1994, 
Wang et a!. 1994). While this paper was in preparation, a report by Gentile et a!. confirmed 
our results by sublocalizing the hTGI' gene to chromosome band 3p21.33-p22 (Gentile et a!. 
1995). 
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HTGASEP 
HrGASEK 
HFXIIIA 
HTGASEC 
HTGASE3 
HTGASEP 
IiTGASEK 
HFXIITA 
HTGASEC 
liTGASE3 
liTGASEP 
HTGASEK 
HFXIIIA 
HTGASEC 
RTGASE) 
RTGASEP 
HTGASEK 
HFXIIIA 
HTGASEC 
RTGASE3 
HTGASEP 
HTGASEK 
HFXIIIA 
HTGASEC 
HTGASE3 
RTGASEP 
HTGASEK 
HFXIIIA 
HTGASEC 
RTGASE3 
HTGASEP 
HTGASEK 
HFXIIIA 
HTGASEC 
HTGASE3 
HTGASEP 
HTGASEK 
HFXIIIA 
HTGASEC 
HTGASE3 
RTGASE? 
HTGASEK 
HFXIIIA 
HTGASEC 
HTGASE3 
HTGASEP 
IlTGASEK 
IIFXI!IA 
HTGASEC 
RTGASE3 
!lTGASEP 
HTGASEK 
HFXIIIA 
HTGASEC 
IITGASE:3 
l-f,IDASKELQ, •• , •••• , •......••• ,.,.,., .•........••• ,., •• , .• , ..• 
---GPRSDVGRWGGNPLQPPTTPSPEPEPEPDGRSRRGGGRSn1ARCCGCCSCRNAADDD 
-AEELVLERCDLELE .•.....•.••••• , ••...•...••• , •• , ••••....••.••• 
-AA. LGVQSINliQKA ..• , • , ••• , • , ••. ,. , ..•• , ., •••.....•..••• , ••••• 
...•••• , •••••••••••..•.•••. , , . , • , •••.•..• , •• , •• , , • , ••• VLH1DF 
HGPEPSDSRGRGSSSGTRRPGSRGSDSRRPVSRGSGVNAAGDGTIREGHLVVNG-DLL8S 
••••. SET8RTAFGGRRAVPPNN8NAAEDDLPTVELQGVVPRGVNLQEFLtNTS-HLFKE 
n 
LNQDNAVSHHlWEFQTSSPVfRRGQVFHLRLVLtl. QPLQ8YHQtK. LEFSTGPNP8IAKH 
RSOQ-RRE---O-YEYOEL1V----P--l·jL-L-8. RTYE-8. DRIT--LLl -N--EVG-G 
RI'IOT-K-0---DKYENNKLIV----S-YVQIDFS . R - YDPRRD-I"RV-YVI -RY -QEN-G 
••. T-GRD---ADLCREKL-V----P-I'l-T-HFEGRNY-ASVDSLTFSW---A--QEAG 
••• F-RQA- --DK-SSQELIL----N-QVUlIM-KGLG •• SNERLEFIDT- - - Y --E8AM 
TLWLDPRTPSDHYN.WQATLQNESGKEVTVAVTSSPNAILGKYQLNVKTGNH1LKSEE. 
-H.-1I-VGKGG.SGG-K-QWKA--QNLNLR-HT-----I--F-FT-R-Q8DAGEFQLP 
- Y • IPV-1VSELQSGK-G-KIVl-lREDRS-RLS1Q---KC-V--FRHY -AVHTPYGVLRTS 
-KARF.-LRDAVEEGD-T--VVDQQDCTLSLQL-TPA--PI-L-R-SLEASTGYQG ••• 8 
-KA-F.-LSNGSS.GG-S-V--ASN-NTL-ISIS-PAS-P1-R-THALQIFSQGG1 ..• S 
, , • • NIL Y LLFNPWCKEDl1VruPDEDERKEY 1 LNDTGCHYVGAARS IKCKPWNFGQFEKN 
FDPR-EI - I -- ----P-- I - YVDH--~I-Q--V --ES-R1 - Y -TEAQ-GERT-- Y ---DHG 
RNPETDT-I------ED-A-YLON-K--E--V---1-VIFY-EVND--TRS-SY----DG 
SFVLGHFI----A--PA-A-YLDS-E--Q--V-TQQ-F1-Q-S-KF--NI-------QDG 
SVKLGTF1 ------LNV-S---GNHA--E--VQE-A- I 1 F--STNR-GHIG-------ED 
VLDCCISLL TE, .• ' .• ,S8LKPTDRRDPVLVCRAJ>fCJlM1SFEKGQGVLIGNWrGDYEGG 
-- -A-LYl -DR, ••••• ,RGl-JPYGG-G-- -N-S-VIS--VNSLDDN--- ----S---SR-
1 --T-LYVMDR •.•. ' .. AQMDLSG-GN-lK-S-VGS--VNAKDDE---V-S-DNI -A Y-
I--1-LI--DVNPKFLKNAGRDCSR-SS--Y-G-VGSG-VNCNDD----L-R-DNN-GD-
I-S1-L-1-DRSLNFRRDAATDVAS-N--KY-G-VLS--1NSNDDN---A---S-T-T--
TTTTTT T 
TAPYKWTGSAPILQQYYNTKQA.VCFGQCWVFAG1LTTVLRALGIPARSVTGFDSAHDTE 
-N-SA-V--VE--LS-LR-GYS,-PY--------VT-----C--LA'l'-T--N-N-----D 
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--Q---ASV1GV-E--VQLNF-HP-1 -A---A--1T--YDNTT- KQl'1fmSVNSH- I , .-R 
NISTKAVGQDRRRDITYEYKYPEGSSEERQVHDHAFLLLSSEREHRRPVKENFLH •. HSV 
L-V--- lSStll1-E--- - 1,--H - - --DA--KAVE'l'-AAHG-KP .. tNYANRGSAEDVA-Q-
L -V --Ql -G-Gr..l}j- --DT- - FQ - - QE - - - LALE T - HlY GAKKPLNTEG-l-1KSRStND-0 F 
K----S--R-E-E---HT-----------EAF'1'R-NH ..•.... LNKLAEKEETGHA-R1 
Y - ------SNA-H-V-DK - ---- --DQ----FQK-LG. , .... KLKPNTPFAATSSl-!GLE 
QSDDVLL. GNSVNFTVILKRKTAALQNVNILGSFELQLYTGKK11AKLC, DLNKTSQ1QGQ 
EAQ-AVl1. -QDUWS-M- INHSSSRRT-KLHLYLSVTF---VSGTIFK, ETK -EVELAPG 
EVENAV-. -KDFKLS ITFRNNSHNRYT1TAYL-ANITF---VPK -EFK, KETFDVTLEPL 
RVGQSMNl1-SO FDV F AH I T NN - - EEYVCRL-LCAR TVS-N - ILGPECG TKY LWL TI,E P F 
TE EQE P S 1 I GKLKV AG1,j - AVGKEVNL VLLLKN L8 RDTKTVTVN - T AWTI I Y - G-LVHEVVI 
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VSEVTL TLDSKTYINSLAI LDDEPVIRGFI IAEIVESKEIHASEVFTSFQY PEFSIELPN 595 
A- DRvnlPvA •• -KEYRPH -v -QGAHLLNVSGHVK--GQVL-KQHTf'RLRT- DL- LT-LG 699 
SFKKEAV- IQ •. AGEYI1GQ- LEQASLHF-VT-R-N-TRDVL-KQKS-VL T I --II -KVRG 639 
SEKSVPLCILYEK •• YRDC-TESNL-KVRALLVEPVINSYLLA-RDLYLEN--IK-RILG 595 
KDSA-HS-- PEEE .. AEHPI KISYAQYERYL!<SDN:t11 R ITAVCK - PDESEVVVERDIILD 593 
TGRIGQLLVCNCIFKNTLAIPLTDVKFSLESLGISSLQTSDHGTVQPGET .• IQSQIKCT 653 
AAW--ECEVQIV---P-PVT--N-V-R--GS-LQRPKILNV-DIGGN-- •• VTLRQSFV 757 
-QW-SDi-ITVTIQ-T-p-KET-RN-~'NH-DGP-VTR Pl·lKKMFREIR -NS- .• V-\</EEV- R 697 
EPKQKRK--AEVSLQ- P- PVA-EGCT-TV-GA-L TEE- KTVE:IPDPVE;AGE EVKVRNDLV 655 
N Pl'L TLEVLNEARVRKPVNVQ}!L FSN P LD- PVRDCV - HVEGS - LLLGNLKI DVPT LG PKE 653 
PIKTGPKKFIVKLSSKQVKEINAQKIVLITK 684 
-VRP--RQL-AS-D-P-LSQVHGVIQ-DVAPAPGDGGFFSDAGGDSIlLGETIPHASRGGA 817 
-~NS-HR-L-ASl-J- - DSLRHVYGELD-Q-QRR PS:t1 732 
-LIll-!-LH- LV-NFE-DKL-AVKGFRN- I -GPA 687 
RSRVRFDILPSRSGT-- LLADFSCNKFPAI -AHLSIDVAE 693 
Figure 7. Comparison of the deduced amino acid sequence ofhTG p with other human TGascs. HTGASEP, 
K, C, 3 and HFXlllA represent hTG p, TGK (Phillips ct al. 1990), TGc (Gentile et al. 1991), TGE (Kim et al. 
1993), and plasma Factor XIlla (Jchinose et a!. 1986), respectively. Bold type residues represent amino 
acids present in all sequences. Hyphens indicate identities with the amino acids of hTGp• Dots represent 
gaps introduced for optimal alignment. Closed triangles indicate amino acids, mentioned in the text, 
important for the catalytic function ofTGases. 
III vitro transcription-translation of hTGp eDNA demonstrated that the core protein without 
any post-translational modifications behaves as a protein of approx. 77 kDa on SDSIP AGE, 
which is slightly larger than its 65 kDa rat DPI (Seitz et al. 1991b, Ho et al. 1992). Results 
of Seitz and co-workers (Enderle-Schmitt et al. 1989, Seitz et al. 1990) suggested that a 
protein of about the same molecular mass, ,vith cross-reactivity to an antibody against 
rTGp, is present in human semen. 
The putative hTGp protein contains seven N-glycosylation consensus sequences distributed 
over the entire protein. Four of these are at identical sites in hTGp and rTGp• However, this 
does not necessarily result in glycosylatioll at these sites. Both TGc and FXIIIa contaill 
several potential N-glycosylation sites, but no glycosylation has been observed (lchinose et 
al. 1990, Greenberg et al. 1991). In the rat, TGp was reported to be glycosylated (Seitz et al. 
1991a, Ho et al. 1992) and to contain a glycosylphosphatidylinositol (GPI) anchor which 
may protect the protein from autoaggregation (Seitz et al. 199Ia). Until now, the identified 
GPI-anchored proteins were demonstrated to contain a hydrophobic sequence at their C-
telminal sequence (Englund 1993). Based upon these results one would not expect a GPI-
anchor for either rTGp or hTGp, because of the lack of a hydrophobic streich of amino acids 
at their C-terminus. It cannot be excluded, however, that for the attaclunent of the GPI-
anchor to rTGp other sequence determinants might be used. It would be of interest to know 
whether hTGp is also glycosylated and has a protective GPI-anchor. 
Androgens are essential for the growth and maintenance of prostate tissue and control the 
fonnation of prostatic secretions. Immunohistochemical and mRNA studies have shown 
that RatDPI or rTGp is androgen-regulated (Ho et al. 1992, Steinhoff et al. 1994). The 
expression of rTGp was demonstrated to be restricted to the dorsal lobe of the prostate and 
the coagulation gland. Expression of the hTGp gene leads to an mRNA of approx. 3.5 kb 
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both in prostatic tissue and in the androgetH'cSpOllsive prostate cancer cell line PC346C. 
The androgen-independent prostate cancer cell line PC-3 (results not shown) as well as the 
androgen-responsive prostate carcinoma cell line LNCaP showed 110 expression of hTGp 
mRNA as determined by Northern-blot hybridization. As far as the tissues tested are 
concemeci, hTGp is exclusively expressed in the prostate. Presently we are examining a 
morc extended number of tissues to confirm prostate-specificity of hTGp expression. 
Androgen-dependent expression of hTGp was observed in PC346C cells. The level 
increased 3-fold in the presence of 0.1 nM of the synthetic androgen R1881. The question 
remains open as to whether the androgen-up-regulated expression of hTGp is due to a direct 
regulation at the transcriptional level or is a consequence of stabilization of the mRNA. 
Indirect evidence obtained by Ho et aL (1992) suggests that the latter is the case for rTGp 
and that androgen acts through prolongation of the rTGp mRNA half-live. At present, only 
a few human genes have been described, for example the prostate-specific genes hGK-I 
and PSA, as being under androgenic control at the transcriptional leveL Both hGK-I and 
PSA contain androgen response elements in their promoters (Riegman et aL 1991a, 199Ib). 
Kinetic studies of the androgen-regulated expression of hTGp mRNA and isolation and 
characterization of the promoter region of hTGp may elucidate at which level androgens 
regulate its expression. Additionally, comparison of the promoter regions of genes 
specifically expressed in the prostate may give some clues to tissue~specific regulatOlY 
elements. 
Unlike hTGp, TGc is up-regulated by androgen withdrawal in the rat ventral prostate 
(Guenette et aL 1994b). However, this may be an indirect consequence of the induction of 
the apoptotic pathway by removal of androgens from the circulation. 
Contrary to rTGp, for which there is a very obvious function in the formation of the 
copulatory plug (Williams-Ashman 1984), little is known about the physiological role of 
hTGp• Most likely the function of hTGp is in semen. However, in contrast to PSA, for 
example, which is also excreted by the prostate, the deduced protein sequence does not 
contain an obvious signal sequence for excretion (Riegman et a1. 1991a). TIle same is tnle 
for rTGp (Ho et aL 1992). For this protein evidence has been obtained that secretion might 
occur via an alternative pathway (Steinhoff et aL 1994), which is also suggested for two 
other TGases, FXIIIa and TOc (Aeschlimann and Paulsson 1994). Some effort has been 
made to obtain evidence for the presence and function of hTGp in human semen. A report 
of Lilja and Laurell (1985) suggests that, in conh·ast to rat seminal clotting, TGase activity 
may not be essential for human semen coagulation. They hypothesized that, besides 
disulphide bridges in particular, non~covalent protein interactions are important for the clot 
stnlCture. In addition, they did not find TOase activity in human semen, while Porta et a1. 
(1986), demonstrated TGase activity in human seminal plasma of normal individuals. 
Others found only TGase activity in infertile patients with semen having prolonged 
liquefaction time (Enderle-Schmitt et aL 1989, Seitz et aL 1990). Besides a role of hTGp in 
coagulation, it may function in suppressing the spenn surface antigenicity, thereby 
preventing an immunological response in the female genital tract. Suppression of 
antigenicity through the involvement of the cross-linking activity of TGase has been 
56 
Androgen-regulated expression of Ii TGp 
reported for rat and rabbit, as well as for human sperm (Mukherjee et aL 1983, Manjunath 
et aL 1984, Paonessa et aL 1984). At last, an intracellular role ofhTGp cannot be excluded. 
Presently, prostate cancer is the most common cancer in the male population of the U.S.A. 
and Europe. A main problem in the treatment of clinically localized prostate cancer is the 
presence of micrometastasis, at time of radical prostatectomy (Zincke et aL 1994). 
Monitoring the presence of prostate cancer cells in tissues and blood before and after 
treatment may offer the possibility to optimize treatment methods (Katz et aL 1995). Given 
its prostate-restricted expression, as suggested by our results, hTGp may represent a 
valuable alternative to PSA as a marker for detection of prostate cancer ce11s, for instance 
by reverse-transcription peR analysis. 
We are interested in prostatic TGases and their possible role in the regulation of human 
prostate tumor growth and metastasis (TGe) and their usefulness as differentiation or tumor 
markers (hTGp) in prostate cancer. The isolation of the cDNA for hTGp and some first 
clues to the specificity and regulation of its expression may help us to discriminate between 
both prostatic TGases, and to get more insight into the putative function(s) of the hTGp 
protein. Currently, antisera against the CHterminal region of either hTGp or TGc are being 
generated to enable us to discriminate at the protein level as well. 
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Abstract 
Human prostate-specific transglutaminase (hTGp) is a cross-linking enzyme secreted by the 
prostate. In this study, we perfonned dot blot analysis of 50 nOlmal human tissues to 
demonstrate unambiguously the prostate~specific expression of hTGp. Fm1hermore, we 
elucidated the genomic organization of the TGM4 gene, the gene encoding hTGp • The 
structure of this gene displays striking similarity to that of other transglutaminase (TGase) 
genes. The TGM4 gene spans approximately 35 kb of genomic DNA and consists of 13 
exons and 12 introns. TIle main transcription initiation site is located 52 bp upstream of the 
translational start codon. A hTGp splice variant of inh'on 1 was detected. This splice variant 
contains an in-frame antisense Alu element insertion, TIle TGA14 promoter was analyzed by 
sequencing and transfection experiments. At positions -1276 to -563, the promoter harhors 
a cyclophilin pseudogene with 94% similarity to the cyclophilin A cDNA. Deletion 
mapping of the TGM4 promoter in the transiently transfected human prostate cancer cell 
line PC346C showed comparable activity of2.1-, 1.5-, and 0.5-kb promoter fragments. 
Introduction 
Human prostate-specific h'ansglutaminase (hTGp) belongs to a family of enzymes that all 
have the ability to catalyze the irreversible cross-linking of peptide-bound glutamine 
residues either with peptide-bound Iysines or with primary amines [such as polyamines 
(Greenberg et al. 1991, Aeschlimann and Paulsson 1994, Dubbink et al. 1996)]. 
Transglutaminases (TGase, EC 2.3.2.13) can be found throughout the body, but each TGase 
type is characterized by its own typical tissue distribution, which can be highly tissue-
specific or without any tissue restriction at all. At present six distinct human TGases have 
been described. These include plasma factor XIIIa (rchinose et al. 1990), keratinocyte 
TGase [TGK (Rice et al. 1992)], epidennal TGase [TGE (Kim et al. 1993)], tissue-type or 
cellular TGase [TGc (Gentile et al. 1991 )], the catalytically inactive TGase-like erythrocyte 
membrane protein band 4.2 (Korsgren et al. 1990), and hTGp (Dubbink et al. 1996). 
In contrast to the other types of TGases, little is known about the physiological function of 
prostatic TOase. Most information on this TOase type has been obtained from studies on rat 
prostatic TGase (rTGp or dorsal protein 1, DP1). DPI is an abundantly expressed secretory 
protein of the dorsal prostate, the coagulating gland, and the lateral type 1 prostate of the rat 
(Wilson and French 1980, Romijn 1990, Hayashi et al. 1991). DPI expression is androgen-
regulated as has been demonstrated in vivo by castration and androgen replacement 
experiments (Ho et al. 1992). Also in explant culture studies, the expression ofDPI can be 
induced by a broad range of natural and synthetic androgens (Lopes et al. 1996). The 
enzyme is believed to be responsible for the cross-linking process during the formation of 
the copulatOly plug after mating (Williams-Aslmlan 1984). 
The function of hTGp, which is expressed at a considerably lower level than DP1, has not 
been unambiguously established. Whereas a role in semen coagulation cannot be excluded, 
other functions of hTGp, related to the appropriate sperm transfer to the female, have been 
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proposed. These include the suppression of spclnl cell immul10genicity and maturation, 
which could be achieved by modifying the surfaces of the male gametes with seminal 
plasma components, e.g., polyamines and the human uteroglobin analogue, the Clara cell 
lO-kDa protein (Manjunath et aL 1984, Porta et aL 1986, Mantile et aL 1993). With the 
cloning of the hTGp cDNA, several characteristics of the enzyme could be resolved; 
additionally hTGp mRNA expression could be monitored (Grant et aL 1994, Dubbink et aL 
1996). The cDNA encodes a protein of77 kDa, and its deduced amino acid sequence shares 
a 53% similarity with DP I. The overall identity with the other human TGases is 
approximately 30%, with the highest similarity in the active site region. 
hTGp mRNA with a length of 3.5 kb could be demonstrated in prostatic tissues and in the 
human prostate cancer cell line PC346C, but was undetectable in other human prostate 
cancer cell lines (Dubbink et aL 1996). Evidence that hTGp expression is limited to the 
prostate and can be stimulated by androgens has been obtained (Dubbink et aL 1996). With 
the pUlpose of studying tlle regulatory mechanisms underlying hTGp expression, we 
isolated the TGM4 gene, the gene encoding hTGp, and its promoter. 
The complete genomic structures of most other human TGases have been described 
(Ichinose and Davie 1988, Korsgren and Cohen 1991, Phillips et aL 1992, Kim et aL 1994a, 
Fraij and Gonzales 1997). Although the sizes of the various TGase genes range from 
approximately 14 kb [TGMI, the gene encoding TGK (Kim et aL 1992)] to over 160 kb 
[FXIl!a (rchinose and Davie 1988)], their basic organization and localization of intrans are 
largely the same. In this study, we further confimled the prostate specificity of hTGp and 
present the TGJvf4 gene stmcture and its 5'-flallking sequences. Functional activity of the 
promoter region was demonstrated after its transfection to PC346C cells, 
Materials alld Methods 
Screening of a human genomic cosmid Iibrmy 
A eosmid library was prepared by subcloning a partial Mbol human genomic DNA digest 
from peripheral blood lymphocytes into the BalllHI site of cosmid vector pTCF (Pan et al. 
1994). The genomic libralY was not amplified before use. Clones (1.2xI06) were screened 
with a random 32P_Iabeled 2.2-kb SacI-HpaT hTGp cDNA fragment (Dubbink et al. 1996). 
For selection of eosmid clones containing the TGM4 promoter region, a 32P-Iabeled 184-bp 
hTGp eDNA fragment corresponding to nucleotides 42-225 was used (Dubbink et al. 1996). 
Rescreening of the same library with a 500-bp N'il-Nsil fragment, isolated from one of the 
selected cos mid clones, containing the 5'-untranslated region (UTR) of the hTGp cDNA and 
the proximal promoter of the TGM4 gene, was performed to obtain a larger segment of the 
TGM4 promoter. Filters were prehybridized for 2 h in a mix containing 5 flg/ml denatured 
pTCF. Hybridizations and wash steps were performed at 65'C, as previously described 
(Dubbink et al. 1996). Cosmid DNA from purified clones was isolated following standard 
methods (Sambrook et al. 1989) or with a Qiagen plasmid isolation kit (Qiagen, Hilden, 
Gennany), Clone inserts were characterized by standard restriction digestion followed by 
Southern blotting and hybridization with 32P-Iabeled hTGp cDNA probes spalming the 
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entire coding region. Finally, the TGM4 exon contents of the selected clones were 
determined by intronic PCR amplification as described below. 
Exoll-illtl'OIl structure of the TGM4 gene 
Oligonucleotides were chosen based upon the stmctural similarities between the other 
known TGase genes. PCR amplifications of cos mid DNA were perfonned with 1-5 U of 
Goldstar DNA polymerase (Invitrogen COl]>., San Diego, CAl, depending on the size of the 
fragment to be amplified, in the presence of 100 ng of each primer in a final volume of 50 
f.l1. All samples were first denaturated at 94°C for 5 min. Amplification followed in 35 
cycles of 94°C for I min; 60°C for I min; noc for 2 min; and with a final extension at 
noc for 10 min. PCR products were analyzed by agarose gel electrophoresis and 
hybridization using the entire hTGp eDNA as probe (Dubbink et al. 1996). The intron sizes 
were detelmined by subtraction of exon sequences from the corresponding fragments 
amplified on genome DNA. The size of intI"on 1 was assessed by a combination of 
restriction enzyme analysis and hybridization experiments. 
Cloning of PCR fragments was perfonned with a TA Cloning kit (Invitrogen) into the 
pCR2.1 vector by a shotgun procedure or by using PCR products isolated from gel 
according to the manufacturer1s protocol. Appropriate clones were selected based upon 
insert sizes. Sequence analysis was perfOlmed by dideoxy nucleotide chain temlination 
using a T7 sequencing kit (Pharmacia, Uppsala, Sweden). 
5 '-Rapid amplification ofcDNA ends 
The transcription initiation site was determined by 5'-rapid amplification of eDNA ends (5'-
RACE) of human prostate Marathon-Ready eDNA (Clontech, Palo Alto, CAl with three 
gene-specific primers, HPSTG 2 [702-684, numbering according to the published hTGp 
eDNA sequence (Dubbink et al. 1996)], 5'-TCATAGCACACATGGCCCT-3'; HPSTG 16 
(322-303), 5'-AGGGTTGCCTGCCAGTTGTA-3'; and HPSTG 17 (548-529), 5'-
CACGTAATGGCAGCCCGTGT-3' in combination with adaptor primer I (API, 
Clontech). PCR was performed as described above. Products obtained were analyzed by 
agarose gel electrophoresis and subsequent Southern blotting and hybridization with the 
exon I-specific oligonucleotide HPSTG 13, (2-22) 5'-GAGATAGAGTCTTCCCTGGCA-
3', and reprobed with primer HPSTG 34 (see Results), 5'-
GTTACTCGGGAGACTGAGGT-3'. Oligonucleotides were end-labeled with [y_32p]ATP 
using T4-polynucleotide kinase (Sambrook et al. 1989). Hybridizations were performed in 
5x SSC/I% SDS (Ix SSC:0.15 M Nael/0.Q15 M sodium citrate). The final wash step was 
perfomled in O.lx SSC/O.I % SDS. Both hybridizations and washes were perfonned at 
3rC.111e amplified fragments obtained with primer HPSTG 16 were cloned in pCR2.!. 
Twelve clones were partly or entirely sequenced as described above. 
Isolation of the TGM4 gene promoter and promoter constl'lIcts 
A 3.0-kb PstI-PstI fragment of one of the selected cosmid clones, which hybridized with 
exon I primer HPSTG 13 and contained the 5'-flanking region of the gene, exon I, and part 
of the first intron of the TGM4 gene, was subcloned into the PstI site of pBluescript SK 
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(Stratagene, La Jolla, CAl. The promoter region present in this fragment was entirely 
sequenced using a double-stranded nested deletion kit and the T7 sequencing kit 
(Phalmacia). For the identification and classification of repetitive sequences, the CENSOR 
program was used (http://charon.1pi.org/-serverl). 
TGM4 gene promoter constmcts were prepared as follows. A BalllHI site was introduced at 
the translational start site by PCR amplification using primers 5'-
CATGCCTAGCTGGATTGCAGAG-3' and 5'-
CGTAGGATCCCTTCAGATTCTCTCCTG-3' (46-26). The PCR product was digested 
with BalllHI and Bg/II, yielding a product of 560 bp, which was then subc10ned into the 
Bg/II site of pGL3-basic (Promega, Madison, WI) in front of the luciferase reporter gene. 
This constmct, pTGM4-0.5Luc (-510 to +54), was checked by double-stranded sequence 
analysis. Two longer constmcts were prepared by subcloning a PvuII-Bg/II fragment and a 
SlIIaI-Bg/II fragment, derived from the above-described consh1lct containing the 3.0-kb 
PstI-PstI fragment, into pTGM4-0.5Luc digested with SlIIaI and BglII. This resulted in the 
constructs pTGM4-I.5Luc (-1508 to +54) and pTGM4-2.ILuc (-2077 to +54), respectively. 
Plasmid isolations were performed with a Qiafilter plasmid isolation kit (Qiagen). 
Cell eultltre, transient transfeefiolls and luci/erase assay 
PC346C cells were culhlred in a Dulbecco's modified Eagle's medium (DMEM)1F12-based 
growth medium (Gibco, Grand Island, NY), as used previously (Dubbink et al. 1996). The 
cells were transfected according to the calcium phosphate method essentially as described 
by (Chen and Okayama 1987), using IxIO· cells per 25-cm' flask and 5 fig of the 
appropriate construct. After a 4-h incubation with the precipitate, the culhlre medium was 
replaced by 15% glycerol in PBS for 90 s at room temperahlre. Subsequently, transfected 
cells were incubated in culture medium for 24 h, Transfections were performed at least 
three times with two independent plasmid isolates. 
Cells were harvested in 400 flllysis buffer, composed of 25 111M Tris-phosphate, pH 7.8, 8 
mM MgCl" I 111M DTT, 1% Triton X-100, and 15% glycerol. Subsequently, 100 fll 
luciferin [0.25 flM (Sigma, St. Louis, MO»)I 0.25 flM ATP was added to 150 fll cell lysate, 
and luciferase activity was measured in a LUMAC 2500 M Biocounter (LUMAC, 
Landgraaf, The Netherlands). 
Northel'll hybridization 
To analyze the expression of hTGp mRNA in normal human tissues, a human RNA master 
blot (Clontech) containing poly(At mRNA of 50 different tissues was used. Under 
conditions recollunended by the manufacturer, hybridization was performed with a 32p_ 
labeled 184-bp fragment of hTGp cDNA corresponding to nucleotides 42-225 (Dubbink et 
al. 1996). Final washes were performed under high-stringency conditions (up to O.lx 
SSC/O.I % SDS at 65°C). 
RNA isolation and RT-PCR 
Total RNA from prostatic tissue specimens was isolated by the LiClIurea method as 
described by Auffray and Rougeon (1980). Subsequent first-sh'and cDNA synthesis was 
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perfolmed at 42°C on 0.5 rig RNA using 25 U M-MLV reverse transcriptase (Perkin-Elmer 
Cetus, Norwalk, CT) and random hexamer primers in the presence of 5 mM MgCI,. PCR 
was carried out essentially as described above. Primers used were HPSTG 13 and HPSTG 
14 (145-125), 5'-GGACTGCTCGTTTGGAACTCC-3'. PCR products were separated on a 
1% agarose gel and cloned in pCR2.1. Selected clones were entirely sequenced on both 
strands as described above. For determining the exon-introl1 boundaries of the described 
splice variant, a 4.5-kb EcoRl-EcoRI fragment of one of the selected eosmid clones, 
containing part of exon II and intron I, was subeloned into the EcoRl site of pGEM-7Zf(+) 
(Promega). Subsequent sequence analysis of the splice boundaries was perfonned with 
primers designed from the spliced sequence. The position of the spliced sequence in intron 
I was determined by PCR analysis of selected cosmid clones as well as by analysis of the 
constntct containing the 4.5-kb EcoRl-EcoRl fragment described above with primers 
designed from eXOI1S I and II in combination with the primers designed from the spliced 
sequence. 
Results 
Exoll-Jlltrolljllllctiolis alld illtroll sizes of the TGM4 gelle 
Screening of a human genomic cosmid library with two hTG, cDNA fragments (see the 
Materials and Methods) yielded clones I and 24.1.3 (Figure I). Restriction mapping and 
subsequent Southern hybridization with the eXon I-specific oligonucleotide HPSTG 13 
showed that clone 24.1.3 contained approximately 650-bp TGM4 promoter sequences. To 
obtain a larger part of the promoter, a 500-bp NsiI-NsiI fragment from cosmid clone 24.1.3, 
comprising the proximal TGM4 promoter and most of exon I, was used for rescreening of 
the genomic library. This led to the isolation of cosmid clone 3.1.1 (Figure I). Combined, 
the three selected clones cover the whole TGM4 gene and a substantial part of the 5'-
flanking region. 
These clones were used to determine the intwn sizes and localizations. Based upon the 
assumption that the TGM4 gene had a genomic organization similar to that of other 
identified TGase genes, specific primer pairs were designed in the predicted neighboring 
exons. All introns (Table I), except intron I, could be PCR amplified. Intron-containing 
amplified fragments were subcloned, and each exoll-intron boundary was sequenced. The 
length of iIltIOn 1 was detennined by restriction mapping, and the sequences of its exon-
intron junctions were resolved by direct sequence analysis of cosmid clone 24.1.3. All 
exon-intron junctions confonned to the gtJag 11Ile of splice donor/acceptor sites [Table I 
(Shapiro and Senapathy 1987)]. Figure 1 and Table I show that the TGM4 gene spans 
approximately 35 kb of genomic DNA and basically consists of 13 exons and 12 introns. 
The exons range in size from 63 to 279 bp; the large exon XIII (1026 bp) includes the 3'-
UTR. Exon I encodes 5'-UTR information and the first six amino acids of the hTG, protein. 
The intron sizes vary from 94 bp (intron 6) to approximately 10.5 kb (intronl). 
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Exon II III IV v VI VII VIII IX X XI XII XllI 
rntroll 5 8 9 10 II 12 
------------ 24.1.3 ----------
Ikb 
3.1.1 
Figure 1. Structural organization of the TGM4 gene. The 5'- and 3'-untrallslatcd regions are indicated as 
open boxes, and the coding exolls are indicated as black boxes. The illtrons are represented by the lines 
between the exons. TIle positions of the cosmid clones are shown at the bottom. With the exception of 
intron I, the drawing is to scale. 
Table 1. Exon-Intron Structure and Splice JUllction Sequences of the TGAf4 gene. 
Illtron eDNA position Splice donor ll1lron length (kb) Splice acceptor 
63 GCATCAAAAGgtgagtgggt 10.5 ttgctgacagAGCTGCAAGT 
2 237 TTCAGCACAGgtgaagcctc 2.0 ggtgtctcagGGCCGAATCC 
3 474 TGGTGTAAAGgtcatgtgaa 2.6 cttgcttcagAGGACATGGT 
4 593 CTITGGTCAGgtaacgattt 2.8 cccaaaatagTTTGAGAAAA 
5 701 GTGTGCTA TGgtaggtatgg 4.6 tgtgtggcagATGAGCTITG 
6 876 CTGACTACAGgtaagtggca 0.1 atcatttcagTGCTGAGAGC 
7 1015 ACTCTGTCTGgtagggttcc 1.9 tttgcggcagGAA TITCCAT 
8 1119 CGAAGCCAGGgtgagtgggt 2.7 ttcccctcagGTGTCTTCTG 
9 1371 TA TCCAGAAGgtgctagcat 2.7 tctctltcagGCTCCTCTGA 
10 1650 CAAGGTCAAGgtaccagaac 0.6 tctttggcagTATCAGAAGT 
II 1820 CTCTATAGAGgtgagctlcc 0.2 cClaclacagTTGCCTAACA 
12 1957 CTGACCATGGgtgagtctgc 2.1 aaltttce'gGACGGTGCAG 
Note TIle capital letters represent coding sequences and lower case letters represent inlron sequences, eDNA 
positions are according to Dubbink et al. (1996). 
Identification of a major transcription start site 
The transcription start site of the TGM4 gene was identified by 5'-RACE using Marathon-
Ready human prostate eDNA. For this purpose three antisense gene-specific primers, 
HPSTG 2, HPSTG 16, and HPSTG 17, were chosen in combination with anchored primer 
AP 1, as schematically drawn in Figure 2A. The most abundant bands obtained by PCR 
amplification and subsequent Southem blot analysis with exoll I-specific oligonucleotide 
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HPSTG 13 are approximately 760, 380, and 600 bp in size, respectively, snggesting that the 
transcription start site is located close to the 5'-end of the published hTGp cDNA sequence 
[(Grant et a!. 1994, Dubbink et a!. 1996) see also Figs. 2A and 2BJ. 
Twelve independent clones obtained from the primer HPSTG 16 PCR products were 
sequenced. Figure 2D shows the 5' sequences of these clones and the frequency at which 
they occurred. \Ve determined the major h'anscription start site, found in five of the clones, 
at the C residue eight nucleotides upstream of the AG 5' end of the published hTGp eDNA 
sequence (Dubbink et a!. 1996, and Figure 2D), i.e., 52 bp upstream of the a'anslational 
start codon. 
A 
API 
B 
D 
5'·UTR 
kb 
0.8 -
0.6· 
0.4 . 
HPSTG16 
~ 
322 
5' ends 
c •• 
ATCNJ 
OOCATCAO 
CAOOCATCAG 
I.e CAOOCATCAO 
aAAGCAC CAOOCA'I'CAG 
HPST017 HPST02 
~ ~ 
• j , 
548 702 
C 
kb 
0.8· 
0.6 • 
0.4 -
number 
of clones 
, 
1 
1 
5 
1 
1 
Figure 2. Determ.ination of the transcription initiation site. (A) The transcription initiation site was 
dctcnnined by performing 51~RACE on Marathon-Ready human prostate eDNA. TIle positions of the gene-
specific primers HPSrG 2, HPSTG 16, and HPSTG 17 arc indicated and numbered according to the 
published eDNA sequence (Dubbink ct al. 1996). The adaptor, which is ligated 10 the eDNA ends by the 
manufacturer, is indicated as a black bar. API is adaptor primer I. The open bar represents the hTGr cDNA 
open reading frame. (B) SOli them blot analysis of the 5'-RACE products with exon I-specific 
oligonucleotide HPSTG 13. (C) Reprobing the same blot with AlII-specific primer HPSTG 34. (0) TIle 5' 
sequences of 12 5'-RACE products and the number of clones containing this sequence. TIle two nucleotides 
in italic letters indicate the 5' nuclcotides of the previously published hTGr eDNA sequence (Dubbink et al. 
1996). 
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A 
yyyyyyncag G splice acceptor consensus 
1 ttttttttag AGTTGAGGTC TCACTTTGTT GCCCAGGCTG GCGTGTTGTG GCTATTCACA 
61 GCTGCAATCA TAGCTCACTG CAGCCTCAAA CTCCTGGGCr ChAGTGATTC TCCCACCrCA 
121 GTCTCCCGAG TAACCGGGAT TACAGgtatg tgact 
B 
splice donor consensus AGgtrag t 
AGAGATAGAGTCTTCCCTGGCATTGCAGGAGAGAATCTGAAGGGATGATGGATGCATCAAAAGAGT 
!·lHDASKEL 
67 TGAGGTCTCACTTTGTTGCCCAGGCTGGCGTGTTGTGGCTATTCACAGCTGCAATCATAGCTCACT 
9 R S H F V A Q A G V L W L F T A A I I A H C 
133 GCAGCCTCAAACTCCTGGGCTCAAGTGATTCTCCCACCTCAGTCTCCCGAG'l'AACCGGGATTACAG 
31 S L K L L G S S D S P T S V S R V T G I T E 
199 AGCTGCAAGTTCTCCACATTGACTTCTTGAA'fCAGGACAACGCCGTTTCTCACCACACATGGGAGT 
53 L Q V L HID FLU Q DNA V S H H T ~I E F 
Figure 3. Altemative splicing of intron 1 of the TGM4 gene. (A) Nucleotide sequence of the intron I Alu 
sequeJlce and the exon-intron boundaries that are involved in alternative splicing of intron I. Consenslls 
splice donor and acceptor sequences are indicated. N, any nucleotide; Y, pyrimidine; R; purine (Shapiro and 
Senapathy 1987). The alternative exon sequence is shown in capital letters, and the intron sequences are 
shown in lowercase letters. The splice consensus ag and gt residues are shown in boldface type. (B) 
Nucleotide and deduced amino acid sequence of the alternative spliced hTGI' eDNA. The AIli insertion is 
underlined. 
A hTGp splice varimlt 
During the experiments for the identification of the transcription start site, several extra 
bands became visible after hybridization with exon I primer HPSTG 13 (Figure 2B). Using 
primer HPSTG 16 for 5'-RACE, which should lead to the smallest PCR products, in 
addition to the 380-bp fragment, bands of 550 bp and I kb were present. Sequence analysis 
of the entire 380- and 550-bp fragments showed that the largest band contained an in-frame 
insertion of 135 bp at cDNA position 63, the site where we determined the position of 
intron I (Table I, Figs. 3A en B). The inserted sequence was part of an AIII-J repeat (Jurka 
and Smith 1988). We did not further study the I-kb fragment. However, reprobing the blot 
with primer HPSTG 34, a primer designed from the AlII sequence, demonstrated that the 1-
kb band also contained this sequence. The AlII repeat was also found to be present in larger 
fragments produced with primers HPSTG 2 ancl HPSTG 17 (compare Figs. 2B and 2C). 
The AlII repeat was also present in hTGp cDNA from prostatic tissues as deduced from RT-
peR with primers designed from exon [ and II (data not shown). The 135-bp spliced AlII 
sequence was localized within a 4.5-kb EcoRI-EcoRI fragment of cosmid clone 3.1.1, the 
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Figure 4. Dot blot analysis of hTGr expression in human tissues. CA) Loading pattern of the human RNA 
master blot used. (8) Re-sult of the dot hlot analysis. The hybridization was performed under high~ 
stringency conditions (see Materials and Methods) with a 184-bp hTGp eDNA fragment corresponding to 
nucleotides 42-225 of its previollsly published sequence (Dubbink ct al. 1996). Each spot contained 85-542 
ng ofpoly(At IllRNA. 
only band hybridizing with primer HPSTG 34. Sequence analysis of this genomic fragment 
with primers designed from the Alu sequence showed that the 135-bp Alu sequence is 
located within a 163-bp Alu repeat. 1110 splice junctions conform to the gtlag mle and 
nearly perfectly match the splice donor and acceptor consensus sequences (Figure 3A). 
PCR analysis of cosmid clones 24.1.3 and 3.1.1 as well as the 4.s-kb EcoRI-EcoRI 
fragment with A III primers in combination with an exon II primer demonstrated that the Alu 
sequence is localized approximately 3,1 kb upstream of exon II in the orientation opposite 
to that of the TGM4 gene (Figure sB). 
Prostate-specific e.\]J1'essioll of h TOp 
The results from a previous study on a limited number of tissues suggested that hTGp is 
prostate-specifically expressed (Dubbink et al. 1996). To analyze the hTG p expression in a 
larger series of nonnal human tissues, a human RNA master blot, containing poly(At 
mRNA from 50 different tissues (Figure 4A), was hybridized with a hTGp cDNA probe that 
was chosen from a region with very low similarity to other TGases. Figure 4B shows that 
hTGp expression is restricted entirely to the prostate. The faint signals present in the kidney 
mRNA and the Escherichia coli DNA spots seem to represent nonspecific reactivity. RT-
peR analysis of kidney mRNA could not continn expression in the kidney (data not 
shown). 
Structural {lJldful/ctioJlal analysis a/the TGA14 gelle promoter 
To analyze the promoter region of the TGM4 gene, a 3.0-kb PstI-Pstl fragment of cosmid 
clone 3.1.1, which hybridized with exon I primer RPSTG 13, was isolated. It contained 
approximately 2.1 kb of the s'-flanking region of the gene, exon T, and the beginning of 
intron I. The sequence of the promoter region is shown in Figure SA. The s'-UTR eDNA 
sequence is completely present in this genomic fragment, indicating the absence of more 
upstream exons. Computer analysis revealed that the TGA14 proximal promoter harbors a 
CATAA motif, 49 bp upstream from the major transcription start site, but no typical 
CCAAT box. Just upstream of the CATAA motif, at positions -96 to -87, the promoter 
contains an Spl binding site. Compmison of the sequences obtained from the proximal 
promoter regions present in cosmids 24.1.3 and 3.1.1 showed a T/G polymorphism at 
position-127. 
A processed cyclophilin A pselldogene with 94% similarity to cyclophilin A cDNA 
(Raendler et al. 1987) was present at position -1276 to -563. Because of the absence of a 
correct start codon (position -1263, Figure SA), and the interl1lption of the open reading 
frame by several deletions and insertions, this gene cannot lead to a functional protein 
product. Further analysis of the TGM4 promoter showed 132 bp of an Alu repeat sequence 
(-1452 to -1320) as well as part ofa LINE-J repetitive element (-1720 to -1492, Figs. SA 
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A 
-2077 CTGCAGA ACAGC~ CCTCTGACTT CATTATTGIT ATTCAGAGTA ACCAGGGTCA 11GCTC1C1G GCTTGCTTAA 
-2000 AGCCAGCAAA GGCAATTGCC CATCCCTGGG CTTTTGGTCT GGAAGAGACC GTTGGCATCA TTATTCAGCC CCCTeACTT! 
-1920 TCAGGTAAGG AGCTAATGAA GACAACATTC CCAGTGACAC ACGGCAAGTT ACTGTGGTGT TGGGGTTTCA GTGTCAGGAG 
-1840 1crCC1CTCT TCCTCTGGCA TTTCTGCTAC TATGCCAGGC TGGCTCCITT CAGIAGACAT AACATCArTG AAAAATACCA 
-1760 CAAGTGCCCC TGTGGAGAGC AGAGCAGATA GCCAITAAAA TTACAAAAGC TTATGCTTTT TGGCCCAACA TTTCA.CTTCA 
-1680 AGGCATTCM TTCTTCCTAT AGArA.CACTC ATGTGAGGG'i' AAAATGATCT CTGTATAACC TTATTCTTTG CAACACTGAT 
-1600 TGTAATAAGG AAATATTGGA AGCAACCCAG 1I1GCC1ATGG GTGGGAGGTG AGTTACATAA ATTAGGGACC ATCCACACAA 
-1520 ACAGAATATG TGCAGCTGTG AAAAGACTGG GCCACCTCTC CATGTGCAAT AGGAACAGCT CCATCTTGCC AGGCGTGGTG 
-1440 GCTCACACCT GTAATCCCAG TACTTTGGGA GGTGAAGGTG GGGCGGATCC CTTGAGCCTA GGCATTCCAG ACCAGCCTGG 
-1360 GCAATGCAGT GATATGCTCT CATTGTGTAA ATAAAACAAA ATAA1ACA1T ATTTGCTTTG CAGATGCCAC TGCCGCCAGA 
-1280 GCCCTGTAAC ATCAGCCATC GTCAACCCCA CCGTGT1CTT CAACATCACC GTTGACGGCA AGCCTTTAGA CCTGCG1CTC 
-1200 CTTCAAGCTG TTTGCAGACA AGGTTCCAAA GCCAGCAGAA AACTTTTGTG CTCTGAGCAC TGGAGAGAAA GGATTTGGTT 
-1120 ATAAGAGTTC CTGCTTTCAC AGAATTATTC CAGGGTTTAT GTGTCAGGGT GGTGACTTCA TACGCCATAA TGGCACTGGT 
-1040 GGCAAGTCCA TCTATGGGGA GAAATTTGAT GATGAGAACT TCATCCTAAA GCATACAGGT CCTGGCATGT TGTCCATGGC 
-960 AMTGCTGGA CCCAATACAA ATGGTTCCCA GTTTTTAATC TGCACTGCCA AGACTGAGTG GTTGGATGGC AAGCTTGTGG 
-880 TCTTTGGCAA GGTGAAGGCA TGAATATTGT GGAGGCCATG GAGTGCTTTG TGTCCAGGAA TGGCAAGACC GGCCAGAAGA 
-800 TCACCATTGC TGACTGTGGA CAGCTCTTAT AAGTTTGACT TGTGTTTTAT CTTAACCACC AGACCATTCC TTCTGTAGCT 
-720 CAGGGGAGCA CCCTCCACCC CATTTGCTCC CAGTATCCTA GAATCTTTGT GCTCTCGCTG CGGTTCCCTT TGGGTTCCAT 
-640 GTTTTCCTTG TTCCCTTCCA TGCCTAGCTG GATTGCAGAG TTAAGTTTAT GATTATGAAA TAAAAACTAA ATAACMAAT 
-560 AATAATAATA GTACATTATT TGCTTCTCAG TGCATACAAC ATCTCTGGAA AGATCTAAAA GAAACTGGTA GTAGGATTCA 
-480 ACAAGGTGGA CAGGGGGCAT TTTTTTCCAT TTTGAACCAT GTGGATGCAT TATATATTCA AAA7GTAAAA C~CTC 
-400 ACAAGCATCT CTTACTTTTT CAACTTGAAG AAAAGAGAAG AAGAAGAAAA CCCTAAAGTC AGTAAAGGTT AGCCTGGGTT 
-320 CCTAGACTTA AGCTTGATAG TAACCAGAAT GTCAGGCCAC ATGTGGTGTA GGTCATAGGG TCCTGGCTTT TGGTCACCCA 
-240 CTGTTAGGCT CATATAACAG ACAAGGAGGT GCCATTGTCC GTTGTCTGTC CCTTTTACAT CAGCTCATCT TGGCTCCTGA 
-160 T1TCCTGGGT CTGATATGGA AGATTCCGGG ATTTTATTAT TTCTAATCAA CATCGCCTTC CCAAACCCCG CCCCTTGGCA 
G 
-80 GCCATAGCAA GGCCACATCT AGCCCAGGAT CACATAA.l1.AA GGGCTGTTTC crCCCCTGAG GACCGACTGT GTGGAAGCAC 
" 
~AGGCATCAG AGATAGAGTC TTCCCTGGCA TTGCAGGAGA GAATCTGAAG GGATGAT03A TGCATCAAAA Gqtgagtggg 
Exon 1 lntron 1 
B 
LI AlII PPIP +1 AlII 
"""' 
100 bp ExonI Intron 1 ExonII 
Figure 5. The 5'-region of the TGM4 gene. (A) Nucleotide sequence of the TGM4 promoter with adjacent 
exon I and part ofintron 1. The experimentally determined major transcription start site (+1) is indicated by 
a double-underlined boldface type letter. The CATAA box (-48) is shown in boldface type and is 
underlined. The translational start sites are shown in boldface, italics. The first lluc1eotides of intron I are 
represented by lowercase letters and the splice conscnsus gt residues in boldfacc type. The PPIP 
pseudogene is underlined and its mutated start site is double-underlined. 111C Alu and L1NE-l repeals are 
shown ill italics. At position -127, a T/G polymorphism is present. (8) Schematic presentation of the 
localization and orientation of thc PPIP pseudogenc, the Alit repeats, and the LlNE-l repeat (LI) in the 
TGM4 promoter and intron 1. With the exception of intron 1, the drawing is to scale. 
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and 5B). TIle Alu repeat cOlTesponds to the Alu-J subtype and the LINE-J repeat to the 
LlME3A subtype (Jurka and Smith 1988, Smit et al. 1995). 
For functional analysis of the TGM4 gene promoter, three promoter constructs, pTGM4-
0.5Luc, pTGM4-1.5Luc, and pTGM4-2.1Luc, were generated, containing 0.5,1.5, and 2.1 
kb of the promoter, respectively. pTGM4-0.5Luc contains the proximal promoter, 
pTGM4-1.5Luc additionally contains the entire PPJP gene and the Alu repeat, and 
pTGM4-2.1 includes these sequences as well as the Ll repeat and more distal promoter 
information (Figure 6). Transient transfections were perfOlmed to the human prostate 
cancer cell line PC346C, the only in vill'O growing prostatic cell line in which endogenous 
hTGp expression has been demonstrated so far (Dubbink et al. 1996). The results presented 
in Figure 6 show that pTGM4-0.5Luc harbors a functional promoter. The two other 
constnlcts containing a larger part of the TGM4 promoter show the same level of activity. 
PnJ/1 B~I" 
pTGM4-2.1lue -1077 
pTGM4-1.SLuc 
pGL3.basic 
o 0,' 1.5 
Luciferase aelility (x IOJ) 
Figure 6. Functional analysis of the TGM4 promoter. PC346C cells were transiently transfected with the 
TGM4 promoter constructs pTGM4-0.5Ltlc, pTGM4-1.5Luc, and pTGM4-2.1 Luc, as described under 
Materials and Methods, (Left) Schematic representations of the constructs, The promoter fragments were 
subcloned in frollt of a luciferasc reporter gene using the indicated restriction enzymes as described under 
Materials and Methods. TIle PPIP pseudogene and the repetitive clements are indicated as black bars (see 
also Figure 5B). Standard errors of three experiments are indicated. 
Discussion 
In this report we describe the organization of the TGM4 gene and identified 2.1 kb of its 
promoter. This completes the isolation of all currently known human TGase-encoding 
genes. 
The TGA/4 gene is about 35 kb in length and is contained in 13 exons and 12 introns. There 
is a striking structural similarity between the TG1H4 gene and the other TGase genes 
including the gene for band 4.2 (Table 2). Only small variations occur in the size of 
corresponding exons, with the exception of the eXOlls encoding the 5'- and 3'-UTRs. 
Whereas there is a Intge variation in intron sizes and thus in gene sizes (varying from 14.1 
to over 160 kb), the number of introns and their localization are largely the same for the 
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Table 2. Intron and exon sizes of the TGase gene family 
Intron size" Il1tron size 
TGM4 TGM2" TGM3" Band 4,2" TGMl" FXma' 
Intron (35)" (32.5) (42.8) (20) Intron (14.1) (>160) 
0.7 nd' 
10.5 2.6 13.4 6.5 2 0.2 nd 
2 2.0 5.1 OJ 0.9 3 1.0 nd 
3 2.6 1.5 0.6 0.6 4 0.4 nd 
4 2.8 2.9 1.8 0.3 5 0.1 nd 
5 4.6 1.1 1.3 0.9 6 0.5 nd 
6 0.1 4.6 0.1 0.3 7 0.4 nd 
7 1.9 0.7 8.6 0.7 8 0.1 nd 
8 2.7 1.6 2.2 0.5 9 2.2 nd 
10 0.5 nd 
9 2.7 1.0 4.0 0.4 11 0.1 nd 
10 0.6 5.4 3J 2.6 12 0.1 nd 
II 0.2 1.1 4.0 2.2 13 0.4 nd 
12 2.1 0.9 0.5 3.1 14 4.6 nd 
Exon size" Exol1 size 
TGM4 TGM2" TGM3" Band 4.2" TGMl" FXllla" 
Exon (35)" (32.5) (42.8) (20) Exon ( 14.1) (>160) 
89 63 
63 144 48 ?ti II 321 148 
I! 174 180 174 186 III 189 189 
III 237 243 240 234 IV 249 252 
IV 119 119 119 119 V 119 119 
V 108 129 129 105 VI 108 108 
VI 175 178 178 178 Vll 175 175 
VI! 139 136 136 139 Vlll 139 139 
Vlll 104 104 104 104 IX 104 104 
X 89 89 
IX 252 243 246 243 Xl 154 154 
X 279 273 309 300 XI! 282 288 
XI 170 161 158 161 Xlll 161 161 
XI! 137 137 134 134 XIV 137 137 
XIll' 1026 1209 645 ? XV 403 1688 
a Gene and inlron size is given in kb, the eXOll size in bp. 
b Data obtained from Ichinose and Davie 1988, Korsgren and Cohen 1991, Kim et al. 1992, 1994a, 
Phillips et al. 1992, Yamanishi et al. 1992, and Fraij and Gonzales 1997. 
c Intran sizes of the FXIIJa gene are not determined (nd) yet. 
d Exon I of the band 4. 2 gene is subjected to alternative splicing. 
c Includes 3'wUTR. 
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different TGase genes, The intron phases (Sharp 1981) of corresponding introns are 
identical in all characterized TGase genes (!chinose and Davie 1988, Korsgren and Cohen 
1991, Phillips et a1. 1992, Kim et a1. 1994a, Fraij and Gonzales 1997), Comparison of their 
organization shows that the TGase genes can be divided into two subclasses, The TGM2, 
TGM3, TGM4, and band 4.2 genes all encompass 13 exons and 12 introns, The FXlIIa and 
TGMI genes contain two extra exons, Exon IX of the former group is separated into two 
exons, X and XI, and their larger 51 untrallslated region is encoded by two exons, I and II. 
The TGM4 promoter contains a cyclophilin A processed pseudogene (PPIP), Cyclophilin A 
is a peptidy1wprolyl cis-trans isomerase (PPIase) and as such is involved in protein folding 
(Fischer et a1. 1989, Takahashi et a1. 1989), It is encoded by a gene of approximately 5,5 kb 
with an exon-intron stmcture (Haendler et a1. 1987, Haendler and Hofer 1990), The human 
genome further contains at least 15 PPIP retropseudogenes, which share an identity of 75-
95% with the cyclophilin A cDNA sequence (Haendler and Hofer 1990, Willenbrink et a1. 
1995), The PPIP pseudogene in the TGM4 promoter shares 94% identity with the 
cyclophilin A cDNA sequence, As in most of the PPIP pseudogenes, the PPIP pseudogene 
upstream of the TGM4 gene is dismpted by deletions and insertions leading to premature 
stop cadons. The PPIP pseudogenes are dispersed over at least seven chromosomes. One of 
the PPIP pseudogenes, PPlP6, is localized at chromosome 3 (Willenbrink et a1. 1995), 
Recently, the TGM4 gene has also been mapped to chromosome 3 (Gentile et a1. 1995, 
Dubbink et a1. 1996), Comparison of the PPIP6 sequence with the PPIP pseudogene in the 
TGM4 promoter showed significant differences (89% identity), which indicates that at least 
two PPIP pseudogcllcs are located at chromosome 3. 
There are at least two other genes with a PPIP pseudogene in their promoter regions: the 
genes encoding cholesterol 7a hydroxylase (Thompson et a1. 1993) and angiotensine I 
converting enzyme (GenBank Accession No, X94359), Both pseudogenes are located 
further upstream in the 5'-flanking sequence, The pseudogene upstream of the cholesterol 
7a hydroxylase gene is in the opposite orientation and at -3.4 kb (Thompson et a1. 1993); 
the pseudogene in the angiotensine I converting enzyme is at 5.4 kb upstream and is 
positioned in the same orientation as the gene (Villard et a1. 1996), At present, there is no 
regulatory function ascribed to these pseudogenes, Functional analysis of the TGM4 gene 
promoter, presented in this s!tldy, in the human prostate cancer celiline PC346C showed 
that basal activity is localized within the proximal 500 bp of the TGM4 promoter and that 
no additional activity is transfened by the larger constmcts containing the PPIP 
pseudogene, the repetitive elements, and more distal promoter information. The presence of 
the PPIP pseudogene and the repetitive elements in the TGM4 promoter do not necessarily 
indicate the 5' border of the regulatory region, As an example, the prostate-specific antigen 
(PSA) promoter contains an upstream enhancer responsible for androgen-regulated and 
tissue-specific expression (Schuur et a1. 1996, Cleutjens et a!. 1997b, Pang et a!. 1997) that 
is separated from the proximal promoter by several Alu-type repeats encompassing 1.1 kb 
of DNA, 
Although only one transcript of 3,5 kb can be detected by Northem blot analysis of hTGp 
mRNA in the prostate cancer cell line PC346C (Dubbink et a1. 1996) and in prostatic 
tissues (unpublished data), we found a complex splicing paUem of intron 1. TIle main 
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transcript is spliced following the exon S011cturC as depicted in Figure 1. One of the less 
abundant transcripts contains an in-frame insertion of a 135-bp antisense Alu repeat 
encoding 45 extra amino acids. The same A III element also seems to be involved in other 
splice variants of intron I, since the Alu-specific primer hybridized with several RT-PCR 
products obtained from prostatic tissues, but reacted with only one band of an EeaRl digest 
of cosmid clone 3.1.1. The boundaries of the 135-bp Alu sequence perfectly reflect the 
splice consensus sequences and are therefore suitable for splice-mediated insertion of this 
fragment into the hTGp mRNA. 
Splice-mediated insertion of iutmnic Alit elements into mature transcripts has been 
described for several RNAs. Most often this concerns the inh'oduction of AlII sequences 
into the 5'- or 3'-UTR of l1lRNAs (Yulug et al. 1995), but insertions of Alu cassettes into 
protein-coding regions have also been reported (Makalowski et al. 1994). Cases have been 
described in which an inherited mutation in a cryptic splice site of an Alu element resulted 
in the acquisition of an additional exol1 in all mature transcripts, thereby causing a 
pathological sioration (Mitchell et al. 1991, Knebelmann et al. 1995). The splice variant 
described here seems to be a normal event in the prostate, since it was detected in all 
prostatic tissues examined. At present, little is known about the influence of Alu cassettes, 
which are not deleterious, on the function of the host protein. One possibility is that it 
influences the localization of the protein within the cell (Makalowski et al. 1994). It is 
therefore tempting to speculate that the Alu insertion may interfere with mechanisms 
underlying the excretion of the hTGp protein. 
Prostate cancer is the most commonly diagnosed cancer in males in Western countries. 
Metastatic prostate cancer is a fatal disease for which there is no curative treatment at 
present (Isaacs 1997). 111erefore, new treatment sO'ategies based upon newly available 
methods must be developed. One such alternative approach is to target cytotoxic genes to 
cells derived from the prostate by means of prostate-specific gene promoters. To date the 
only human gene promoter that has been extensively characterized for its ability to direct 
tissue-specific expression is the promoter of the PSA gene (Schuur et al. 1996, Cleutjens et 
al. 1997a, 1997b, Pang et al. 1997). Previously, we obtained preliminary evidence for the 
prostate specificity of hTGp (Dubbink et al. 1996). In this report, we clearly demonstrate 
that the expression of hTGp is strictly confined to the prostate. Now that we have identified 
the TGM4 gene SO'ucture and isolated a large part of the TGM4 promoter, it is possible to 
investigate the mechanisms underlying this prostate-specific expression. Elucidation of the 
different mechanisms playing a role in prostate-specific gene expressionl11ay finally lead to 
the development of a well-defined and highly specific anti-cancer treatment based on a 
molecular approach. 
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Abstract 
Human prostate-specific transglutaminase (hTGp) is a cross-linking enzyme encoded by the 
TGM4 gene, The TGM4 gene promoter was characterized by deletion mapping and mutational 
analysis. Promoter constl11cts, containing the minimal promoter requirements, could efficiently 
drive transcription in tl,e prostate cancer cell lines PC346C and LNCaP and the hepatic cancer 
cell line Hep3B, The region between positions - I 13 and -6 I was demonstrated to be essential 
for core promoter activity. Further analysis revealed the functional importance of an Spl 
binding motif, 5'-ACCCCGCCCC-3', at positions -96 to -87, TIus sequence is a binding site of 
the ubiquitous transcription factors Sp I and Spl 
Introduction 
Human prostate-specific transglutaminase (hTGp) belongs to the transglutaminase (TOase, Be 
2,3.2,13) family that comprises at least seven members (Aeschlimann and Paulsson 1994, 
Aeschlimalll et al. 1998). TGases are involved in the fOlTIlation of stable protein-protein or 
protein-polyamine bonds through the catalysis of the acyl h'ansfer reaction between a peptide 
bound glutamine and primaty amine groups. hTGp is supposed to cross-link seminal proteins 
and polyamines, for instance to the surface of spenTI cells, \vhich could result in a decreased 
inl!l1tlllogenic response in the female urogenital h'act (POlia et al. 1986), TI,e expression of 
hTGp is entirely restricted to the prostate and regulated by androgens (Dubbink et al. 1996, 
1998), In conh'ast to other prostatic markers, e,g, prostate-specific antigen (PSA) and prostatic 
acid phosphatase (Lilja and Abrahamsson 1988), hTGp is only produced by a subset of the 
luminal prostatic epitllClial cells (Dubbink et al. 1999b), At present, the molecular mechanism 
underlying hTGp expression is unknown. 
hTGp is encoded by the TGM4 gene, Recently, we resolved tile genomic stmcture of tile TGM4 
gene and detennined the sequence of 2,1 kb of its promoter (Dubbiuk et al. 1998), We 
demonstrated the ftmctional activity of the TGM4 promoter by transient transfection 
experinlents using the human prostate cancer cell line PC346C, the only cell line in which 
hTGp expression was found (Dubbink et al. 1996), Basal activity was shown to reside within 
the proximal 0,5 kb of tile TGM4 promoter. 
To further characterize the molecular mechanisms underlying the expression of hTGp, we 
pelfonned transfections to prostatic and non-prostatic Imman cell lines with several promoter 
deletion constlUcts. TIle region between positions -113 and -61 was shown to be essentia1. We 
demonstrated the imp0l1ance of an Sp 1 binding motif within this region. Transcription factors 
Sp I and Sp3 were shown to bind to this motif, 
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Materials and Methods 
Cell cullure 
PC346C cells were cultured in a Dulbecco's modified Eagle's medium (DMEM)/F12-based 
growth medium (Gibco, Grand Island, NY, U,S,A,), as described previously (Dubbink et al. 
1996), LNCaP and Hep3B cells were cultured in RPMI 1640 and DMEM (Gibco), 
respectively, botll supplemented with 5% (v/v) fetal calf semm and antibiotics, Prior to 
h'ansfections, RPMI medium was substituted by DMEM with 5% (v/v) FCS, 
Generation ofTGA14 promoter COlls/ructs 
For transfections, TGM4 promoter fragments were cloned in pGL3,basic (Promega, Madison, 
WI, U,S,A,), pTGM4-0,5Luc (-510 to +54), pTGM4-I.5Luc (-1508 to +54) and pTGM4-
2,ILuc (-2077 to +54) have been described previously (Dubbink et al. 1998), Deletiou 
constl1lcts of the proximal promoter were prepared using a nested deletion kit (Pham1Ucia, 
Uppsala, Sweden), For this pmpose, the pTGM4-0,5Luc constmct was digested witll KpnI and 
BglII and processed according to the manufacturer's protocol. Clones were selected by HindlII 
digestions followed by sequencing analysis with a 17 sequence kit (Phal111acia), 
A CC to AA mutation at positions -93 and -92 of tlle TGM4 promoter, within tlle Sp 1 binding 
motif, was introduced by PCR (pTGM4-113Luc,mut), PCR amplification was performed with 
primer 5'-ACGGGGTACCAACATCGCCTfCCCAAACCAAGCCCCITGGCAG-3' 
(position -113 to -80, mutation indicated in boldface, italics) and a primer designed from 
pGL3,basic as described previously (Dubbink et al. 1996), For cloning purposes, tlle promoter 
primer was provided with a KpnI site (underlined), pTGM4-II3Luc (see the Results section) 
was used as a template for PCR amplification, The PCR product was purified from gel, 
digested witll KpnI and HindlII and ligated into pGL3,basic, The inhnduction of the mutation 
was verified by sequencing. Plasmid isolations for transfedions were perfolDled with a 
Qiafilter plasmid isolation kit (Qiagen, Hilden, Gel111any), 
Transiem tl'al1,~fectiol1s and luei/erase assay 
The cells were transfected according to the calcium phosphate method essentially as described 
(Chen and Okayama 1987), using 1xlO' cells per 25-cm' flask and 5 ~lg of tlle appropriate 
constmct. After a 4-h incubation with the precipitate, the culhue medium was replaced by 15% 
glycerol in PBS and incubated for 90 sec at room temperature, Subsequently, transfected cells 
were cultured in medium for 24 h, Transfections were perfonned at least four times in 
dnplicate with two independent plasmid isolates, 
Cells were hmvested in 400 pi lysis buffer (25 nu\1 Tris-phosphate pH7,8, 8 mM MgCI" I 
111M DIT, 1% Triton X-IOO and 15% glycerol), Subsequently, 100 ~t1luciferill (0,25 ~IM) 
(Sigma, St. Louis, MO, U,S,A,)I 0.25 pM ATP was added to 10 ~t! (LNCaP and Hep3B) or 
150 ~t1 (PC346C) cell lysate, Luciferase activity was measured in a LUMAC 2500 M 
Biocounter (LUMAC, Landgraaf, The Netherlands), 
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Electrophoretic mobility shifl assay (EMSA) 
Nuclear extracts were prepared as described (Dignam et al. 1983). Double stranded 
oligonucleotides used for gel retardation were as follows: 
-113/-6I.wt: 
5' tcgaCAACATCGCCTTCCCAAACCCCGCCCCTTGGCAGCCATAGCAAGGCCACATCg 3' 
3' GTTGTAGCGGAAGGGTTTGGGGCGGGGAACCGTCGGTATCGTTCCGGTGTAGcagct 5' 
-113/-6I.mut: 
5' tcgaCAACATCGCCTTCCCAAACCAAGCCCCTTGGCAGCCATAGCAAGGCCACATCg 3' 
3' GTTGTAGCGGAAGGGTTTGGTTCGGGGAACCGTCGGTATCGTTCCGGTGTAGcagct 5' 
-101l-80.wt: 
5' tcgaCCCAAACCCCGCCCCTTGGCAG 3' 
3' GGGTTTGGGGCGGGGAACCGTCagct 5' 
The sequences of these oligonucleotides con'espond to human TGM4 promoter sequences -113 
to -61 (wild-type and mutant, mutation in boldface, italics) and -101 to -80 (wild-type), 
respectively. 5'-overhanging sequences, introduced for labelling purposes, are indicated in 
lower case letters. The oligonucleotides were labelled by the incorporation of a-32P_dA TP with 
MMLV-reverse transcriptase. For EMSA's, 20-S0xlO' cpm of each probe was added to 20 !Il 
reaction mixture, containing 2 !Ig poly (dI-dC), 2 !Ig BSA, 10 !IM ZnCI" 1 mM DTI and 2 J.ll 
lOx binding buffer (100 mM Hepes pH 7.6, 300 mM KCl, 62.S mM MgCI, and 40% ficoll), 
and 10 !Ig LNCaP nuclear protein. Competition experiments were perfonned in the presence of 
a 200-fold excess of Ule indicated non-labelled oligonucleotides. TIle double stranded Spl and 
NFl consensus oligonucleotides (S'-ATICGATCGGGGCGGGGCGAGC-3' and 5'-
CCTTIGGCATGCTGCCAATATG-3') were purchased from Promega. In supershift 
experiments, the reaction mixture was incubated for 30 min at 4 °C with 2 ~ll mouse 
monoclonal antibody against Spl and/or Sp3 (Santa Cmz Biotechnology Inc., Santa Cmz, CA, 
U.s.A.). Oligonucleotide-protein complexes were separated from free probes by 4% non-
denaturing polyaclylamide gel electrophoresis. 
Results 
Characterizatioll of the TGM4 promoter ill differellt humall cell lilies 
Previously we localized the main transcription start site of Ule TGM4 gene at 52 bp upstream of 
the ATG translational start codon and demonstrated that Ule S'-f1anking -SIO/+54 sequence 
harbors a functional promoter in transiently transfected PC346C cells (Dubbink et al. 1998). 
The proximal promoter contains a CAT AA motif at positions -48 to -44. 
To study the activity of the TGM4 promoter in different cell lines and Ule cis-acting elements 
involved, eight luciferase repoder gene constl1lcts were prepared with progressive 5' to 3' 
deletions. All constmcts contained the entire S'-untranslated region of Ule TGM4 gene. 
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Figure 1. Functional analysis of the TGM4 promoter in several human ceillincs. Transfectiolls ofPC346C (solid 
bars), LNCaP (open bars) and Hcp3B (shaded bars) cells with several deletion constmcts were perfonned as 
described in Materials and Methods. A schematic representation of the deletion COllslmcts is shown at the left-
hand side, Relative luciferase activities are presented as percentages of the activities of pTGM4-2. lLuc, which 
was set to 100%. Standard errors of the mean of four independent, duplicate experiments are shown. Mean 
luciferase activities. which are not corrected for tmnsfection efficiency, ofPC346C, LNCaP and Hep3B obtained 
with reporter cOl1stmct pTGM4-2.1Luc were 6 x 103,5 x Wt and 2 xlO) lighlunils, respectively. 111ese values 
were obtained from 150 ~I, 10 pI and 10 pi cell lysate, respectively. 
TI,e longest conso.uct, pTGM4-2.ILuc, contained 2.1 kb of the TGM4 promoter (-2077 to 
+54), the sholiest contained 61 bp upso.·eam of the o.·allscription stali site (pTGM4-6ILuc, -61 
to +54) (Figure I). Two Imman prostate cancer cell lines, PC346C and LNCaP, and the human 
liver cancer cell line Hep3B were transiently transfected with the different constl11cts. Because 
the luciferase activities showed large variations among the cell lines due to differences in 
transfection efficiencies (for pTGM4-2.ILuc activities in each cell line, see legend to Figure I), 
the activities of pTGM4-2.ILuc in the different cell lines were set to 100% for better 
comparison. 
Deletion mapping showed tilat conso.llcts containing between 2.1 kb and 0.5 kb of the TGM4 
promoter had similar relative activities (Figure I). In all cell lines, the luciferase activities 
gradually increased by furtiler promoter deletion to -113. Promoter truncation to -61 led in all 
cases to a dramatic drop in activity, almost to background level, demonstrating tilat essential 
regulatory elements are located between -113 and -61. 
EMSA of the minilllal TGM4 promoter 
Between -113 and -61 the TGM4 promoter sequence contains a candidate Spl binding motif, 
5'-ACCCCGCCCC-3', at positions -96 to -87 (Figure 2A). To investigate the proteins that can 
bind between -113 and -61, EMSAs were perfonned with LNCaP nuclear protein extracts 
(Figure 2B). EMSAs with oligonucleotide -113/-6I.wt demonstrated several retarded protein-
oligonucleotide complexes, CI, C2, C3 and C4 (Figure 2B, lane 2, and below), which could be 
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A 
AA 
-113 CAA CATCGCCTTC CCAAACCCCG CCCCTTGGCA GCCATAGCAA GGCCACATCT 
-60 AGCCCAGGAT CACATAAAAA GGGCTGTTTC CTCCCCTGAG GACCGACTGT GTGGAAGCAC 
+1 ~AGGCATCAG AGATAGAGTC TTCCCTGGCA TTGCAGGAGA GAATCTGAAG GGATG 
B 
Labelled oligo 
Nuclear extract 
Competitor 
CI 
C2 ~ 
C3 --
C4 --
F --
-113/-6I.wt 
+ + + + 
self Spl NFl 
2 3 4 5 
-IOI/-80.wt 
+ + t + 
self Sp I NFl 
678910 
Figure 2. (A) Sequence of the TOAM promoter. TIle major transcription start site (+1) is double underlined and 
in boldface. TIle CATAA box (-48) is in boldface, TIle translational start site is shown in boldface, italics, TIle 
putative Spl binding site is underlined and in boldface. At position -93 and -92 the functional CC to AA 
mutation is indicated. (B) EMSAs of the TGM4 promoter with LNCaP nuclear extracts, LNCaP nuclear extracts 
were incubated with labelled oligonucleotide -I J 3/-61.wt spanning the TGM4 promoter between -113 and -61 or 
with oligonucleotide -10 I 1-80.wt just overlapping the Spl binding motif, and further analYled as described in 
Materials and Methods. Oligonucleotides are indicated above the panels: lanes 1-5, oligonucleotide -113/-6 t.wl; 
lanes 6·10, oligonucleotide -I 01/·80.w1. Lanes I and 6, controls without LNCaP nuclear extracts. Lanes 2 and 7, 
no competitor added; lanes 3 and 8, competition with the same oligonucleotide (unlabelled); lanes 4 and 9, 
competition with consensus Spl oligonucleotide and lanes 5 and 10, competition with consensus NFl 
oligonucleotide. el, e2, CJ and e4, specific protein-oligonUcleotide complexes; F, free oligonucleotides. 
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Figure 3. (A) EMSA of an oligonucleotide mutated in the putative Spl binding motif present in the TGM4 
promoter with LNCaP nuclear extracts. LNCaP nuclear extracts were incubated with labelled oligonucleotide -
113/-61 ,mul, which contains a CC to AA mutation at positions -93 and -92 (see Figure 2A), and furtJlcr analyzed 
as described in Matenals and Methods. Lane I, control without nuclear extract; lane 2, incubation in the 
presence of nuclear extract. C4, retarded complex which does not contain proteins binding to the Spi binding 
motif; F, free oligonucleotides. (B) Functional analysis of the Spl binding site in the TGM4 core promoter. 
Transfections of PC346C (solid bars), LNCaP (opcn bars) and Hcp3B (shaded bars) cells with the indicated 
constmcts were perfonned as described in Materials and Methods. Both pTGM4-I13Luc and pTGM4-6ILuc 
represent wild-type constmcts; pTGM4-1 I3Luc.l11ut represents the -93, -92 mutant constmct. Luciferase 
activities are presented as percentages of the activities of the pTGM4-113LlIc constmct which is sel to 100%. 
Standard errors orthe mean offollr independent, duplicate experiments are shown. 
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competed by an excess of unlabelled oligonucleotide -113/-61. wt (lane 3). Complexes Cl, C2 
and C3 could also be competed by an excess Spl consensus oligonucleotide (lane 4), but not 
by an excess of an NFl consensus oligonucleotide (lane 5). EMSAs Widl oligonucleotide -
101/-80.wt confmlled the ulvolvement of Ule Spl bUldulg site Ul complexes CI, C2 and C3 
(lanes 6-10). 
EMSA and jimctional analysis 0/ the plltative SpJ binding site within the TGM4 core promoter 
To confmn whether the complexes, which could be specifically competed by the Sp 1 
consensus oligonucleotide, uldeed represented protein interactions with the candidate Sp I 
bindulg site, EMSAs with mutant oligonucleotide -113/-6I.mut were performed (Figure 3A). 
This oligonucleotide contauled a CC to AA mutation at positions -93 and -92 (mutation 
indicated in Figure 2A). Contrary to the wild-type oligonucleotides, retarded complexes CI, C2 
and C3 were absent when oligonucleotide -113/-6I.mut was used (Figure 3A). 
To prove Ule functional significance ofUle Spl bUlding motif, a pTGM4-I13Luc.mut conSU1lct 
was generated which contauled the same mutation as described for oligonucleotide -113/-
6l.mut. The mutant TGM4 promoter was tested in parallel Widl the wild type constl1lcts 
pTGM4-I13Luc and pTGM4-6ILuc by transient transfections Ul PC346C, LNCaP and Hep3B 
cells (Figure 3B). 11,e results clearly demonstrated that mutation of the Sp I bUldulg site 
completely abolished promoter activity in all three cell lines, showing the inlportance of the 
Spl bUldulg motif in transcriptional regulation of the TGM4 gene. 
Transcription/actors SpJ and Sp3 bind to the SpJ binding lIIoti/in the TGM4 cOl'e promoter 
Several proteuls which can direct Uleir regulatOlY actions Ull'ough the Spl binding motif are 
known (Hagen et al. 1992, Kingsley and Wino to 1992, Sogawa et al. 1993). To identifY which 
of these proteins bind to Ule Sp I sequence Ul Ule TGM4 promoter, supershift experiments with 
specific antibodies against the Spl and Sp3 transcription factors were performed. In the EMSA 
with oligonucleotide -101/-80.wt (Figure 4, lane 2) Ule upper band (CI) was supershifted by 
the Spl antibody (lane 3), whereas the two lower bands (C2 and C3) were supershifted by the 
Sp3 antibody (lane 4). Addition of both Spl and Sp3 antibodies to the reaction mixtures 
resulted in supershifts of all three specific bands (lane 5). Experiments with oligonucleotide -
1l3/-6I.wt gave identical results (data not shown). These fmdings confmned that tile upper, 
apparently sUlgle, retarded band Ul Ule EMSA shown in Figure 2B (lane 2) consisted of two 
proteul-oligonucleotide complexes Widl comparable mobility. 
Discussion 
We studied the TGM4 promoter in the prostate cancer cell lines PC346C and LNCaP and Ul fue 
liver cancer cell line Hep3B. Of fuese celliules, only the PC346C cell line is known to express 
hTGp (Dubbink et a1. 1996). In all cell lines, Ule TGM4 promoter showed a high basal 
transcriptional activity, which gradually increased if sholier promoter fragments were 
analyzed. 111is demonstrates that Ule upstream region negatively ulfluenced basal transcription 
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levels in a non cell-type specific fashion. Our findings suggest that the proslate-specific activity 
ofthe TGM4 promoter is located outside the 2.1 kb proximal TGM4 promoter. 
So far, PSA is the only human proslale marker of which regulation has been extensively 
studied at Ule molecular level. TIle PSA promoter fragment which appears to be most important 
for prostate-specific expression ofpSA, bolll ill vitro and in n'ansgenic mice, is located within a 
complex 400 bp enhancer region at -4.3 to -3.9 kb, showing Ihat prostate reslriction can be 
coordinated by upslream elements far from the proxintal promoter (Schuur et al. 1996, 
Cleutjens et al. 1997a, 1997b, Wei et al. 1997). Essential delerminants for the tissue-specific 
expression of hTGp might also be located fhrther upslream or downslream of the TGM4 
transcription start site. 
A difference between the TGM4 and Ule PSA proxintal promoter is Ule much lower basal 
activity of the latter in different cel1lilles, including LNCaP. Androgens increased the activity 
of the PSA promoter (Riegman et al. 1991b, Cleutjens et al. 1996, 1997b, Schuur et al. 1996), 
but not of Ule proximal TGM4 promoter (data not shown). This suggests Ulat the previously 
found androgen regulation of hTGp (Dubbink et al. 1996) is not directed via the proximal 
TGM4 promoter. In this respect it is imp0l1ant 10 nole that the upslream element of the PSA 
promoter conferring prostate specificity is also Ule most essential region for androgen-regulated 
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expression of PSA (Schuur et al. 1996, Cleuljens et al. 1997b), which might implicate that 
prostate specificity and androgen regulation interact with each other. Further studies are 
necessary to detemline the mechanisms of tissue specificity and androgen regulation of the 
TGM4 gene expression. 
The results presented in this report demonstrated Ure importance of Ure Spl binding motif 5'-
ACCCCGCCCC-3' at position -96 to -87 for the high basal activity of Ure TGM4 promoter. 
This Sp 1 sequence has previously been described as a medium affinity binding site of Ure Sp 1 
multigene family (Kadonaga et al. 1986). Several proteins have been identified which can bind 
to Spl binding motifs (Hagen et al. 1992, Kingsley and Winoto 1992, Sogawa et al. 1993). The 
nuclear Spl and Sp3 proteins which bind to the Spl binding motif in the TGM4 core promoter 
are both widely distributed transcription factors with similar binding specificities and affinities 
which is reflected in the structural identity of their DNA-binding domains (Hagen et al. 1992, 
Kingsley and Winoto 1992). The presence of several Sp3-oligonuc1eotide complexes in the 
EMSA may be due to different translation products of Sp3 mRNA and was also described for 
other promoters (Kingsley and Winoto 1992, Hagen et al. 1994). 
The precise role of Sp I and Sp3 in TGM4 gene regulation cannot be deduced from the 
experiments described here. Sp 1 is a transcriptional activator, whereas Sp3 can either repress or 
activate transcription through interaction with the Spl binding motif. WheUrer Sp3 acts as 
stimulator or repressor depends on Ure promoter, Ure number of DNA binding sites involved 
and the cellular context (Hagen et al. 1994, Majello et al. 1997). Functional studies in cells 
lacking endogenous proteins of Ure Sp 1 [,nrily may elucidate the relative contribution of both 
factors to TGM4 promoter activity. Altlrough Sp I and Sp3 are ubiquitous transcription factors, 
they are involved in expressional regulation of many genes with a tissue-specific distribution 
(Sa110relli et al. 1990, Noti et al. 1996, Ohtaka-Maruyama et al. 1998). One possible 
mechanism, which has been proposed for the myeloid-specific transcription factor PU.I, might 
be urat a tissue-specific factor changes Ure chromatin structrlre rendering the Spl binding site 
accessible to Ure corresponding proteins (Chen et al. 1993). nre expression ofhTGp is not only 
tissue-specific, but is also extremely heterogeneous in Ure prostate (Dubbink et al. 1999b). One 
nright speculate that Ure relative cellular amounts of Sp I and Sp3 contribute to the fmal TGM4 
transcription level. 
Acknowledgements 
We thank Frank van der Parme for photography. 
84 
Chapter 5 
Human Prostate-Specific Transglutaminase: A New Prostatic 
Marker with a Unique Distribution Pattern 
Hendrikus J. Dubbink' , Robert F. Hoedemaeker', Theodorus H. van del' Kwast', 
Fritz H. Schroder', and Johannes C. Romijn' 
From the Departments of Urology' and Pathology', Josephine Nefkens Institute, 
Erasmus University, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands 
Lab Invest (1999): 79,141-150 
85 
Chapter 5 
Abstract 
Human prostate-specific transglutaminase (hTGp) is a cross-linking enzyme, the 
physiologic function of which has not been established unequivocally yet. To gain insight 
into its distribution, we raised antisera against hTGp• By using Western blotting analysis, 
we found that these antisera specifically recognize a 77-kDa protein in prostatic fluids, 
seminal plasmas, and prostatic tissues. The concentrations of hTGp in these fluids and 
tissues were found to be highly variable among individuals. Immunohistochemical 
examination of several fOlmalin-fixed paraffIn-embedded human tissues revealed an 
exclusive expression in the prostate. TIle histologic localization and distribution of hTGp 
within the prostate was assessed by studying multiple sections from tumor-containing 
prostatectomy specimens and needle biopsies. hTGp expression was entirely restricted to 
luminal epithelial cells. No basal epithelial cells or stromal cells were stained. Within the 
prostate, large areas without any hTGp-positive cells were seen. Immunopositive cells were 
present either in a scattered pattern or concentrated in single or multiple glands in which all 
luminal epithelial cells expressed hTGp• TIle latter staining pattern OCCUlTed frequently, but 
not exclusively, in the peripheral zone, whereas scattered expression was most often 
observed in tlle transition zone. Expression of the hTGp protein could occasionally be 
observed in high grade prostatic intraepithelial neoplasia, but was not detected in prostate 
carcinoma cells. The expression pattern as observed for hTGp has not been found thus far 
for any other prostate-specific marker. 
Inh'oduction 
Prostate cancer is the most frequently diagnosed cancer in men in Western countries, and 
once metastasized it is a fatal disease (Isaacs 1997). Recent research on the prostate, 
therefore, has been focussed mainly on its deregulated growth. As a consequence, a 
relatively small contribution was made to the further elucidation of the basic physiologic 
functions of the prostate. For that purpose, the identification and characterization of 
prostate-specific proteins could be of crucial importance. Human prostate-specific 
transglutaminase (hTGp) might represent such a new prostatic marker (Dubbink et al. 1996, 
1998). 
On the basis of its cDNA sequence, hTGp belongs to the transglutaminase family [TGase, 
Ee 2.3.2.13 (Greenberg et al. 1991, Aeschlimann and Paulsson 1994, Dubbink et al. 
1996)]. TIlese calcium-dependent enzymes catalyze the fonnation of irreversible 8-(Y-
glutamyl)lysyl protein-protein or protein-polyamine bonds throughout the body. TGase-
mediated cross-links can stabilize large protein complexes and for example account for the 
mechanical strength of the skin (Eckert et al. 1997) and for optimal wound healing, eg, 
blood coagUlation (Muszbek et al. 1996). More subtle protein modifications brought about 
by TGases seem to be important for extracellular matrix formation and may influence cell 
adhesion properties (Gentile et al. 1992, Aeschlimann and Paulsson 1994). 
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At present, little is known about the physiologic role of hTGp• Many more studies have 
been perfomled on its analogue in the rat, ratTGp (rTGp), or dorsal protein 1 (DPI). DPI is 
a secretory glycoprotein (Seitz et al. 1991a, Ho et al. 1992, Esposito et al. 1996) that is 
responsible for the rapid cross-linking of the copulatOlY plug after Illating (WilliaIlls-
Aslmlan 1984). DP 1 activity might further lead to seminal fluid and sperm modifications 
resulting in a reduced inIDlUnogenicity of semen (Paonessa et al. 1984, Porta et al. 1993, 
Peluso et al. 1994). The enzyme is abundantly expressed in epithelial cells of the dorsal 
prostate, the coagulating gland (anterior prostate), and the lateral type I prostate and is also 
expressed in minor amounts by the lateral type 2 prostate, but not in the ventral prostate 
(Wilson and French 1980, Romijn 1990, Seitz et al. 1990, Hayashi et al. 1991, Kinbara and 
Cunha 1996). DPI immunoreactivity has also been detected in myoepithelial and stromal 
cells, but not in acinar cells of salivary glands (AuIlluller et al. 1995). Expression of DP I in 
rat urogenital tissues is androgen-regulated and can be influenced by mesenchymal 
components (Kinbara et al. 1996). DPI levels are reduced by castration and restored by 
subsequent androgen replacement (Wilson and French 1980, Seitz et al. 1990, Ho et al. 
1992). In explant cultures of rat prostatic tissue, DPI expression could only be 
demonstrated when grown in the presence of androgen (Lopes et al. 1996). 
In human seminal plasma, a calcium-dependent TGase activity was detected (Porta et al. 
1986, Enderle-Sclmlitt et al. 1989, Ablin et al. 1990), which might correspond to hTGp• 
TGase/hTGp does not seem to playa role in the formation of the soft gel, which is quickly 
formed upon ejaculation, because this does not contain TGase-specific bounds (Lilja and 
Laurell 1985). However, hTGp may be involved in spenn maturation and suppression of 
semen antigenicity by the introduction of covalent modifications (James and Hargreave 
1984, Porta et al. 1986, Ablin et al. 1990). Several candidate substrates have been described 
through which hTGp may exert its function including polyamines that are present in high 
concentrations in semen (Porta et al. 1986) and the major gel-fOlming proteins in human 
semen semenogelin I and [[ (Peter et al. 1998). 
Until recently, studies on hTGp have been hampered by the fact that the protein could not 
be isolated and immunologically detected. The recent identification of the hTGp cDNA 
(Grant et al. 1994, Dubbink et al. 1996) made it possible to study its expression and 
regulation as well as to resolve the genomic shllcture of the corresponding TGM4 gene 
(Dubbink et al. 1996, 1998). The 35-kb TGM4 gene encompasses 13 exons and 12 introns 
and is transcribed into a 3.5-kb mRNA encoding a 77-kDa protein. hTGp expression was 
up-regulated by androgens in the androgen-responsive human prostate cancer cell line 
PC346C (Dubbink et al. 1996). By screening of a large series of normal tissues hTGp 
mRNA expression was found entirely restricted to the prostate (Dubbink et al. 1996, 1998). 
To increase our knowledge of hTGp, we raised antisera against the C-terminal region of the 
protein so that we could study the presence and localization of hTGp in more detail. We 
examined hTGp expression in benign and malignant prostate tissues and in fluids from the 
prostate and seminal vesicles. An extended large series of normal human tissues was 
investigated immunohistochemically for the expression of hTGp. The results from these 
studies further substantiate the prostate-specific expression of hTGp and revealed an up to 
now unique expression pattern in the prostate. 
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Materials and Methods 
Tissues alld fluids 
hTGp expression was studied in benign prostate tissue, BPH, prostate cancer, and in a 
variety of human tissues of other origin (Table I). Standard sextant needle biopsy 
specimens from the apical, intermediate, and basal part of the prostate were obtained from 
participants of a screening program for prostate cancer (Hoedemaeker et al. 1997). To study 
the hTGp distribution within the nOlmal prostate, entirely benign biopsy sets were selected 
from participants with a semm PSA value below 4.0 ng/ml. By these criteria, biopsy sets 
were considered to be obtained from benign prostates. BPH tissues were obtained from 
transurethral resections. Prostate cancer tissues were obtained from radical prostatectomy 
specimens from the European Randomized Study for Prostate Cancer [ERSPC 
(Hoedemaeker et al. 1997)). To avoid fixation artefacts, radical prostatectomy specimens of 
men with a diagnosis of prostate cancer were entirely fixed by formalin injections 
(Hoedemaeker et al. 1998). EvelY radical prostatectomy specimen was systematically 
sectioned and totally embedded in paraffin. Human tissues of other origin (Table I) were 
obtained as formalin-fixed paraffin-embedded archival material from the Department of 
Pathology. 
Prostatic fluids and seminal vesicle fluids were obtained from radical prostatectomy 
specimens by means of gentle massage. Semen samples were obtained from men visiting 
the Andrology Clinic. The samples were allowed to liquefy at room temperature. Sperm 
cells, debris, or both, were removed by centrifhgation at 10,000 x g at room temperature. 
For most experiments these seminal plasmas were freshly used. The remainder was stored 
at -20°C until fmther use. 
Preparation offi.lsion constructs 
TIle hTGp-GST and TGc-GST fusion constnlcts were obtained by in-frame subcloning of a 
1.3 kb Sau3AI-Sau3AI fragment of hTGp cDNA (Dubbink et al. 1996) and a 350 bp 
BamHI-BaIllHI fragment ofhTGc cDNA (Gentile et al. 1991), respectively, into the BalllHI 
site of the bacterial expression vectOf pGEX-3X (Phannacia, LKB Biotech, Uppsala, 
Sweden). The hTGp-GST and TGc-GST fusion constmcts encode the C-terminal amino 
acids 531-684 ofhTGp (Dubbink et al. 1996) and 476-593 ofhTGc (Gentile et al. 1991), 
respectively. hTGc cDNA was kindly provided by Dr. P.I.A. Davies (Deparhnent of 
Pharmacology, Houston, TX) and pGEX-3X by Dr. A. Hoogeveen (Deparhnent of Clinical 
Genetics, Rotterdam, The Netherlands). 
Induction and purificatioll o//usioll proteills 
Fusion proteins were isolated from cultures of Escherichia coli strain JMIOI transformed 
with the fusion constmcts. Ovemight cultures were diluted 1:10 in 500 ml of2xYT medium 
containing 100 J.lg/ml ampicillin and grown to an OD"o of 1.2. IPTG was then added to a 
final concentration of 0.1 mM and bacteria were grown for another 4 h. Bacteria were 
pelleted, resuspended in 25 ml ice-cold PBS, and sonicated 10 times I minute on ice. After 
the addition of Triton X-I 00 to a final concentration of I % and an incubation of 30 minutes 
88 
ImmulloexpressioJt of hTG p 
at 4°C, the bacteriallysates were centrifuged at 3000 x g for 15 minutes at 4°C. The pellet 
fractions, containing inclusion bodies consisting largely of fusion protein but presumably 
contaminated with bacterial proteins, were washed three times with 25 ml of buffer 
composed of 25 mM Tris (pH 7.5), I mM EDTA, 100 mM NaCI, and 1% Triton X-I00. 
Fusion proteins were further purified by 7 % Prep Cell SDS-PAGE (Bio-Rad, Munich, 
Germany). Collected fractions were dialyzed against 10 mM ammonium hydrogen 
carbonate (NH,HCO,), concentrated by a Centriprep 10 concentrator (Amicon, Beverly, 
MA), and used for immunizations. 
Immzmizafiolls 
Two polyclonal antisera (1919.2 and 1920.2) were obtained by repeated intradenual 
injections of 150 ~lg of the hTGp-GST fusion protein into New Zealand White rabbits. For 
primary injections the concenh'ated fusion protein ,vas mixed with an equal volume of 
complete Freunds adjuvants (Difco laboratories, Detroit, MI). Booster injections were 
perfomled with incomplete in stead of complete Freunds adjuvants 3 and 9 weeks after the 
first injections. Blood samples were allowed to clot for 1 hour at 4°C. The clots were 
removed by centrifugation at 3000 x g. Sera were stored in aliquots at -20°C, 
Weslel'l1 blotting 
Protein preparations for Westenl blot analysis of prostatic tissue specimens were obtained 
by homogenization of the tissues in RIPA buffer [150 mM NaCI, 1.0% Triton X-I00, 1.0% 
deoxycholate, 0.1% SDS, 5 mM EDTA and 10 mM Tris (pH 7.4)], containing a protease 
inhibitor cocktail (Complete, Boeluinger, Mannheim, Germany). Debris was removed by 
centrifugation at 350,000 x g in a tabletop centrifuge (Optima® TLX; Beckman 
Instmments, Inc., Fullerton, CA) for 10 minutes at 4°C. Protein concentrations in the 
supernatant were measured with the Bio-Rad protein assay by using BSA as a standard. 
Samples of prostatic tissue, prostatic fluid, seminal vesicle fluid and seminal plasma were 
subjected to 10% SDS-PAGE. Prestained markers (Novex, San Diego, CAl were used as 
size standards. The separated proteins were electrophoretically transferred to nitrocellulose 
filters. The filters were blocked with PBS containing 5% nonfat dry milk and 0.1 % Tween 
20 for 1 h. Polyclonal antisera and pre immune sera were diluted I :5000 in blocking 
solution and incubations were performed ovemight at 4°c' Subsequent incubations with a 
I :3000 dilution of the secondary alkaline phosphatase (AP)-conjugated goat anti-rabbit 
antibody (DAKO, Glostrup, Denmark) were carried out at room temperature for I h. The 
blots were developed by using a chromogenic AP substrate (GIBCO, Grand Island, NY) or 
a chemiluminescence detection reagent (DuPont NEN, Boston, MAl. Competition 
experiments were perfonned by the addition of I ~lg of the hTGp-GST or TGc-GST fusion 
protein during the incubation with the primary antisera, 
Immzt1lohislochemical staining 
Five micrometers fOlnlalin~ fixed paraffin~embedded sections of human tissues were 
deparaffmized, and endogenous peroxidase activity was blocked by incubation with 3% 
H20 2 in methanol for 20 minutes. The sections were pre incubated with PBS containing 5% 
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BSA (PBS-BSA) and 10% normal goat senUll (DAKO) for 15 minutes. Prein1l1lune or 
immune sera were then applied at a I: I 000 dilution in PBS~BSA at room temperature for 
30 minutes. After rinsing three times with PBS containing 0.1% Tween 20 (PBS-Tween), 
the sections were incubated with biotinylated anti-inullunoglobulins (1:50, Multilink, 
Biogenex, San Ramon, CAl in PBS-BSA at room temperature for 30 minutes. After rinsing 
three times ,vith PBS-Tween, the sections were incubated ,,,ith horseradish peroxidase-
labeled streptavidin (1:50, Biogenex) in PBS-BSA containing 2% nomlal goat semm 
(DAKO) and 2% normal human serum for 30 minutes at room temperature and washed 
three times with PBS. Immunoreactivity was visualized with 150 mg of diaminobenzidine 
hydrochloride (DAB, Fluka, Neu-Dlm, Germany) in 200 ml of PBS supplemented with 
0.08% H202. The sections were counterstained with Mayer's hematoxylin. Competition 
experiments were performed by incubation of the inunune sera with 3 fIg (in a 100 !rl final 
volume) of either the hTGp-GST or the TGc-GST fusion protein, 1 hour before and during 
the incubation with the primary antisera. Serial sections of all tissues listed in Table 1 were 
tested in parallel with pre immune serum of the same rabbit that had been used for the 
preparation of antisemm 1920.2. 
Results 
Specificity of hTGp antisera 
Polyclonal antisera were raised against the C-terminal region of hTGp) because this part has 
the lowest similarity with other TGases. Reactivity and specificity of the antisera were 
checked by Westem blot analysis of prostatic fluid, considering that this secretory product 
is likely to contain relatively high concentrations of hTGp. Initial screening results indicated 
that lot 1920.2 was the most reactive and specific antiserum. By using this antiselUll1, it was 
shown that prostatic fluid contained hvo immunoreactive bands, a major band of 77 kDa 
and a minor band of approximately 72 kDa (Figure lA, lane 2). The bands were specific 
because preimmune serum showed no reactive proteins (Figure lA, lane 1) and both bands 
disappeared by competition with the hTGp-GST fusion protein, but not with a control 
fusion protein, TGc-GST, containing the C-terminal region of human cell\llar or tissue-type 
TGase (Figure lA, lanes 6 and 5, respectively). Antisenull dilutions up to 80,000 times still 
showed immunoreactivity (Figure lA, lanes 3 and 4). 
By using the same strategy, immunohistochemical reactivity and specificity of antiselllm 
1920.2 was detenllined (Figs. 1, B to E). In benign prostatic glands, several luminal 
epithelial cells were stained with the antisenllll (Figure 1 C). Inullunostaining could be 
competed for only by the hTGp-GST fusion protein (Figure IE) but not by the TGc-GST 
(Figure ID) fusion protein. The background staining, which can be observed in the sections 
incubated with the fusion proteins, is likely to be due to immunoreactivity against the GST-
portion of nonspecifically bound fusion protein. The control with preimmune senllll was 
entirely negative (Figure lB). 
Comparable results for both Western blotting and inmlUnohistochemislly were obtained 
with the other antiserum 1919.2. Antigen retrieval by microwave irradiation of the sections 
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Figure 1. Specificity of polycionai antiserum 1920.2 as determined by Westem blot analysis of prostatic 
fluid (A) and immunohistochemical staining of serial sections of formalin~fixed paramn~embedded benign 
prostatic hypertrophy (BPH) tissue (B~E). Similar results were obtained with antiserum 1919.2. (A) 
Westem blot analysis. Each lane contains I ~d of prostatic fluid. Lane 1: preimmune serum (I :5000). Lanes 
2~4: immune serum diluted 1:5000 (lane 2), 1:20,000 (lane 3), and 1:80,000 (lane 4). Lanes 5 and 6 are 
competition experiments with the nlsion proteins TGc~GST (containing the C~terJ11inal region of human 
cellular or tissue~type TOase) and hTGp-GST, respectively, and demonstrate specificity for both the 77~kDa 
band and the 72~kDa band. (B~E) Immunohistochemical staining. Preimmune and immune serum dilutions 
were I: 1000. (8) Preimmune serum; (C) immune serum; (D) immune serum in competition with ftlsion 
protein TGcOST; and (E) immune serum in competition with fusion protein hTOp~GST. The background 
staining in D and E seemed to be due to immulloreactivity against the GST~portion of fusion proteins that 
nOl1specifically attached to the sections. Original magnifications, x88. 
did not improve the staining results, suggesting that the antisera recognized easily available 
epitopes. Preliminary experiments with these antisera using frozen sections showed a high 
background. 
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Figure 2. Western blot analysis of seminal plasmas, 
prostatic fluids, and normal prostatic tissues. 
Antiserum dilutions were I :5000. (A) Prostatic fluid. 
Each lane contains I ~ll of fluid. Note the variation in 
size oflhe minor band (70 -to n kD<1). (8) Semina 
plasma. Each lane contains 10 IJI of seminal plasma 
of different individuals. Note the variation i 
expression level of hTGp• (C) Prostate tissue 
extracts. Each lalle contains 20 ,...g of protein. Lanes 
1-3, BPH tissues; Lanes 4-6, nomlui prostate tissue 
obtained from radical cystoprostatectomy specimens 
Note that oilly in one of six individuals could clear 
hTGr expression be demonstrated. After long 
exposure also in lane 2 and 6, a low expression 0 
hTG p became apparent. 
Western bioi allalysis of II TOp expressioll ill prostatic fluids, semillal plasmas, semillal 
vesicle fluids and prostatic tissues 
We examined eight prostatic fluids and 30 seminal plasmas for hTGp expression with 
antisemm 1920.2. Figure 2, A and B, show representative examples of this study. The 77-
kDa protein could be demonstrated in all prostatic fluids and in all but one (not shown) 
seminal plasmas. In most prostatic fluids, the minor band was also present, but its exact size 
varied between individuals (70 -to 72 kDa). Both prostatic fluid and seminal plasma 
sometimes additionally contained specific bands of approximately 33 kDa as well as high 
molecular mass bands (>200 kDa). No expression was observed in seminal vesicle fluids 
(data not shown). 
The hTGp expression levels in seminal plasmas strongly varied among individuals (Figure 
2B). Also in a series of prostatic tissues hTGp expression was highly variable. Only in one 
of six examined prostatic tissues could a clear expression be demonstated (Figure 2C). Also 
in two other tissue lysates, after long exposure, very low expression could be detected, 
Prostate-specific expressioll of hTOp 
To confinn the prostate-specific expression of hTGp indicated in our previous studies at the 
mRNA level (Dubbink et al. 1996, 1998), a large panel of nonnal human tissues was 
examined by immunohistochemistry. No specific immunoreactivity could be detected in 
any tissue other than the prostate. In Table I, the tissues tested in this immunohistochemical 
screening are summarized together with the earlier obtained results. 
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Tissue Immunohistochemical mRNA 
Adrenal gland 
Appendix lid 
Aorta nd 
Bladder 
Bone marrow nd 
Brain 
Breast 
Cartilage lid 
Cervix nd 
Colon 
Epididymus lid 
Esophagus lid 
Fat tissue lid 
Heart 
Kidney 
Liver 
Lung 
Lymph node 
Ovary 
Pancreas 
Parathyroid gland lid 
Peripheral leukocyte lid 
Pituitary gland lid 
Placenta 
Prostate + + 
Salivary gland 
Seminal vesicles nd 
Skeletal muscle 
Skin nd 
Small intestine 
Spleen 
Stomach 
Tongue nd 
Testis 
Thymus 
Thyroid gland 
Tonsil nd 
Trachea 
Ureter lid 
Uterus 
ImmUlloe.\1)ressioll of !tTGp 
" Expression of hTGp was determined by 
iilullunohistochemistry with antiserum 1920.2, 
In parallel, serial sections were incubated with 
preinll11Une senllJ}, Antiserum and preimmune 
serum dilutions were I: I 000. TIle results 
obtained in previous studies, in which the tissue 
specificity was investigated by Northern blot 
analysis (Dubhink et a!. 1996) and by spot blot 
analysis using a human RNA master blot 
(Dubbink et al. 1998), are also summarized in 
this table, In addition to the tissues presented in 
this table, 110 expression of hTGp could be 
demonstrated in several tissues of fetal origin 
(Dubbink et al. 1998). ND, not determined. 
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Immullohistochemical analysis of hTGp expression in prostatic tissues 
Positive staining was observed only in the cytoplasm of the secretory prostatic epithelial 
cells. No basal epithelial cells or stromal cells were found to stain positive (see eg, Figure 3, 
B and E). Immunopositive cells were usually heavily stained and could be clearly 
distinguished from the sunounding negative cells. Positive epithelial cells can have a tall 
colurmlar or cuboidal appearance, but also cells with a typical atrophic mOlphology can be 
intensively positive. Sometimes the luminal content of prostatic ducts showed 
immunoreactivity (data not shown). 
To investigate the distribution of hTGp expression throughout the prostatic gland and to 
address its expression in prostate carcinoma tissue, we stained a large number of sections 
(Table 2) obtained from entirely paraffin-embedded radical prostatectomy specimens. Four 
different staining patterns could be classified: (I) negative, ie, large entirely hTGp negative 
areas; (2) focal staining, ie, regions with only few single, but intensively stained cells 
(Figure 3A); (3) moderate staining, ie, regions with several positive cells with a scattered 
distribution pattern (Figure 3B) and/or single or only few glands in which all luminal 
epithelial cells were stained (Figure 3C) and (4) extensive staining, ie, regions with many 
stained cells in multiple glands in which all luminal epithelial cells expressed large amounts 
of hTGp (Figure 3D) and/or in which the positive cells were alternated with negative cells 
(Figure 3E). 
We studied whether a particular staining pattem could be associated with the prostate basis 
or apex, or with the peripheral or transition zone. TIle extensive and moderate hTGp 
staining patterns were relatively more conmlon at the basal side, whereas the focal staining 
pattern was dominant in the apex of the prostate (data not shown). Further evaluation of 
staining distribution showed that the moderate and extensive staining patterns occurred 
most frequently, but not exclusively, in the peripheral zone, whereas the focal staining 
pattern was observed more frequently in the transition zone (Table 2). Most benign 
prostatic hyperplasia (BPH) tissues obtained by transurethral resection, which generally 
consist of transition zone tissue (McNeal 1988), showed little or no hTGp-expressing cells, 
a finding that agrees with the absence of expression in most of the BPH tissues analyzed by 
Western blotting (Figure 2C). No hTGp expression was demonstrated in any of the prostate 
carcinoma cells (Figwe 3F). In contrast to prostate carcinoma cells, prostatic intra epithelial 
neoplasia (PIN) lesions were occasionally positive for hTGp (Figure 3G). 
Figure 3. Distribution pattents of hTGr in prostate tissues. The tissues were formalill~fixed and paraffin~ 
embedded. Antiserum 1920.2 was used in a I: I 000 dilution. (A) Focal staining pattemj (B) moderate 
staining pattern, scattered distribution; (C) moderate staining pattern, positive glands with all luminal 
epithelial cells being stained; (D) extensive staining pattern, many entirely positive glands; (E) extensive 
staining pattern, glands with positive cells altemated with negative cells; (F) prostate carcinoma tissue, 
entirely negative; (0) strongly positive prostatic intraepithelial neoplasia lesions surrounded by negative 
tumor tissue; (H) basal cell hyperplasia of prostate glands with one row of hTGp~posilive cells. Original 
magnifications: F, xli; C, D and G, x44; A, x88; H, x176; Band E, x361. 
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To examine the correlation between lOunUllosta1l11l1g and Western blot analysis results, 
sections were made from tissues that were found strongly positive (Figure 2C, lane 5) or 
almost negative (Figure 2C, lane 2) by Westelll blot analysis. The latter tissue specimen 
contained only some scattered positive cells whereas the other tissue showed an area with 
many immunopositive glands. Strikingly, these positive glands contained one single row of 
stained luminal cells that were positioned on top of a multilayered cell population with the 
characteristics of a basal cell hyperplasia (Figure 3H). This example clearly demonstrated 
that hTGp expression is restricted to the secretmy cells of the prostate. 
Distribution ofhTGp in the /lormal prostate as approached by a /leedle biopsy study 
To perform a more systematic analysis of the hTGp distribution through the prostate, we 
investigated needle biopsy sets of II prostates, which are considered to be without 
abnormalities, with antiselllm 1920.2. Because the biopsy specimens were small and 
contain relatively few glands, only three groups of staining pattenlS were discriminated: 
entirely negative, focal expression, and extensive staining. The results indeed suggest that 
immunopositive cells tend to occur at a higher frequency at the basal side of the prostate 
(data not shown). 
Table 2. Expression patterns and distribution ofhTGp within the prostate*. 
Staining Transitional Peripheral 
pattern zone zone Total 
Extensive 4 (II) 12 (23) 16 (18) 
Moderate 6 (17) 26 (50) 32 (36) 
Focal 22 (61) II (21) 33 (38) 
Negative 4 (II) 3 (6) 7 (8) 
Total 36 (100) 52 (100) 88 (100) 
hTGp distribution was assessed by screening 20 tumor-containing prostates. From each prostate, at least 
fouf sections were stained of which at least two contained adenocarcinoma, A total number of 88 sections 
was examined, Four staining patterns were distinguished: entirely negative sections; focal expression (only 
few separate positive cells); moderate expression (many positive cells with scattered distribution 
occasionalJy in combination with some entirely positive glands); and extensive staining (many stained cells 
in multiple glands in which all luminal epithelial cells expressed large amounts ofhTG p and/or in which the 
positive cells were alternated with negative cells). If more than one staining pattem was present, sections 
were grouped into the pattern with the most positive cells. Tumor-containing tissue sections always 
contained surrounding benign prostatic glands, in which inullulloposilive cells could occassionally be 
detected, The staining distibution seemed not to be dependent on the presence of tumor. Numbers refer to 
the frequency at which the specified staining patterns were observed at the indicated site; percentages are 
given in parentheses. 
96 
!m11/UIl0e.\preSS;0I1 ofhTGp 
Discussion 
In this study, we describe the generation ofa polyclonal antisenlln, 1920.2, directed against 
the C-tenninal region of hTOp, which enabled us to visualize the enzyme by 
innnunobiotting and innnunohistochemistry of formalin-fixed paraffin-embedded tissue 
sections. The 1920.2 hTOp antisemm seems to be highly specific, because no cross-
reactivity was observed with other TOase types expressed in the prostate such as FXIIIa 
and tissue-type TOase (Friedrichs et al. 1995, Muszbek et al. 1996). No immunoreactivity 
was found in blood plasma samples (FXllIa) and in lysates from the human prostate cancer 
cell line PC-3, known to contain high amounts of tissue-type TOase [own unpublished 
results (Friedrichs et al. 1995)]. The antisenlln lVas suitable to detect hTOp expression in 
archival material, indicating that hTGp epitopes are well conserved during storage and, 
therefore, allowed retrospective studies. 
The size of the most abundant inmlllnoreactive band with antisemm 1920.2, both in 
prostate tissue, prostatic fluid, and seminal plasma, is 77 kDa. A protein of similar size has 
been found to be cross-reactive with an antisemm against rat DPI (Aumuller and Seitz 
1990, Friedrichs et a!. 1995) and could be translated from hTOp cDNA (Dubbink et al. 
1996). The latter suggests that the protein does not undergo large modifications, before and 
after being secreted into semen. In prostatic fluid, a slightly smaller band could also be 
observed. This varied in size between individuals from about 70 to 72 kDa. We have also 
found this band in a prostate tissue extract (data not shown), but never in seminal plasmas. 
The functional significance of two different molecular forms of hTOp remains to be 
resolved. It is possible that only one of the two fOlll1S represents the active protein. 
Cleavage of the largest band could perhaps result in an enzymatically active smaller protein 
or could represent a first step in the degradation of active hTOp protein. Rat DP 1 is known 
to be a glycoprotein and experiments suggested that DP 1 in its glycosylated state remains 
protected against its own cross-linking activity (Seitz et a!. 1991a, Esposito et al. 1996). 
Biochemical experiments are necessary to solve the glycosylation status of hTOp and the 
mechanisms by which hTOp is guarded against autoaggregation. 
Prostatic fluids and seminal plasmas may both contain specific high molecular mass bands, 
suggesting that hTO, can incOlporate itself into larger protein complexes. In addition, we 
demonstrated specific bands of approximately 33 kDa band and Slnaller in both fluids. 
TIlese bands appeared to represent breakdown products, because incubation of fresh 
seminal plasmas at 37 'C showed the appearance of the 33-kDa band and disappearance of 
the 77-kDa band in time (data not shown). Some studies indicated that a semipurified 
protein fraction of 20 -to 40 kDa from seminal plasma still contained TOase activity (Porta 
et a!. 1986, Ablin et al. 1990), whereas others stated that proteins of that size have lost their 
enzymatic activity (EnderJe-Sclmlitt et al. 1989). 
We could identify hTO, in all but 1 of the 30 seminal plasma samples examined. In contrast 
to our results, Aumliller and Seitz (1990) could only show expression in about 30% of the 
investigated seminal plasmas (300 samples). An explanation for their lower detection rate 
might be the very low hTOp expression levels present in some individuals together with the 
use of rat DP 1 antisemm, which is less specific for hTGp• The large variations in expression 
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levels we observed by immunoblotting conespond very well with the large fluctuations that 
Porta et aJ. (1986) found for TGase enzymatic activity in nOlmal human seminal plasmas. 
In 30% of the cases (6 of 18 cases) no activity was measurable, suggesting that 
immunoblotting is a more sensitive method for hTGp detection. Together, these results 
strongly suggest that previously measured TGase activity was entirely due to hTGp and that 
there is a natural variation in hTGp expression in seminal plasma. Whether there is a direct 
correlation between TOase activity and imlTIunoblot data is presently under investigation. A 
separate study is necessary to investigate the natural expression of hTGp in seminal plasma 
and whether the enzyme might be involved in certain fertility disorders. 
hTGp could excluSively be demonstrated in fluids derived from the prostate and in prostate 
tissue sections, but not in other human tissues. These results confirmed an earlier study in 
which we could detect hTGp mRNA only in the prostate [Table I (Dubbink et aJ. 1996, 
1998)]. It further extends these data and shows that also no expression in individual cells 
could be detected in any human tissue or cell type other than prostate epithelium. This 
differs from its rat analogue DP I, which is also present in salivary glands (Aumuller et aJ. 
1995). 
We immunohistochemically evaluated hTGp expression in benign and malignant prostate 
tissues. Like other secreted prostate markers, eg, prostate specific antigen (PSA), prostatic 
acid phosphatase (PAP), and prostatic secretory protein94 (PSP94; ~-microseminoprotein; 
~-inhibin) (Lilja and Abrahamsson 1988), hTGp expression was confined strictly to the 
cytoplasm of the secretory epithelial cells and could not be detected in the stromal 
compartment of the prostate. To our knowledge, an expression and distribution pattc111 
similar to what we have found for hTGp has not been described previously for any other 
prostate marker. In the normal prostate, a uniform staining for PSA, PAP, and PSP94 of 
most if not all epithelial cells can be found with only slight variations in staining intensity 
from cell to cell (Brar et aJ. 1988, Lilja and Abrahamsson 1988). The striking difference in 
expression patterns between these prostate markers and hTGp suggests that they are 
differentially regulated. The significance of the differences in hTGp distribution patterns 
between the transition and the peripheral zones is unclear. It might be interesting to know 
whether the heterogeneic expression pattern of hTGp reflects the presence of functionally 
distinct cell populations within the human prostate. 
Of interest is a comparison with DP 1 expression, which is often used as a marker for 
functional differentiation of the epithelium of the rat dorsolateral prostate and coagulating 
gland. 111e number of individual DP I-positive cells increases with age and under the 
influence of androgen (Lopes et aJ. 1996), and DPI expression is controlled by stromal 
components (Hayashi et aJ. 1993, Kinbara et aJ. 1996). It would be interesting to know 
which factors could induce hTGp expression. Androgen-sensitivity of hTGp expression ill 
vitro has already been found (Dubbink et aJ. 1996) but obviously Calmot alone explain the 
observed in vivo expression patterns with local variations. 
PIN lesions are considered to represent precursor lesions of prostate adenocarcinoma 
(Bostwick 1995). In this respect, it is remarkable that some PIN lesions were found to be 
hTGp positive, whereas associated prostatic adenocarcinoma was entirely negative. TIlis 
may suggest that PIN lesions loose their ability to express hTGp during further progression 
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toward tumor tissue. At least two explanations can be given for the lack of hTGp staining of 
adenocarcinoma cells: carcinoma cells either loose the capacity to express hTGp or arise 
exclusively from hTGp-negative prostate cells. Poorly differentiated tumors have lower 
PSA, PAP, and PSP94 expression compared with well-differentiated tumors (Abrahamsson 
et al. 1988). For these markers, however, a decline in expression is easily detectable 
because all normal prostate cells stain for these markers, 
An important conclusion that can be drawn from this study is that hTGp represents a new 
highly specific prostate marker. The data suggest that the enzyme may not be very useful as 
a diagnostic and prognostic tool in prostate cancer, but the question remains how tissue~ 
specificity is regulated and whether regulatory DNA elements and factors involved in 
directing tissue-specific expression can be identified. At present TGM4 promoter studies 
are under way as a first step toward the elucidation of the regulatOlY mechanisms 
underlying hTGp expression (Dubbink et al. 1998). 
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General discnssion and future aspects 
This thesis describes the characterization of the TGase hTGp and its conesponding gene. 
hTGp expression was found to be strictly confined to prostate tissues, the prostate cancer 
cell line PC346C and fluids containing secretOlY products of the prostate, prostatic fluid 
and seminal plasma. Within the prostate, expression was exclusively found in a subset of 
luminal epithelial cells. hTGp expressing cells were sometimes found to be distributed in a 
scattered pattem or concentrated in single or multiple glands, but also large areas without 
hTGp positive cells were present. Possible functions which can be attributed to seminal 
plasma components, including hTGp, have been discussed in the Introduction and will not 
be further addressed. 
hTGp expression ill seminal plasma 
hTGp expression in seminal plasma was found to be highly variable among individuals. In 
about one third of the samples expression appeared to be very low. This observation agrees 
well with a report of Porta et aJ. (1986), who demonstrated TGase activity in 60% of 
normal seminal plasmas. A causal relationship between aberrant hTGp expression and 
fertility problems of some of the donors of our study cannot be excluded, but it seems more 
likely that most if not all observed expression levels represent natural variation. Like hTGp, 
PSA expression is also variable in seminal plasmas of different individuals (Rittenhouse et 
aJ. 1998). Part of these fluctuations might be due to normal differences in the relative 
contributions of prostate, seminal vesicle and urethral gland secretions to seminal plasma 
(Mann and Lutwak-Mann 1981). In case of hTGp, it may additionally result from the 
heterogeneous expression within the prostate (Chapter 5) combined with a lack of 
coordinated secretion. In this respect, it would be of interest to study whether there is a 
correlation between seminal plasma expression levels of hTGp and other prostate secretory 
proteins, such as PSA and PAP. In a small series of 4 seminal plasma samples, variation in 
hTGp and PSA levels did not correlate, but a systematic study with larger numbers of 
seminal plasmas would be required to answer this question more definitely. 
The question remains how hTGp could efficiently fUllction in inmll111omodulation of 
spermatozoa or as spenn cell surface modifier (Chapter 1), thus helping in optimizing the 
fertilization process, if it is present at such different levels. This may imply that only small 
amounts of this enzyme are adequate or that the enzyme is redundant in the sense that other 
proteins have complementary functions in seminal plasma. Alternatively, hTGp might have 
its major function within the prostate rather than in the semen. 
II Tap expression in the prostate 
The heterogeneous expression patterns of hTGp, described in Chapter 5, distinguish this 
enzyme from other prostate secretory proteins, PSA, PAP, and PSP94, which are 
abundantly expressed throughout the entire prostate (Lilja and Abrahamsson 1988). It is not 
clear how the specific expression of hTGp can be explained. No other characteristic features 
of hTGp expressing cells could be identified so far. To achieve that, it would be necessary 
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to get detailed inununohistochemical expression data of whole prostates. Regional 
differences in expression patterns may reflect microheterogeneity present in the prostate in 
e.g. hormone or growth factor envirolmlent and the influence of the underlying stroma on 
the normal function of the secretory epithelium (Cunha et al. 1987, Tenniswood 1997). 
Possibly, hTGp is involved in local tissue remodeling processes, like those that have been 
attributed to other TGase types, such as apoptosis or ECM fomlation. Resolving the 
mechanisms underlying this differential expression may yield infolTIlation on nonnal 
physiological processes occurring in the prostate. 
Study of differential expression in the prostate can be done by comparison of gene 
expression profiles of entirely hTGp-positive and hTGp-negative glands. An experimental 
approach to perfOlll1 this could be by large-scale sequencing of cDNA libraries to generate 
Expressed Sequence Tags (EST) databases of the selected tissue areas (He et al. 1997, 
Nelson et al. 1998). Another useful high-throughput sequencing method may be Serial 
Analysis of Gene Expression or SAGE (Veleulescu et al. 1995, Zhang et al. 1997), which 
allows analysis of relatively small amounts ofmRNA (Datson et al. 1999). Gene expression 
profiles may also be obtained via micro-atTay technology (Schena et al. 1995). 
Figure 1. Northem blot analysis of a panel of human prostate tumor xcnografts (van Weerden et a!. 1996) 
for the expression ofhTGp. 
Prostate-specific expression ofhTGp 
A major issue in this thesis is the prostate-specific expression of hTGp as demonstrated by 
Northem (spot) blotting (Chapters 2 and 3) and immunohistochemical staining (Chapter 5). 
In addition, the enzyme was shown to be usually absent in PIN lesions and malignant 
prostate tissue and thus not suitable as a tumor marker. Northern blot analysis of a 
xenograft panel of human prostate cancer tissues (van Weerden et al. 1996) largely 
confirms this obselvation, because, with the exception of two xenografts of the PC346 
lineage, all other xenogra!1s do not express hTGp (Figure I). Similarly, only the PC346C 
prostate cancer cell line, which has been established from a PC346 xenograft (RomUn et al. 
1995), expresses hTGp, whereas others do not (Chapter 2). 
Fm1her support for the prostate-specificity and preference of hTGp for normal prostate 
epithelium comes from large-scale sequencing projects of eDNA libraries of many different 
tissues as part of the ongoing Cancer Genome Anatomy Project (CGAP). Of the 440 cDNA 
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libraries, 27 were prepared from prostate tissues, including 13 from normal prostate tissue, 
5 from microdissected PIN lesions, and 8 from cancer tissue. Table 1 shows the frequency 
of hTGp, PSA, PAP, and PSP94 ESTs ill distinct libraries of prostate and non-prostate 
origin. In contrast to PSA, PAP and PSP94, expression of hTGp is absent in non-prostate 
tissue and PIN lesions and only one EST was found in eDNA from tumor tissue (see also 
Huang et al. 1999). Of interest is further that hTGp expression was relatively high in a 
prostate library subtracted with brain, liver and placental tissue, leading to emichment of 
prostate-specific cDNAs (Nelson et al. 1999). Additionally, the data in Table 1 illustrate 
that the overall expression of hTGp in prostate tissues is much lower in comparison with 
PSA, PAP and PSP94, possibly reflecting the heterogeneous distribution of hTGp-positive 
cells in the prostate (Chapter 5). However, the CGAP and Genbank database do not 
completely overlap. A search in the GenBank database with the hTGp cDNA sequence 
additionally showed ESTs in cDNA libraries of non-prostate tissue, i.e., Ewing sarcoma (I), 
placenta (I), uterus carcinoma (I), colon tumor (I), a colon cell line (I), fetal lung (2), lung 
tumor (1), and pooled libraries offetal, adult and tumor origin (3). 
Table 1. Frequency of hTGp, PAP, PSA and PSP94 expression in eDNA libraries 
Prostate tissues 
Total ESTs b Non~Prostate Prostate Normal PIN 
hTGp 26 0 26 25 0 
PAP 231 7 224 91 78 
PSA 539 80 459 172 163 
PSP94 359 24 335 182 85 
Total ESTs C 1.335.367 61.172 35.771 9.785 
tf Data obtained from http://www.ncbi.nim.nih.gov/ncicgap/cgapba.cgi. 
" Total number ofESTs in the CGAP database of the corresponding proteins at time of analysis. 
C Total number of ESTs sequenced at time of analysis. 
TGM4 promoter research awl prostate cancel' gene-therapy 
Tumor 
55 
124 
68 
14.941 
Because the expression of hTGp is largely confined to prostate epithelium, basic research 
011 the regulation of its prostate-specific expression may be useful for future gene-
therapeutic protocols. A major problem in the treatment of non-organ confined inoperable 
prostate cancer is that after an initial response to endocrine therapy (androgen withdrawal), 
metastasized prostate cancer often becomes androgen independent leading to therapeutic 
failure (Stearns and McGarvey 1992, Koivisto et a1. 1998). No other effective treatment 
schedules leading to prolonged survival are presently available. Therefore, novel 
therapeutic approaches need to be developed to circumvent or treat hornlOne-refractory 
disease (Carducci et a1. 1996). In this respect, gene-therapeutic strategies based upon 
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cytotoxic-gene targeting by prostate-specific gene promoters might be of value. TI,e 
ultimate goal will be the development of highly prostate-specific promoter constructs which 
are capable of high levels of effector gene expression in all prostatic tumor cells 
independent of localization, androgen dependence and other properties. Insight into the 
regulatOlY elements and factors underlying prostate-specific expression of prostate-specific 
genes, including the TGM4 gene, may provide the basis for the construction of such 
therapeutic vectors. 
So far, the molecular mechanisms underlying prostate-specific expression of hTGp are 
unclear. The promoter studies presented in Chapter 4 have shown that this is not directed 
via the 2.1 kb of the proximal TGM4 promoter. TIle regulatory regions may be present 
downstream the transcriptional start site or more upstream in the promoter, like has been 
described for the PSA promoter. Both in vitro and in transgenic mice, prostate-specific PSA 
expression appears to be mediated by a complex upstream enhancer region at -4.3 to -3.9 
kb, (Schuur et al. 1996, Cleutjens et al. 1997a, 1997b, Pang et al. 1997). Furthennore, 
studies with PSA promoter constmcts hooked to effector genes have shown their ability to 
direct selective cytotoxicity towards PSA-producing cells both bl vitro and in vivo in 
xenograft models (Rodriguez et al. 1997, Gotoh et al. 1998, Segawa et al. 1998). These 
results suggest that prostate-specific promoter-based gene therapy may be a promising 
approach in the treatment of advanced prostate cancer. 
The TGM4 promoter and the development a/prostate callcer models 
Regulatory elements in the TGM4 promoter or elsewhere in the gene that are able to drive 
prostate-specific expression may also be useful for the generation of transgenic mice prone 
to develop prostate cancer. The advantage of such models above available xenograft models 
(van Weerden et al. 1996) is that these models may become suitable for studying the early 
stages, development and progression of prostate cancer against a standardized genetic 
background. Mice transgenes prepared with the probasin promoter linked to transforming 
SV 40 large T antigen have shown that this is an attractive approach, because these mice 
display different steps of prostate carcinogenesis (Kasper et al. 1998). Because rodent 
DPlIrTGp is abundantly expressed in several prostate lobes, the mouse TGM4 promoter 
may be of additional value for the development of transgenic prostate cancer models, using 
a similar or variant approach e.g. tissue-specific knockout of putatively essential genes in 
development of prostate cancer. Studies to implement TGM4 promoter research in 
programs meant to develop prostate tumor models are now underway. 
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Summary 
The human prostate is a secretory organ that is characterized by the abundant production 
and secretion of several proteins. Many prostate-specific proteins are excreted into semen 
by the luminal epithelium of the prostate \vhere they arc supposed to function in optimizing 
the reproductive process (reviewed in Chapter I). One of these secretory proteins is the 
TGase hTGp of which the role in semen is so far unclear. This thesis deals with the 
evaluation of hTGp at the genomic and expressional level with the pUlpose to ultimately 
increase the knowledge of prostate physiology. 
Based upon the expected similarity with other members of the TGase family (reviewed in 
Chapter I), the complete hTGp cDNA was isolated from a human prostate cDNA library 
(Chapter 2). The cDNA, with a length of 2983 bp, encodes for a protein of 684 amino acids 
with a predicted molecular mass of 77 kDa and a pI of 6.94. In vitro transcription-
translation confinncd the size of the protein. TIle deduced amino acid sequence contains the 
active-site cysteine embedded in the GQC\VVF A sequence, which is characteristic for 
functional TGases (Chapter I). Northern blotting analysis of prostate cancer cell lines 
showed neither hTGp expression in the androgen~responsive LNCaP cells nor in the 
androgen~independent PC3 cells. hTGp expression was only demonstrated in the androgen-
sensitive PC346C cell line revealing a 3.5 kb mRNA. The level of hTGp mRNA expression 
was stimulated up to 3-fold by the presence of (synthetic) androgen. The gene encoding 
hTGp, TGM4, was found to be localized on chromosome 3. 
Chapter 3 describes the genomic organization of the TGM4 gene. The TGM4 gene spans 35 
kb of genomic DNA, consists of l3 exons and 12 introns and has striking shl1ctural 
similarity with the other TGase genes, RT~PCR analysis showed a complex splicing pattern 
of intron 1. It was found that an anti~sense A III element was involved which is located 
approximately 3.5 kb upstream of exon II. A major transcriptional initiation site was 
detennined to be located at 52 bp upsh'eam of the translational start codon. The TGM4 gene 
promoter was analysed by sequencing and transfection experiments. The most prominent 
shllchlral feahues of the TGM4 promoter were a CATAA motif at positions -48 to -44, an 
Spl binding motif at position-96 to -87 and a PPIP pseudogene at positions -1276 to -563. 
Deletion mapping of 2.1 kb of the TGM4 promoter in transiently transfected PC346C cells 
showed comparable activity of 2.1-, 1.5-, and O.5-kb promoter fragments, demonsh'ating 
that the proximal promoter is responsible for basal activity. 
By different methods, including Northern (spot) blotting and immunohistochemical 
staining, the expression ofhTGp was shown to be strictly confined to the prostate (Chapters 
2, 3 and 5). Because of its potential value in a gene-therapeutic setting, it is important to 
know which mechanisms underly the prostate-specific expression of hTGp at the molecular 
level. Therefore, the 2.1 kb TGM4 promoter region was further studied in the prostate cell 
lines, PC346C and LNCaP, and the hepatic cancer cell line, Hep3B (Chapter 4). The data 
showed, however, that the 2.1 kb proximal promoter was equally active in all cell lines, 
suggesting that other sequence determinants are necessary for tissue-specificity. Extensive 
deletion mapping of the TGM4 promoter showed that the most proximal promoter between 
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positions -113 and -61 was responsible for basal promoter activity. This region contained 
the sequence 5'-ACCCCGCCCC-3' at positions -96 to -87, which perfectly matches a 
medium affmity binding site of the Sp I multigene family. The functional importance of this 
binding motif was determined by mutational analysis. By EMSAs of LNCaP nuclear 
extracts, it was demonstrated that the Spl binding site binds to the ubiquitous transcription 
factors Spl and Sp3. 
In Chapter 5 the generation of a specific polyclonal antisenllll against the C-terminal region 
of hTGp is described. The antisemm was suitable for Western blotting and 
immunohistochemical staining of f011l1alill-fixed paraffin-embedded tissues. hTGp 
expression in prostatic tissues, prostatic fluids and seminal plasmas was addressed by 
Western blotting. The expression was found to be highly variable, in particular in the tissue 
extracts and in seminal plasmas. In few prostatic tissues, in most seminal plasmas and in all 
prostatic fluids hTGp expression could be detected as a 77 kDa protein by Western blotting. 
Additionally, in prostatic tissues and in prostatic fluids a protein band of 72 kDa was 
observed. Furthermore, breakdown products of approximately 33 kDa and smaller and high 
molecular mass bands could be demonstrated in both fluids. The latter may represent 
protein complexes containing hTGp possibly formed by its own cross-linking activity. 
Immunohistochemical analysis of several f011l1alin-fixed paraffin-embedded human tissues 
showed no expression in any other tissue or cell type than prostate epithelium, continning 
the results obtained by Northern (spot) blotting (Chapters 2 and 3). Extensive 
immunohistochemical analysis of prostate tissue sections and needle biopsies containing 
prostate adenocarcinoma and/or llonnal tissue showed a remarkable expression pattem of 
hTGp within the prostate. hTGp expression was entirely restricted to the luminal epithelium 
and no expression was found in basal epithelial and stromal cells. Within the prostate, large 
areas without any hTGp positive cells were seen. Inununopositive cells were present either 
in a scattered pattern or concentrated in single or mUltiple glands in which all glandular 
cells expressed hTGp• The latter staining pattem occurred frequently, but not exclusively, in 
the peripheral zone, whereas scattered expression was most often observed in the transition 
zone. hTGp protein expression could occasionally be observed in high grade prostatic 
intraepithelialneoplasia, but was not detected in prostate carcinoma cells. The expression 
pattem as observed for hTGp has not been found thus far for any other prostate-specific 
marker. 
Although it still remains difficult to asses the physiological role of hTGp, several data have 
been obtained and tools are generated which may help to elucidate the precise biological 
importance of this enzyme. Because of its prostate-specificity and its typical expression 
pattern within the prostate, studying hTGp may also help in understanding physiological 
processes in the prostate. hTGp may tum out not to be useful as a diagnostic or prognostic 
tool in prostate cancer, because of its heterogeneous cellular expression pattem and down-
regulated expression in tumor tissue, but it is discussed that the identification of DNA 
modules and other regulatory factors involved in prostate-specific expression of hTGp 
might be helpful in the development of gene-therapeutic protocols to specifically eliminate 
metastasized prostate cancer cells 
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In de menselijke prostaat ,vorden verschillende eiwitten geproduceerd, waarvan vele 
gesecreteerd worden in het semen. Deze eiwitten worden verolldersteld te functioneren bij 
het optimaliseren van het voortplantingsproces (een overzicht hiervan is gegeven in 
hoofdstuk 1). Een van deze eiwitten is prostaat-specifiek transgiutaminase, hTGp, waarvan 
de functie tot nu onduidelijk is. Het in dit proefschrift beschreven onderzoek had tot doel de 
eigenschappen van hTGp vast te stellen teneinde inzicht te verkrijgen in de (veronderstelde) 
rol van hTGp in door de prostaat gereguleerde fysiologische processen. 
Door gebmik te maken van de verwachte overeenkomst met andere leden van de TOase 
familie (voor overzicht zie hoofdstuk I), kon het complete hTGp cDNA gelsoleerd worden 
uit een humane prostaat cDNA bank (hoofstuk 2). Het cDNA, met een Iengte van 2983 bp, 
codeert voor een eiwit van 684 aminozuren met een te verwachten molecuulmassa van 77 
kDa en een pI van 6.94. JI/ vitro transcriptie-translatie experimenten bevestigden dit voor 
wat betreft de grootte. De afgeleide aminozuursequelltie bevat een aeHef-centrum cysteine 
dat is ingebed in de GQCWVFA sequentie, die karakteristiek is voor fuuctionele TGases 
(hoofdstuk I). Met behulp van Northel1l blot analyse van prostaatkankercellijnen kon geen 
hTGp expressie aangetoond worden in de androgeen-responsieve cellijn LNCaP en de 
androgeen-onafhankelijke cellijn PC3, maar weI in de androgeen-gevoelige cellijn PC346C. 
Hierin werd cen hTGp mRNA vall 3.5 kb gevonden, waarvan het expressie niveau 
drievoudig werd verhoogd onder invloed van (synthetisch) androgeen. Het gen voor hTGp, 
TGM4, werd gelokaliseerd op chromosoom 3. 
Hoofdstuk 3 beschrijft de genomische organisatie van het TGM4 gen. Het TGM4 gen 
beslaat 35 kb genomisch DNA en bevat 13 exonen en 12 intronen en heeft een opvallende 
structurele overeenkomst met andere TGase genen. RT-PCR analyse toonde een complex 
splicingspatroon aan van intron I. Hierbij was een 3.5 kb stroomopwaarts van exon II 
gelegen anti-sense Alu element betrokken. Een belangrijke transcriptiestartplaats werd 
bepaald op 52 bp stroomopwaarts yan het translatiestartcodon. De TGM4 promoter werd 
gekarakteriseerd door sequentieanalyse en trallsfectiestudies. De meest opvallende 
structurele kenmerken van de TGM4 promoter waren een CATAA motief op positie -48 tot 
-44, een Sp I bindingsplaats op positie -96 tot -87 en een PIPP pseudo-geu op positie -
1276 tot -563. Deletieconstmcten met 2.1-, 1.5- of 0.5 kb TGM4 promoter fragmenten, 
getest in de PC346C cellijn, waren vergelijkbaar aetief, waarmee aangetoond werd dat de 
proximale promoter verantwoordelijk is voor de basale activiteit. Door middel van 
verschillende methoden, waaronder Northern (spot) blotten en innnunohistochemische 
aankleuring, werd aangetoond dat de expressie van hTGp volledig beperkt is tot de prostaat 
(hoofdstuk 2, 3 en 5). 
In verband met mogeJijke toekol11stige gen-therapeutische toepassingen zan het van belang 
kunnen zijn de moleculaire mechanismen welke ten grolldslag Iiggen aan de prostaat-
specifieke expressie van hTGp te identificeren. Daarom werd de 2.1 kb TGM4 promoter 
regio verder onderzocht in de prostaatkankercellijnen, PC346C en LNCaP, en de 
Ievercellijn, Hep3B (hoofdstuk 4). De 2.1 kb proximale promoter was eehter vergelijkbaar 
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actief in aUe ceUijnen wat suggereert dat elders gelegen DNA elementen nodig zijn voor 
weefselspecificiteit. Uitgebreide deletie analyse van de TGM4 promoter toonden aan dat de 
proximale promoter tussen positie -113 en -61 verantwoordelijk is voor de bas ale promoter 
activiteit. Deze regio bevat de sequentie 5 '-ACCCCGCCCC-3 , op positie -96 en -87, 
welke identiek is aan een bindingsplaats met een gemiddelde affiniteit voor de Spl 
multigen familie. Het functionele belang van deze bindingsplaats werd bepaald door 
mutatie analyse. Door middel van EMSAs met kemextracten van LNCaP ceUen werd 
aangetoond dat de aigemeen voorkomende transcriptiefactoren Sp I and Sp3 binden aan de 
Sp I bindingsplaats. 
In hoofdstuk 5 wardt de ontwikkeling van een specifiek polyclonaal antisemm tegen de C-
temunus van hTGp beschreven. Het antiserum bleek geschikt voar Western blot analyse en 
inmmnohistochemische aankleuring van fonnaline-gefixeerd en paraffine-ingebed weefseL 
hTGp expressie in prostaatweefsels, prostaatvloeistof en seminaal plasma werd onderzocht 
door middel van Western blot analyse. De expressie vertoonde grate variaties, in het 
bijzonder in de weefselextracten en in seminale plasma's. In weinig prastaatweefsels, in 
bijna aIle seminale plasma's en in aIle prastaatvloeistofmonsters kon hTGp expressie 
worden aangetoond als een eiwit van 77 kDa. Verder werden afbraakproducten van 33 kDa 
en kleiner en weUicht door autokatalyse gevormde hoog moleculaire banden aangetoond in 
beide typen vloeistofmonsters. 
Immunohistochemische analyse van verschillende formaline-gefixeerde en paraffme-
ingebedde humane weefsels kon geen expressie aantonen in andere weefsels of celtypes 
dan prostaatepitheel, hetgeen de door Northern (spot) blotten verkregen resultaten 
(hoofdstuk 2 en 3) bevestigt. Uitgebreide imnlllllohistochemische analyse van 
prostaatweefsels en naaldbiopten die adenocarcinoma en/of nonnaal prostaatweefsel 
bevatten toonden een opmerkelijke distributie aan van hTGr in de prostaat. hTGp expressie 
was volledig beperkt tot de lumina Ie epithelia Ie ceUen. In bas ale epithelia Ie en stromale 
ceUen werd geen expressie gevonden. Grote gebieden zonder enige hTGp positieve eel 
waren aanwezig. Immullopositieve cellen lagen verspreid of waren geconcentreerd in een 
of meerdere klierbuisjes waarin aUe klierceUen hTGp tot expressie brachten. Het 
laatstgenoemde expressiepatroon kwam vaak, maar niet uitsluitend, voor in de perifere 
zone, tenvijl verspreid liggende cellen het meest werden gezien in de transitionele zone. 
hTGp expressie werd een ellkele keel' gevonden in hoog-gradige preneoplastische 
intraepitheliale neoplasie van de prostaat, maar niet in prostaatcarcinomacellen. Het 
expressiepatroon zoals waargenomen voor hTGp is tot Bn toe niet gevonden voor andere 
prostaat-specifieke markers. 
Hoewel het moeilijk blijft om de fysiologische rol van hTGp in te schatten zijn er veel 
gegevens verkregen en experimentele hulpmiddelen gegenereerd die er mogelijk aan 
kunnen bijdragen hierin meer inzicht te verkrijgen. Vanwege zijn prostaat-specificiteit en 
typische distributie kan verder onderzoek aan hTGp mogelijk helpen bij het ophelderen van 
de fysiologische processen die zich afspelen in de prostaat. hTGp is hoogst waarschijnlijk 
niet geschikt als diagnostische of prognostische marker bij prostaatkanker, vanwege zijn 
heterogene expressiepatroon en afwezigheid in tUlllorweefsel. De identificatie vall DNA 
modules en andere regulerende factoren die betrokken zijn bij de prostaat-specifieke 
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expressie vall hTGp zou kUl1l1ell helpell bij het olltwikkelell vall gell-therapeutische 
proto collen am specifiek metastaserende prostaatkankercellell te elimineren. 
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